US20210253538A1 - Aminopyrazines and related compounds useful as mitochondrial uncouplers - Google Patents
Aminopyrazines and related compounds useful as mitochondrial uncouplers Download PDFInfo
- Publication number
- US20210253538A1 US20210253538A1 US17/049,145 US201917049145A US2021253538A1 US 20210253538 A1 US20210253538 A1 US 20210253538A1 US 201917049145 A US201917049145 A US 201917049145A US 2021253538 A1 US2021253538 A1 US 2021253538A1
- Authority
- US
- United States
- Prior art keywords
- alkyl
- compound
- phenyl
- amino
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 192
- 230000002438 mitochondrial effect Effects 0.000 title claims abstract description 62
- XFTQRUTUGRCSGO-UHFFFAOYSA-N pyrazin-2-amine Chemical class NC1=CN=CC=N1 XFTQRUTUGRCSGO-UHFFFAOYSA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims abstract description 56
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 21
- 206010022489 Insulin Resistance Diseases 0.000 claims abstract description 20
- 201000011510 cancer Diseases 0.000 claims abstract description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 18
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 18
- 208000008589 Obesity Diseases 0.000 claims abstract description 17
- 235000020824 obesity Nutrition 0.000 claims abstract description 17
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims abstract description 16
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 14
- 230000003247 decreasing effect Effects 0.000 claims abstract description 10
- 206010063837 Reperfusion injury Diseases 0.000 claims abstract description 9
- 239000003937 drug carrier Substances 0.000 claims abstract description 8
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims abstract description 8
- 230000001105 regulatory effect Effects 0.000 claims abstract description 8
- 102000004877 Insulin Human genes 0.000 claims abstract description 7
- 108090001061 Insulin Proteins 0.000 claims abstract description 7
- 230000009471 action Effects 0.000 claims abstract description 7
- 208000010706 fatty liver disease Diseases 0.000 claims abstract description 7
- 229940125396 insulin Drugs 0.000 claims abstract description 7
- 206010019280 Heart failures Diseases 0.000 claims abstract description 6
- 208000018737 Parkinson disease Diseases 0.000 claims abstract description 6
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims abstract description 6
- 230000014101 glucose homeostasis Effects 0.000 claims abstract description 5
- 125000001424 substituent group Chemical group 0.000 claims description 65
- 238000000034 method Methods 0.000 claims description 63
- -1 —CHO Chemical group 0.000 claims description 50
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims description 30
- 125000004432 carbon atom Chemical group C* 0.000 claims description 30
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims description 29
- 125000003118 aryl group Chemical group 0.000 claims description 29
- 229910052739 hydrogen Inorganic materials 0.000 claims description 27
- 239000001257 hydrogen Substances 0.000 claims description 27
- 229910052736 halogen Inorganic materials 0.000 claims description 26
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 26
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 25
- 150000002367 halogens Chemical group 0.000 claims description 24
- 229910052760 oxygen Inorganic materials 0.000 claims description 22
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 20
- 238000011282 treatment Methods 0.000 claims description 20
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 19
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 17
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 17
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 15
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 13
- 230000000694 effects Effects 0.000 claims description 13
- 239000008103 glucose Substances 0.000 claims description 12
- 125000004043 oxo group Chemical group O=* 0.000 claims description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 11
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 11
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 10
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 10
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 10
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 8
- 206010012601 diabetes mellitus Diseases 0.000 claims description 8
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 7
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 7
- KVCJYYMLTBZFJT-UHFFFAOYSA-N 2-[3-(trifluoromethyl)anilino]pyridin-3-ol Chemical compound OC1=CC=CN=C1NC1=CC=CC(C(F)(F)F)=C1 KVCJYYMLTBZFJT-UHFFFAOYSA-N 0.000 claims description 7
- MITDZVOEPPARRS-UHFFFAOYSA-N 3-[4-(trifluoromethyl)anilino]-1H-pyrazin-2-one Chemical compound FC(C1=CC=C(C=C1)NC=1C(=NC=CN=1)O)(F)F MITDZVOEPPARRS-UHFFFAOYSA-N 0.000 claims description 7
- 150000002431 hydrogen Chemical class 0.000 claims description 7
- YDKKWJKPOBTDAI-UHFFFAOYSA-N 2-[4-(trifluoromethyl)anilino]pyridin-3-ol Chemical compound FC(C1=CC=C(C=C1)NC1=NC=CC=C1O)(F)F YDKKWJKPOBTDAI-UHFFFAOYSA-N 0.000 claims description 6
- XTRUPCUOKDMVFY-UHFFFAOYSA-N 3-(2,3,4,5,6-pentafluoroanilino)-1H-pyrazin-2-one Chemical compound FC1=C(C(=C(C(=C1F)F)F)F)NC=1C(=NC=CN=1)O XTRUPCUOKDMVFY-UHFFFAOYSA-N 0.000 claims description 6
- OFSCJMKUYZNGTR-UHFFFAOYSA-N 3-(2-fluoroanilino)-1H-pyrazin-2-one Chemical compound FC1=C(C=CC=C1)NC=1C(=NC=CN=1)O OFSCJMKUYZNGTR-UHFFFAOYSA-N 0.000 claims description 6
- BLXINFAIOKMDER-UHFFFAOYSA-N 3-(4-decylanilino)-1H-pyrazin-2-one Chemical compound C(CCCCCCCCC)C1=CC=C(C=C1)NC=1C(=NC=CN=1)O BLXINFAIOKMDER-UHFFFAOYSA-N 0.000 claims description 6
- XZTVBGAJDMRJTK-UHFFFAOYSA-N 3-(dodecylamino)-1H-pyrazin-2-one Chemical compound C(CCCCCCCCCCC)NC=1C(=NC=CN=1)O XZTVBGAJDMRJTK-UHFFFAOYSA-N 0.000 claims description 6
- SSJDQYKQNJFRDC-UHFFFAOYSA-N 3-[3,5-bis(trifluoromethyl)anilino]-1H-pyrazin-2-one Chemical compound C1(=NC=CN=C1NC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1)O SSJDQYKQNJFRDC-UHFFFAOYSA-N 0.000 claims description 6
- CLTSDPMCHAZJGD-UHFFFAOYSA-N 3-[3-(3-methoxyphenyl)anilino]-1H-pyrazin-2-one Chemical compound COC=1C=C(C=CC=1)C1=CC(=CC=C1)NC=1C(=NC=CN=1)O CLTSDPMCHAZJGD-UHFFFAOYSA-N 0.000 claims description 6
- RODJEGCMKANXDH-UHFFFAOYSA-N 3-[3-(trifluoromethyl)anilino]-1H-pyrazin-2-one Chemical compound FC(C=1C=C(C=CC=1)NC=1C(=NC=CN=1)O)(F)F RODJEGCMKANXDH-UHFFFAOYSA-N 0.000 claims description 6
- HMZISWHEBGAYLB-UHFFFAOYSA-N 3-[4-(4-fluorophenyl)anilino]-1H-pyrazin-2-one Chemical compound OC1=C(NC2=CC=C(C=C2)C2=CC=C(F)C=C2)N=CC=N1 HMZISWHEBGAYLB-UHFFFAOYSA-N 0.000 claims description 6
- GAQPGSQZJUISKQ-UHFFFAOYSA-N 3-[4-(trifluoromethoxy)anilino]-1H-pyrazin-2-one Chemical compound FC(OC1=CC=C(C=C1)NC=1C(=NC=CN=1)O)(F)F GAQPGSQZJUISKQ-UHFFFAOYSA-N 0.000 claims description 6
- LNLANMBXNKIWIU-UHFFFAOYSA-N 3-phenylmethoxy-N-[4-(trifluoromethoxy)phenyl]-5-(trifluoromethyl)pyrazin-2-amine Chemical compound N(C1=CC=C(OC(F)(F)F)C=C1)C1=C(N=C(C=N1)C(F)(F)F)OCC1=CC=CC=C1 LNLANMBXNKIWIU-UHFFFAOYSA-N 0.000 claims description 6
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 5
- XBEKIRVYFXMZKK-UHFFFAOYSA-N 3-[4-(trifluoromethoxy)anilino]-6-(trifluoromethyl)-1H-pyrazin-2-one Chemical compound N(C1=CC=C(OC(F)(F)F)C=C1)C1=NC=C(C(F)(F)F)N=C1O XBEKIRVYFXMZKK-UHFFFAOYSA-N 0.000 claims description 5
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 5
- BSOVFANSERTDFA-UHFFFAOYSA-N N-(6-bromo-2-oxo-1H-pyrazin-3-yl)-2-fluorobenzamide Chemical compound BrC=1N=C(C(=NC=1)NC(C1=C(C=CC=C1)F)=O)O BSOVFANSERTDFA-UHFFFAOYSA-N 0.000 claims description 5
- OPWDQWFIFMTIGD-UHFFFAOYSA-N N-(6-bromo-2-oxo-1H-pyrazin-3-yl)-3-fluorobenzamide Chemical compound BrC=1N=C(C(=NC=1)NC(C1=CC(=CC=C1)F)=O)O OPWDQWFIFMTIGD-UHFFFAOYSA-N 0.000 claims description 5
- 125000005311 halosulfanyl group Chemical group 0.000 claims description 4
- 125000002950 monocyclic group Chemical group 0.000 claims description 4
- HOXJBCDERAOGOC-UHFFFAOYSA-N 3-[4-(trifluoromethoxy)anilino]-6-[4-(trifluoromethyl)phenyl]-1H-pyrazin-2-one Chemical compound FC(OC1=CC=C(C=C1)NC=1C(=NC(=CN=1)C1=CC=C(C=C1)C(F)(F)F)O)(F)F HOXJBCDERAOGOC-UHFFFAOYSA-N 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- 230000035772 mutation Effects 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 102000015735 Beta-catenin Human genes 0.000 claims description 2
- 108060000903 Beta-catenin Proteins 0.000 claims description 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 206010027476 Metastases Diseases 0.000 claims description 2
- 208000020990 adrenal cortex carcinoma Diseases 0.000 claims description 2
- 208000007128 adrenocortical carcinoma Diseases 0.000 claims description 2
- 150000003857 carboxamides Chemical class 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 230000001771 impaired effect Effects 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 230000009401 metastasis Effects 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 abstract description 17
- 230000001965 increasing effect Effects 0.000 abstract description 16
- 230000007423 decrease Effects 0.000 abstract description 14
- 238000004519 manufacturing process Methods 0.000 abstract description 14
- 210000000170 cell membrane Anatomy 0.000 abstract description 4
- 230000005779 cell damage Effects 0.000 abstract 1
- 208000037887 cell injury Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 60
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 53
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 47
- 201000010099 disease Diseases 0.000 description 32
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 31
- 239000007787 solid Substances 0.000 description 30
- 230000015572 biosynthetic process Effects 0.000 description 26
- 238000005160 1H NMR spectroscopy Methods 0.000 description 23
- 238000003786 synthesis reaction Methods 0.000 description 23
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 21
- 208000035475 disorder Diseases 0.000 description 21
- 150000001412 amines Chemical class 0.000 description 19
- 239000003814 drug Substances 0.000 description 19
- 235000019439 ethyl acetate Nutrition 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 238000004293 19F NMR spectroscopy Methods 0.000 description 17
- 239000000463 material Substances 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 16
- 241000282414 Homo sapiens Species 0.000 description 16
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 15
- 229910052805 deuterium Inorganic materials 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 14
- 125000000217 alkyl group Chemical group 0.000 description 13
- 229910052799 carbon Inorganic materials 0.000 description 13
- 235000015097 nutrients Nutrition 0.000 description 13
- 235000021068 Western diet Nutrition 0.000 description 12
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 11
- 125000000753 cycloalkyl group Chemical group 0.000 description 11
- 239000003925 fat Substances 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 239000011159 matrix material Substances 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 230000006378 damage Effects 0.000 description 10
- 230000027721 electron transport chain Effects 0.000 description 10
- 208000014674 injury Diseases 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 208000027418 Wounds and injury Diseases 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 125000001072 heteroaryl group Chemical group 0.000 description 9
- 231100000252 nontoxic Toxicity 0.000 description 9
- 230000003000 nontoxic effect Effects 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 241000282412 Homo Species 0.000 description 8
- 102000015494 Mitochondrial Uncoupling Proteins Human genes 0.000 description 8
- 108010050258 Mitochondrial Uncoupling Proteins Proteins 0.000 description 8
- 230000036541 health Effects 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 230000003647 oxidation Effects 0.000 description 8
- 238000007254 oxidation reaction Methods 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- MNMFOHDKDACCSN-UHFFFAOYSA-N 2-chloro-3-phenylmethoxypyrazine Chemical compound ClC1=NC=CN=C1OCC1=CC=CC=C1 MNMFOHDKDACCSN-UHFFFAOYSA-N 0.000 description 7
- 230000002407 ATP formation Effects 0.000 description 7
- 241000124008 Mammalia Species 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 7
- 235000005911 diet Nutrition 0.000 description 7
- 230000037213 diet Effects 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 125000005843 halogen group Chemical group 0.000 description 7
- 210000003470 mitochondria Anatomy 0.000 description 7
- 239000012044 organic layer Substances 0.000 description 7
- 125000006413 ring segment Chemical group 0.000 description 7
- 238000010898 silica gel chromatography Methods 0.000 description 7
- ZJZLHUZOCHSRGQ-UHFFFAOYSA-N 2,3-dichloro-5-iodopyrazine Chemical compound ClC1=NC=C(N=C1Cl)I ZJZLHUZOCHSRGQ-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 0 [1*]N(C[2*])C1=CC([4*])=C([5*])C=C1O[3*] Chemical compound [1*]N(C[2*])C1=CC([4*])=C([5*])C=C1O[3*] 0.000 description 6
- 230000032683 aging Effects 0.000 description 6
- 239000006185 dispersion Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 125000005842 heteroatom Chemical group 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- 230000036284 oxygen consumption Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- QLLRUGRNZMPUIW-UHFFFAOYSA-N 2-chloro-3-phenylmethoxypyridine Chemical compound ClC1=NC=CC=C1OCC1=CC=CC=C1 QLLRUGRNZMPUIW-UHFFFAOYSA-N 0.000 description 5
- AVYHXGVOSTVAKN-UHFFFAOYSA-N 3-amino-6-bromo-1h-pyrazin-2-one Chemical compound NC1=NC=C(Br)NC1=O AVYHXGVOSTVAKN-UHFFFAOYSA-N 0.000 description 5
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000004770 neurodegeneration Effects 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- NOLUNAOIBMHCAP-UHFFFAOYSA-N 2-chloro-3-phenylmethoxy-5-(trifluoromethyl)pyrazine Chemical compound C(C1=CC=CC=C1)OC=1C(=NC=C(N=1)C(F)(F)F)Cl NOLUNAOIBMHCAP-UHFFFAOYSA-N 0.000 description 4
- PZCWBZARKLQZDN-UHFFFAOYSA-N 5-[4-(trifluoromethyl)phenyl]pyrazin-2-amine Chemical compound C1=NC(N)=CN=C1C1=CC=C(C(F)(F)F)C=C1 PZCWBZARKLQZDN-UHFFFAOYSA-N 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 239000004599 antimicrobial Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 125000000392 cycloalkenyl group Chemical group 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 235000012631 food intake Nutrition 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 208000019622 heart disease Diseases 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000004061 uncoupling agent Substances 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 4
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- QISCHXLTPQIMCO-UHFFFAOYSA-N 2,3-dichloro-5-(trifluoromethyl)pyrazine Chemical compound FC(F)(F)C1=CN=C(Cl)C(Cl)=N1 QISCHXLTPQIMCO-UHFFFAOYSA-N 0.000 description 3
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 3
- PWDPEVCAWXRZBH-UHFFFAOYSA-N 3-chloro-5-[4-(trifluoromethyl)phenyl]pyrazin-2-amine Chemical compound C1(=C(N=C(C=N1)C1=CC=C(C(F)(F)F)C=C1)Cl)N PWDPEVCAWXRZBH-UHFFFAOYSA-N 0.000 description 3
- 102000004482 ATP Translocases Mitochondrial ADP Human genes 0.000 description 3
- 108010017236 ATP Translocases Mitochondrial ADP Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 241001559542 Hippocampus hippocampus Species 0.000 description 3
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 108010021111 Uncoupling Protein 2 Proteins 0.000 description 3
- 102000008219 Uncoupling Protein 2 Human genes 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 125000003282 alkyl amino group Chemical group 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 150000001721 carbon Chemical class 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 125000001188 haloalkyl group Chemical group 0.000 description 3
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 3
- 201000008980 hyperinsulinism Diseases 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 125000005017 substituted alkenyl group Chemical group 0.000 description 3
- 125000000547 substituted alkyl group Chemical group 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- MLCNOCRGSBCAGH-UHFFFAOYSA-N 2,3-dichloropyrazine Chemical compound ClC1=NC=CN=C1Cl MLCNOCRGSBCAGH-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- ZPDVMHRNPFMHTO-UHFFFAOYSA-N 3-chloro-N-[4-(trifluoromethoxy)phenyl]-5-[4-(trifluoromethyl)phenyl]pyrazin-2-amine Chemical compound C1=C(OC(F)(F)F)C=CC(=C1)NC1=C(N=C(C2=CC=C(C(F)(F)F)C=C2)C=N1)Cl ZPDVMHRNPFMHTO-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 241000167854 Bourreria succulenta Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 208000033962 Fontaine progeroid syndrome Diseases 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 229940125907 SJ995973 Drugs 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 208000002847 Surgical Wound Diseases 0.000 description 2
- 229910001069 Ti alloy Inorganic materials 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229940127003 anti-diabetic drug Drugs 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 230000019522 cellular metabolic process Effects 0.000 description 2
- 230000004098 cellular respiration Effects 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 235000019693 cherries Nutrition 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000011256 inorganic filler Substances 0.000 description 2
- 229910003475 inorganic filler Inorganic materials 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000010954 inorganic particle Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000004898 mitochondrial function Effects 0.000 description 2
- XZMHJYWMCRQSSI-UHFFFAOYSA-N n-[5-[2-(3-acetylanilino)-1,3-thiazol-4-yl]-4-methyl-1,3-thiazol-2-yl]benzamide Chemical compound CC(=O)C1=CC=CC(NC=2SC=C(N=2)C2=C(N=C(NC(=O)C=3C=CC=CC=3)S2)C)=C1 XZMHJYWMCRQSSI-UHFFFAOYSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- 125000006574 non-aromatic ring group Chemical group 0.000 description 2
- 230000009437 off-target effect Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 239000011343 solid material Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 230000035924 thermogenesis Effects 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- 229910052719 titanium Inorganic materials 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- AHWNMFUPCUBQQD-GXTPVXIHSA-N 1-[(2S,3S,4S,5R)-2,3,4-trifluoro-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound F[C@@]1([C@]([C@@](O[C@@H]1CO)(N1C(=O)NC(=O)C=C1)F)(O)F)O AHWNMFUPCUBQQD-GXTPVXIHSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- RTUDBROGOZBBIC-UHFFFAOYSA-N 1-iodo-4-(trifluoromethoxy)benzene Chemical compound FC(F)(F)OC1=CC=C(I)C=C1 RTUDBROGOZBBIC-UHFFFAOYSA-N 0.000 description 1
- 102000008645 11-beta-Hydroxysteroid Dehydrogenase Type 1 Human genes 0.000 description 1
- 108010088011 11-beta-Hydroxysteroid Dehydrogenase Type 1 Proteins 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 125000005273 2-acetoxybenzoic acid group Chemical group 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- RSOPTYAZDFSMTN-UHFFFAOYSA-N 2-chloropyridin-3-ol Chemical compound OC1=CC=CN=C1Cl RSOPTYAZDFSMTN-UHFFFAOYSA-N 0.000 description 1
- RAAGZOYMEQDCTD-UHFFFAOYSA-N 2-fluorobenzoyl chloride Chemical compound FC1=CC=CC=C1C(Cl)=O RAAGZOYMEQDCTD-UHFFFAOYSA-N 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- 125000005925 3-methylpentyloxy group Chemical group 0.000 description 1
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 1
- RLBJPMURTWCBMZ-UHFFFAOYSA-N 5-bromo-3-chloropyrazin-2-amine Chemical compound NC1=NC=C(Br)N=C1Cl RLBJPMURTWCBMZ-UHFFFAOYSA-N 0.000 description 1
- KRRTXVSBTPCDOS-UHFFFAOYSA-N 5-bromopyrazin-2-amine Chemical compound NC1=CN=C(Br)C=N1 KRRTXVSBTPCDOS-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- LBNPJWAMIOMZPX-UHFFFAOYSA-N CC1=CC=C(C2=CN=C(N)C(Cl)=N2)C=C1 Chemical compound CC1=CC=C(C2=CN=C(N)C(Cl)=N2)C=C1 LBNPJWAMIOMZPX-UHFFFAOYSA-N 0.000 description 1
- RZSGKUUISFOIBT-UHFFFAOYSA-N CC1=CC=C(C2=CN=C(N)C=N2)C=C1 Chemical compound CC1=CC=C(C2=CN=C(N)C=N2)C=C1 RZSGKUUISFOIBT-UHFFFAOYSA-N 0.000 description 1
- SSLIONNENJZYQY-UHFFFAOYSA-N CC1=CC=C(C2=CN=C(NC3=CC=C(OC(F)(F)F)C=C3)C(Cl)=N2)C=C1 Chemical compound CC1=CC=C(C2=CN=C(NC3=CC=C(OC(F)(F)F)C=C3)C(Cl)=N2)C=C1 SSLIONNENJZYQY-UHFFFAOYSA-N 0.000 description 1
- KKJIPAVSXMQZMX-UHFFFAOYSA-N CC1=CC=C(C2=CN=C(NC3=CC=C(OC(F)(F)F)C=C3)C(O)=N2)C=C1 Chemical compound CC1=CC=C(C2=CN=C(NC3=CC=C(OC(F)(F)F)C=C3)C(O)=N2)C=C1 KKJIPAVSXMQZMX-UHFFFAOYSA-N 0.000 description 1
- IMCQXCPTQKOHCY-UHFFFAOYSA-N CC1=CN=C(Cl)C(Cl)=N1 Chemical compound CC1=CN=C(Cl)C(Cl)=N1 IMCQXCPTQKOHCY-UHFFFAOYSA-N 0.000 description 1
- IFWFSILKXRMXQZ-UHFFFAOYSA-N CC1=CN=C(Cl)C(OCC2=CC=CC=C2)=N1 Chemical compound CC1=CN=C(Cl)C(OCC2=CC=CC=C2)=N1 IFWFSILKXRMXQZ-UHFFFAOYSA-N 0.000 description 1
- CAIXUIGDMQMKTF-UHFFFAOYSA-N CC1=CN=C(NC2=CC=C(OC(F)(F)F)C=C2)C(O)=N1 Chemical compound CC1=CN=C(NC2=CC=C(OC(F)(F)F)C=C2)C(O)=N1 CAIXUIGDMQMKTF-UHFFFAOYSA-N 0.000 description 1
- HHQIGPIGVHTTAK-UHFFFAOYSA-N CC1=CN=C(NC2=CC=C(OC(F)(F)F)C=C2)C(OCC2=CC=CC=C2)=N1 Chemical compound CC1=CN=C(NC2=CC=C(OC(F)(F)F)C=C2)C(OCC2=CC=CC=C2)=N1 HHQIGPIGVHTTAK-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 206010008531 Chills Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108091006149 Electron carriers Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- YPZRHBJKEMOYQH-UYBVJOGSSA-L FADH2(2-) Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1COP([O-])(=O)OP([O-])(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C(NC(=O)NC2=O)=C2NC2=C1C=C(C)C(C)=C2 YPZRHBJKEMOYQH-UYBVJOGSSA-L 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Natural products OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229940122355 Insulin sensitizer Drugs 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920001410 Microfiber Polymers 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000238367 Mya arenaria Species 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- UOZODPSAJZTQNH-UHFFFAOYSA-N Paromomycin II Natural products NC1C(O)C(O)C(CN)OC1OC1C(O)C(OC2C(C(N)CC(N)C2O)OC2C(C(O)C(O)C(CO)O2)N)OC1CO UOZODPSAJZTQNH-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000006270 Proton Pumps Human genes 0.000 description 1
- 108010083204 Proton Pumps Proteins 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 238000009012 ROS assay kit Methods 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- ZWBTYMGEBZUQTK-PVLSIAFMSA-N [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,32-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23-dioxospiro[8,33-dioxa-24,27,29-triazapentacyclo[23.6.1.14,7.05,31.026,30]tritriaconta-1(32),2,4,9,19,21,24,26,30-nonaene-28,4'-piperidine]-13-yl] acetate Chemical compound CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c4NC5(CCN(CC(C)C)CC5)N=c4c(=NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C ZWBTYMGEBZUQTK-PVLSIAFMSA-N 0.000 description 1
- ALMFIOZYDASRRC-UHFFFAOYSA-N [4-(trifluoromethyl)phenyl]boronic acid Chemical compound OB(O)C1=CC=C(C(F)(F)F)C=C1 ALMFIOZYDASRRC-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000007000 age related cognitive decline Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000005431 alkyl carboxamide group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003200 antithyroid agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960003159 atovaquone Drugs 0.000 description 1
- KUCQYCKVKVOKAY-CTYIDZIISA-N atovaquone Chemical compound C1([C@H]2CC[C@@H](CC2)C2=C(C(C3=CC=CC=C3C2=O)=O)O)=CC=C(Cl)C=C1 KUCQYCKVKVOKAY-CTYIDZIISA-N 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 150000001669 calcium Chemical class 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000020827 calorie restriction Nutrition 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- JQXXHWHPUNPDRT-BQVAUQFYSA-N chembl1523493 Chemical compound O([C@](C1=O)(C)O\C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2C=NN1CCN(C)CC1 JQXXHWHPUNPDRT-BQVAUQFYSA-N 0.000 description 1
- 239000007958 cherry flavor Substances 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- WDQPAMHFFCXSNU-BGABXYSRSA-N clofazimine Chemical compound C12=CC=CC=C2N=C2C=C(NC=3C=CC(Cl)=CC=3)C(=N/C(C)C)/C=C2N1C1=CC=C(Cl)C=C1 WDQPAMHFFCXSNU-BGABXYSRSA-N 0.000 description 1
- 229960004287 clofazimine Drugs 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229960000860 dapsone Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000002999 depolarising effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 125000005265 dialkylamine group Chemical group 0.000 description 1
- 125000005432 dialkylcarboxamide group Chemical group 0.000 description 1
- 125000005266 diarylamine group Chemical group 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 229960000285 ethambutol Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 1
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 description 1
- 239000011714 flavin adenine dinucleotide Substances 0.000 description 1
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 229960005102 foscarnet Drugs 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000005908 glyceryl ester group Chemical group 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005241 heteroarylamino group Chemical group 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- 230000002102 hyperpolarization Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960003350 isoniazid Drugs 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- ANYSGBYRTLOUPO-UHFFFAOYSA-N lithium tetramethylpiperidide Chemical compound [Li]N1C(C)(C)CCCC1(C)C ANYSGBYRTLOUPO-UHFFFAOYSA-N 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000013227 male C57BL/6J mice Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000003658 microfiber Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000005787 mitochondrial ATP synthesis coupled electron transport Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229950006238 nadide Drugs 0.000 description 1
- 239000002121 nanofiber Substances 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 150000002829 nitrogen Chemical class 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 229940124583 pain medication Drugs 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- UOZODPSAJZTQNH-LSWIJEOBSA-N paromomycin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO UOZODPSAJZTQNH-LSWIJEOBSA-N 0.000 description 1
- 229960001914 paromomycin Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 1
- 229960004448 pentamidine Drugs 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- LFULEKSKNZEWOE-UHFFFAOYSA-N propanil Chemical compound CCC(=O)NC1=CC=C(Cl)C(Cl)=C1 LFULEKSKNZEWOE-UHFFFAOYSA-N 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 229960005206 pyrazinamide Drugs 0.000 description 1
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 description 1
- 150000003216 pyrazines Chemical class 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 description 1
- 229960000611 pyrimethamine Drugs 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 229960002026 pyrithione Drugs 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 231100000272 reduced body weight Toxicity 0.000 description 1
- 239000012783 reinforcing fiber Substances 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960000885 rifabutin Drugs 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000007892 solid unit dosage form Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- DZZWHBIBMUVIIW-DTORHVGOSA-N sparfloxacin Chemical compound C1[C@@H](C)N[C@@H](C)CN1C1=C(F)C(N)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1F DZZWHBIBMUVIIW-DTORHVGOSA-N 0.000 description 1
- 229960004954 sparfloxacin Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004306 sulfadiazine Drugs 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 229940066769 systemic antihistamines substituted alkylamines Drugs 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001302 tertiary amino group Chemical group 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- 125000005259 triarylamine group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- MWKJTNBSKNUMFN-UHFFFAOYSA-N trifluoromethyltrimethylsilane Chemical compound C[Si](C)(C)C(F)(F)F MWKJTNBSKNUMFN-UHFFFAOYSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/18—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/16—Halogen atoms; Nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
Definitions
- Cellular respiration is a physiological process with a fundamental goal of producing energy in the form of ATP.
- chemical energy derived from nutrients is converted into ATP.
- the oxidation of nutrients in the mitochondrial matrix generates high-energy electron carriers nicotinamide adenine dinucleotide (NADH) and flavin adenine dinucleotide (FADH 2 ) that are oxidized by the mitochondrial electron transport chain (ETC) located in the mitochondrial inner-membrane (MIM).
- ETC mitochondrial electron transport chain located in the mitochondrial inner-membrane
- Electron flow through the ETC is an exergonic process that drives a series of proton pumps to efflux protons from the matrix into the inter-membrane space (IMS) against their concentration gradient.
- the resulting proton concentration ( ⁇ pH) and electrical ( ⁇ ) gradient is known as the proton-motive force (pmf).
- MIM proton-motive force
- mitochondrial ATP production involves the coupling of electron transport to phosphorylation reactions via a proton gradient across the MIM.
- Mitochondrial uncoupling describes processes that uncouple nutrient oxidation from ATP production. Mitochondrial uncoupling is a normal physiological process that occurs as either basal or inducible proton leak from the intermembrane space. Basal proton leak accounts for ⁇ 20-25% of the basal metabolic rate of mammals. The reason for such metabolic inefficiency is not entirely understood; however, membrane lipid composition and abundance of the adenine nucleotide translocase (ANT) are factors that contribute to basal rates of proton leak. Induced proton leak is driven by reactive species and fatty acids that activate uncoupling proteins (UCPs). UCPs are located in the MIM and facilitate the transfer protons into the matrix independent of ATP synthase.
- UCPs uncoupling proteins
- UCP1-5 There are five known UCPs in mammals, UCP1-5, that have distinct tissue localization. The best-characterized UCPs are UCP1 and UCP2.
- UCP1 is expressed in brown and beige adipose tissue and has a role in non-shivering thermogenesis. UCP1 is unlikely to operate as a simple proton channel, but instead transfers protons via a mechanism that requires long-chain fatty acids.
- UCP2 has a broad tissue distribution and no role in thermogenesis. UCP2 uncouples mitochondria to prevent hyperpolarization and decrease mitochondrial superoxide production.
- Small molecule mitochondrial uncouplers either act directly as protonophores by transporting protons into the matrix independently of protein complexes or, alternatively, mediate uncoupling via proteins such as ANT.
- Protonophoric uncouplers are lipophilic enough to enable passage through the MIM and weakly acidic to enable partial and reversible pH-dependent ionization.
- Mitochondrial uncoupling has two major phenotypes of therapeutic relevance including increased nutrient oxidation to compensate for lack of efficiency in ATP production and decreasing superoxide production from the ETC.
- the ETC is a primary source of reactive oxygen species (ROS) in most tissues.
- ROS reactive oxygen species
- ETC-derived superoxide formation occurs via a non-enzymatic process when single electrons on co-enzymes or prosthetic groups in redox centers interact with molecular oxygen.
- Single electrons in the ETC only transiently exist in redox centers and the dwell time for single electrons in an unstable state increases the likelihood of superoxide production.
- Mitochondrial uncouplers decrease mitochondrial superoxide production by stimulating faster electron transfer that decreases the dwell time for single electrons in the ETC.
- mitochondrial uncouplers The therapeutic potential of mitochondrial uncouplers is related to their dual roles in increasing nutrient oxidation and decreasing ROS production from the ETC.
- increased nutrient oxidation promotes leanness and is a therapeutic strategy to treat obesity and related metabolic diseases.
- mitochondrial ROS are linked to numerous pathologies including ischemia-reperfusion injury, inflammation, insulin resistance, neurodegeneration, and many other pathologies.
- mitochondrial uncouplers prevent ROS production, which is advantageous compared to antioxidants that scavenge ROS that has already been produced. As such, decreasing mitochondrial ROS production has significant therapeutic potential with advantages over antioxidant scavengers.
- Mitochondrial uncouplers are known and have been shown to be effective for treating obesity.
- DNP 2,4-dinitrophenol
- mice treated with DNP demonstrate improved serological glucose, triglyceride, and insulin levels, as well as decreased oxidative damage, reduced body weight, and increased longevity.
- DNP has off-target effects on other cellular membranes resulting in a narrow therapeutic index. DNP was subsequently withdrawn from the North American market by the US Food and Drug Administration in 1938.
- variables in Formula I e.g. X 1 , X 2 , Z, and R 1 -R 5 carry the following values.
- X 1 and X 2 are chosen from N and CH, wherein at least one of X 1 and X 2 is N.
- Z is absent (R 2 is bound to N) or Z is —C( ⁇ O)—.
- R 1 is hydrogen or C 1 -C 8 alkyl, C 2 -C 8 alkenyl, or C 2 -C 8 alkynyl.
- R 2 is C 1 -C 12 alkyl, C 2 -C 8 alkenyl, or C 2 -C 8 alkynyl; or
- R 2 is —C 0 -C 4 alkyl(C 3 -C 7 cycloalkyl), —C 0 -C 4 alkyl(bridged C 7 -C 12 cycloalkyl), —C 0 -C 4 alkyl(aryl), —C 0 -C 4 alkyl(mono- or bi-cyclic heteroaryl), or —C 0 -C 4 alkyl(3- to 7-membered heterocycloalkyl), each of which is optionally substituted with one or more substituents independently chosen from R 11 and 0 or 1 substituents R 12 .
- R 3 is H or C 1 -C 8 alkyl, C 2 -C 8 alkenyl, or C 2 -C 8 alkynyl, or
- R 3 is —C 0 -C 4 alkyl(C 3 -C 7 cycloalkyl) or —C 0 -C 4 alkyl(aryl), which is optionally substituted with one or more independently chosen R 11 substituents.
- R 4 and R 5 are independently selected from halogen, hydroxyl, amino, nitro, cyano, —CHO, —COOH, C 1 -C 2 haloalkyl, C 1 -C 2 haloalkoxy, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylester, —C 0 -C 4 alkyl(mono- or di-C 1 -C 6 alkylamino), C 2 -C 6 alkanoyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, Wherein in each C 0 -C 4 alkyl, C 1 -C 8 alkyl, C 1 -C 12 alkyl, C 2 -C 8 alkenyl, or C 2 -C 8 alkynyl, aryl, optionally substituted with R 13 , and mono- or bicyclic heteroaryl, optionally substituted with R 13 .
- R 1 , R 2 , and R 3 one or more carbon atoms is optionally replaced by O, NR 10 , —C(O)—, —C(O)O—, —OC(O), —S(O)n-, —C(O)NR 10 —, or —NR 10 C(O)— where n is 0, 1, or 2, and in which the C 0 -C 4 alkyl, C 1 -C 8 alkyl, C 2 -C 8 alkenyl, or C 2 -C 8 alkynyl is optionally substituted with one or more substituents R 13 .
- R 10 is independently chosen at each occurrence from hydrogen, C 1 -C 6 alkyl, and —C 0 -C 2 alkyl(C 3 -C 7 cycloalkyl).
- R 11 is independently selected at each occurrence from halogen, hydroxyl, amino, nitro, cyano, —CHO, —COOH, oxo, halosulfanyl, and C 1 -C 10 alkyl, C 2 -C 8 alkenyl, and C 2 -C 8 alkynyl, wherein in each C 1 -C 10 alkyl, C 2 -C 8 alkenyl, and C 2 -C 8 alkynyl, in the definition of R 11 one or more carbon atoms is optionally replaced by O, NR 10 , —C(O)—, —C(O)O—, —OC(O), —S(O)n-, —S(O)nNR 10 , —NR 10 S(O)n-, —NR 10 C(O)NR 10 , —C(O)NR 10 —, or —NR 10 C(O)— where n is 0, 1, or 2, and in which each C 0 -C 4 alky
- R 12 is selected from —C 0 -C 4 alkyl(C 3 -C 7 cycloalkyl), —O—C 0 -C 4 alkyl(C 3 -C 7 cycloalkyl), —C 0 -C 4 alkyl(aryl), —O—C 0 -C 4 alkyl(aryl), —C 0 -C 4 alkyl(5- to 6-membered heteroaryl), —O—C 0 -C 4 alkyl(5- to 6-membered heteroaryl), —C 0 -C 4 alkyl(3- to 6-membered heterocycloalkyl), and —O—C 0 -C 4 alkyl(3- to 6-membered heterocycloalkyl), each of which is optionally substituted with one or more substituents independently chosen from halogen, hydroxyl, amino, nitro, cyano, —CHO, —COOH, oxo, C 1 -C
- R 13 is independently chosen at each occurrence from halogen, hydroxyl, amino, nitro, cyano, —CHO, —COOH, oxo, C 3 -C 7 cycloalkyl, and phenyl.
- the disclosure includes a pharmaceutical composition, comprising a compound or salt of Formula I, together with a pharmaceutically acceptable excipient.
- the disclosure includes a method of treating or preventing a condition responsive to mitochondrial uncoupling, comprising administering a therapeutically effective amount of a compound or salt of Formula I to a patient in need of such treatment.
- Conditions responsive to mitochondrial uncoupling include obesity, type II diabetes, fatty liver disease, insulin resistance, Parkinson's disease, ischemia reperfusion injury, heart failure, non-alcoholic fatty liver disease (NALFD), and non-alcoholic steatohepatitis (NASH).
- the disclosure includes a method of regulating glucose homeostasis or insulin action in a patient comprising administering a therapeutically effective amount of a compound or salt of Formula I to a patient in need thereof.
- the disclosure also includes a method of treating hyperlipidemia, glycemia, glucose tolerance, insulin sensitivity, adiposity, insulin resistance, obesity, or diabetes in a patient comprising administering a therapeutically effective amount of a compound of Formula I to the patient.
- additional therapeutically active compound refers to the use or administration of a compound for an additional therapeutic use for a particular injury, disease, or disorder being treated.
- a compound for example, could include one being used to treat an unrelated disease or disorder, or a disease or disorder which may not be responsive to the primary treatment for the injury, disease or disorder being treated.
- administering should be understood to mean providing a compound of the disclosure to a subject in need of treatment.
- An “agonist” is a composition of matter which, when administered to a mammal such as a human, enhances or extends a biological activity attributable to the level or presence of a target compound or molecule of interest in the subject.
- “Alleviating a disease or disorder symptom,” means reducing the severity of the symptom or the frequency with which such a symptom is experienced by a subject, or both.
- an “antagonist” is a composition of matter which when administered to a mammal such as a human, inhibits a biological activity attributable to the level or presence of a compound or molecule of interest in the subject.
- a “Compound of Formula I” as used herein, refers to any compound within the scope of Formula I and, unless the context indicates otherwise, includes the pharmaceutically acceptable salts of Formula I.
- delivery vehicle refers to any kind of device or material which can be used to deliver compounds in vivo or can be added to a composition comprising compounds administered to a plant or animal. This includes, but is not limited to, implantable devices, aggregates of cells, matrix materials, gels, etc.
- a “disease” is a state of health of an animal wherein the animal cannot maintain homeostasis, and wherein if the disease is not ameliorated then the animal's health continues to deteriorate.
- a “disorder” in an animal is a state of health in which the animal is able to maintain homeostasis, but in which the animal's state of health is less favorable than it would be in the absence of the disorder. Left untreated, a disorder does not necessarily cause a further decrease in the animal's state of health.
- an “effective amount” or “therapeutically effective amount” means an amount sufficient to produce a selected effect, such as alleviating symptoms of a disease or disorder.
- an effective amount of a combination of compounds refers collectively to the combination as a whole, although the actual amounts of each compound may vary.
- inhibitor refers to the ability of a compound of the disclosure to reduce or impede a described function, such as having inhibitory sodium channel activity. Preferably, inhibition is by at least 10%, more preferably by at least 25%, even more preferably by at least 50%, and most preferably, the function is inhibited by at least 75%.
- inhibitor reduce
- block are used interchangeably herein.
- injecting or applying includes administration of a compound of the disclosure by any number of routes and means including, but not limited to, topical, oral, buccal, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, vaginal, ophthalmic, pulmonary, or rectal means.
- an “instructional material” includes a publication, a recording, a diagram, or any other medium of expression which can be used to communicate the usefulness of compound of the disclosure in the kit for effecting alleviation of the various diseases or disorders recited herein.
- the instructional material may describe one or more methods of alleviating the diseases or disorders in a cell or a tissue of a mammal.
- the instructional material of the kit of the disclosure may, for example, be affixed to a container which contains the identified disclosure compound or be shipped together with a container which contains the identified compound.
- the instructional material may be shipped separately from the container with the intention that the instructional material and the compound be used cooperatively by the recipient.
- mitochondrial uncoupling also referred to as “uncoupling,” refers to the process whereby protons enter the mitochondrial matrix via a pathway independent of ATP synthase and thereby uncouple nutrient oxidation from ATP production. This process can be pharmacologically induced by small molecule mitochondrial protonophores, which directly shuttle protons across the mitochondrial inner membrane into the matrix.
- the primary pathway for energy production in aerobic cells involves the oxidation of nutrients (including fats, carbohydrates, and amino acids) in mitochondria, which promotes the efflux of protons out of the mitochondrial matrix. This process creates a pH and electrochemical gradient across the mitochondrial inner membrane.
- Protons normally re-enter the mitochondrial matrix via ATP synthase, which results in ATP production. Protons can also re-enter the mitochondrial matrix via pathways independent of ATP synthase, which ‘uncouples’ nutrient oxidation and proton efflux from ATP production.
- modulate means changing the level of an activity, function, or process.
- modulate encompasses both inhibiting and stimulating an activity, function, or process.
- parenteral administration of a pharmaceutical composition includes any route of administration characterized by physical breaching of a tissue of a subject and administration of the pharmaceutical composition through the breach in the tissue.
- Parenteral administration thus includes, but is not limited to, administration of a pharmaceutical composition by injection of the composition, by application of the composition through a surgical incision, by application of the composition through a tissue-penetrating non-surgical wound, and the like.
- parenteral administration is contemplated to include, but is not limited to, subcutaneous, intraperitoneal, intramuscular, intrasternal injection, and kidney dialytic infusion techniques.
- per application refers to administration of a compositions, drug, or compound to a subject.
- composition shall mean a composition comprising at least one active ingredient and a pharmaceutically acceptable carrier, such as a pharmaceutically acceptable excipient.
- a “pharmaceutically acceptable excipient” means an excipient that is useful in preparing a pharmaceutical composition/combination that is generally safe, non-toxic and neither biologically nor otherwise undesirable, and includes an excipient that is acceptable for veterinary use as well as human pharmaceutical use.
- the term also encompasses any of the inactive agents approved for use pharmaceutical compositions in by a regulatory agency of the US Federal government or listed in the US Pharmacopeia for use in animals, including humans.
- pharmaceutically acceptable carrier includes any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water, emulsions such as an oil/water or water/oil emulsion, and various types of wetting agents.
- the term also encompasses any of the agents approved by a regulatory agency of the US Federal government or listed in the US Pharmacopeia for use in animals, including humans.
- “Pharmaceutically acceptable” means physiologically tolerable, for either human or veterinary application.
- “pharmaceutical compositions” include formulations for human and veterinary use.
- “Plurality” means at least two.
- prevention means to stop something from happening or to significantly reduce the likelihood of something happening, such as by taking advance measures against something possible or probable outcome.
- prevention includes an action taken to decrease the chance of getting a disease or condition.
- a “preventive” or “prophylactic” treatment is a treatment administered to a subject who does not exhibit signs, or exhibits only early signs, of a disease or disorder.
- a prophylactic or preventative treatment is administered for the purpose of decreasing the risk of developing pathology associated with developing the disease or disorder.
- prodrug refers to an agent that is converted into the parent drug in vivo. Prodrugs are often useful because, in some situations, they may be easier to administer than the parent drug. They may, for instance, be bioavailable by oral administration whereas the parent is not. The prodrug may also have improved solubility in pharmaceutical compositions over the parent drug, or may demonstrate increased palatability or be easier to formulate.
- a “subject” of analysis, diagnosis, or treatment is an animal. Such animals include mammals, preferably a human. As used herein, a “subject in need thereof” is a patient, animal, mammal, or human, who will benefit from the method of this disclosure.
- symptom refers to any morbid phenomenon or departure from the normal in structure, function, or sensation, experienced by the patient and indicative of disease.
- a “sign” is objective evidence of disease. For example, a bloody nose is a sign. It is evident to the patient, doctor, nurse and other observers.
- a “therapeutic” treatment is a treatment administered to a subject who exhibits signs of pathology for the purpose of diminishing or eliminating those signs.
- a “therapeutically effective amount” of a compound is that amount of compound which is sufficient to provide a beneficial effect to the subject to which the compound is administered.
- treat includes treating, ameliorating, or inhibiting an injury or disease related condition or a symptom of an injury or disease related condition.
- the disease, injury or disease related condition or a symptom of an injury or disease related condition is prevented; while another embodiment provides prophylactic treatment of the injury or disease related condition or a symptom of an injury or disease related condition.
- Alkyl is a branched or straight chain saturated aliphatic hydrocarbon group, having the specified number of carbon atoms, generally from 1 to about 8 carbon atoms.
- the term C 1 -C 6 alkyl as used herein indicates an alkyl group having from 1, 2, 3, 4, 5, or 6 carbon atoms.
- Other embodiments include alkyl groups having from 1 to 6 carbon atoms, 1 to 4 carbon atoms or 1 or 2 carbon atoms, e.g. C 1 -C 8 alkyl, C 1 -C 4 -alkyl, and C 1 -C 2 -alkyl.
- alkyl examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, 3-methylbutyl, t-butyl, n-pentyl, sec-pentyl, heptyl, and octyl.
- C 0 -C n alkyl is used together with another group, e.g.
- Alkenyl is a branched or straight chain aliphatic hydrocarbon group having one or more double carbon-carbon bonds that may occur at any stable point along the chain, having the specified number of carbon atoms.
- alkenyl include, but are not limited to, ethenyl, propenyl, 1, 3-butadienyl, 1-butenyl, hexenyl, and pentenyl.
- Alkynyl is a branched or straight chain aliphatic hydrocarbon group having one or more triple carbon-carbon bonds that may occur at any stable point along the chain, having the specified number of carbon atoms.
- alkynyl include, but are not limited to, ethynyl, propynyl, 1-butynyl, 2-butynyl, and 1-pentynyl.
- Alkanoyl is an alkyl group as defined above covalently bound to the group it substitutes by an carbonyl bridge (—C( ⁇ O)—). The carbonyl oxygen is included in the count of carbons in the substituted group.
- a C 2 alkanoyl is —C( ⁇ O)CH 3 .
- Alkoxy is an alkyl group as defined above with the indicated number of carbon atoms covalently bound to the group it substitutes by an oxygen bridge (—O—).
- alkoxy include, but are not limited to, methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, 2-butoxy, t-butoxy, n-pentoxy, 2-pentoxy, 3-pentoxy, isopentoxy, neopentoxy, n-hexoxy, 2-hexoxy, 3-hexoxy, and 3-methylpentoxy.
- Alkylamino is an alkyl group as defined herein covalently bound to the group it substitutes by an amino linkage.
- An alkylamino group can be a mono-alkyl group in which the amino is a secondary amino (alkylNH—) or a di-alkyl group in which the amino is a tertiary amino (alkyll)(alkyl2)N—.
- the alkyl groups of a di-alkylamino are the same or different.
- Alkylester is an alkyl group as defined herein covalently bound to the group it substitutes by an ester linkage.
- the ester linkage may be in either orientation, e.g., a group of the formula —OC(O)-alkyl or a group of the formula —C(O)O-alkyl.
- Aryl indicates a mono-, bi- or tri-cyclic ring system having at least one aromatic ring.
- Aryl groups contain only carbon in the aromatic ring or rings.
- An aryl group may be fused to a non aromatic ring containing N, O, or S heteroatoms.
- Typical aryl groups contain 1 to 3 separate, fused, or pendant rings and from 6 to about 18 ring atoms, without heteroatoms as ring members. When indicated, such aryl groups may be further substituted with carbon or non-carbon atoms or groups.
- Example include phenyl, naphthyl, bi-phenyl, tetrahydronaphthyl, indanyl, and indenyl group.
- Cycloalkyl is a saturated hydrocarbon ring group, having the specified number of carbon atoms.
- Monocyclic cycloalkyl groups typically have from 3 to about 8 carbon ring atoms, from 3 to 7 ring atoms, or from 3 to 6 (3, 4, 5, or 6) carbon ring atoms.
- Cycloalkyl substituents may be pendant from a substituted nitrogen, oxygen, or carbon atom, or a substituted carbon atom that may have two substituents may have a cycloalkyl group, which is attached as a spiro group.
- Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
- a “bridged cycloalkyl” is a cycloalkyl group that has two or more rings containing only carbon ring atoms, and one of the carbon rings contains a “bridge” of 1 carbon atom or 2-3 unbranched carbon atoms connected to two “bridgehead” atoms in the carbon ring.
- the bridgehead atoms are usually non-adjacent carbon ring atoms.
- Examples of bridge cycloalkyl groups include, but are not limited to, bicyclo[2.2.2]octanyl, bicyclo[3.3.1]nonanyl, adamantanyl, and bicyclo[3.3.3]undecanyl groups.
- Halogen or “halo” includes bromo, chloro, fluoro, and iodo.
- Haloalkyl indicates both branched and straight-chain alkyl groups having the specified number of carbon atoms, substituted with 1 or more halogen atoms, up to the maximum allowable number of halogen atoms.
- haloalkyl include, but are not limited to, trifluoromethyl, difluoromethyl, 2-fluoroethyl, 2,2,2-trifluoroethyl, and penta-fluoroethyl.
- Haloalkoxy indicates a haloalkyl group as defined herein attached through an oxygen bridge (oxygen of an alcohol radical).
- Halulfanyl is a sulfur substituted with one or more halogen atoms, up to the maximum allowable number of halogen atoms.
- Heteroaryl is a ring or ring system having at least one aromatic ring containing a heteroatom independently chosen from N, O, and S with remaining ring atoms being carbon. Fused rings may or may not contain heteroatoms and need not be aromatic. It is preferred that the total number of heteroatoms in a heteroaryl ring system is not more than 4 and that the total number of S and O atoms in a heteroaryl ring system is not more than 2. Monocyclic heteroaryl groups typically have from 5 to 7 ring atoms.
- bicyclic heteroaryl groups are 9- to 10-membered heteroaryl groups, that is, groups containing 9 or 10 ring atoms in which one 5- to 7-member aromatic ring is fused to a second aromatic or non-aromatic ring.
- the total number of S and O atoms in an aromatic ring of the heteroaryl group exceeds 1, these heteroatoms are not adjacent to one another.
- heteroaryl groups include, but are not limited to, oxazolyl, pyranyl, pyrazinyl, pyrazolopyrimidinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, quinolinyl, tetrazolyl, thiazolyl, thienylpyrazolyl, thiophenyl, triazolyl, benzo[d]oxazolyl, benzofuranyl, benzothiazolyl, benzothiophenyl, benzoxadiazolyl, dihydrobenzodioxynyl, furanyl, imidazolyl, indolyl, and isoxazolyl.
- Heterocycloalkyl is a saturated cyclic group containing 1 or more ring atoms independently chosen from N, O, and S with remaining ring atoms being carbon.
- heterocycloalkyls include tetrahydropyranyl, tetrahydrofuranyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, oxazolidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, thiazolidinyl, and pyrrolidinyl.
- “Pharmaceutically acceptable salts” includes derivatives of the disclosed compounds in which the parent compound is modified by making inorganic and organic, non-toxic, acid or base addition salts thereof.
- the salts of the present compounds can be synthesized from a parent compound that contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting free acid forms of these compounds with a stoichiometric amount of the appropriate base (such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate, or the like), or by reacting free base forms of these compounds with a stoichiometric amount of the appropriate acid.
- Alkali metal (for example, sodium, potassium or lithium) or alkaline earth metal (for example calcium) salts of organic (e.g., carboxylic) acids can also be made.
- Such reactions are typically carried out in water or in an organic solvent, or in a mixture of the two.
- Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines or nitrogen-containing heteroaryl rings (e.g. pyridine, quinoline, isoquinoline); alkali or organic salts of acidic residues such as carboxylic acids; and the like.
- the pharmaceutically acceptable salts include the conventional non-toxic salts and the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
- conventional non-toxic acid salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, malonic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, mesylic, esylic, besylic, sulfanilic, 2-acetoxybenzoic, fumaric, succinic, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, ⁇ -ketoglutarate, ⁇ -glycerophosphate, isethionic, HO 2 C—(CH 2 ) n —CO 2 H where n is 0-4, and the like.
- Salts derived from inorganic bases include by way of example only, sodium, potassium, lithium, ammonium, calcium and magnesium salts.
- Salts derived from organic bases include, but are not limited to, salts of primary, secondary and tertiary amines, such as alkyl amines, dialkyl amines, trialkyl amines, substituted alkyl amines, di(substituted alkyl) amines, tri(substituted alkyl) amines, alkenyl amines, dialkenyl amines, trialkenyl amines, substituted alkenyl amines, di(substituted alkenyl) amines, tri(substituted alkenyl) amines, cycloalkyl amines, di(cycloalkyl) amines, tri(cycloalkyl) amines, substituted cycloalkyl amines, disubstituted cycloalkyl amine,
- amines where the two or three substituents, together with the amino nitrogen, form a heterocyclic or heteroaryl group.
- suitable amines include, by way of example only, isopropylamine, trimethyl amine, diethyl amine, tri(iso-propyl) amine, tri(n-propyl) amine, ethanolamine, 2-dimethylaminoethanol, tromethamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, Nalkylglucamines, theobromine, purines, piperazine, piperidine, morpholine, Nethylpiperidine, and the like.
- carboxylic acid derivatives would be useful in the practice of this disclosure, for example, carboxylic acid amides, including carboxamides, lower alkyl carboxamides, dialkyl carboxamides, and the like.
- substituted means that any one or more hydrogens on the designated atom or group is replaced with a selection from the indicated group, provided that the designated atom's normal valence is not exceeded. Unless otherwise specified, each substituent is selected independently of other substituents. “Optionally substituted” means that 0 to the maximum allowable number of substituents are present. When the substituent is oxo (i.e., ⁇ O) then 2 hydrogens on the atom are replaced. When an oxo group substitutes a heteroaromatic moiety, the resulting molecule can sometimes adopt tautomeric forms.
- a pyridyl group substituted by oxo at the 2- or 4-position can sometimes be written as a pyridine or hydroxypyridine.
- Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds or useful synthetic intermediates.
- a stable compound or stable structure is meant to imply a compound that is sufficiently robust to survive isolation from a reaction mixture and subsequent formulation into an effective therapeutic agent.
- substituents are named into the core structure.
- aminoalkyl means the point of attachment of this substituent to the core structure is in the alkyl portion and alkylamino means the point of attachment is a bond to the nitrogen of the amino group.
- a dash indicates a point of attachment for a substituent.
- —C 1 -C 4 alkyl(cycloalkyl) is attached at the 1 to 4 carbon alkylene linker.
- Certain compounds of the disclosure may contain one or more asymmetric elements such as stereogenic centers, stereogenic axes and the like, e.g. asymmetric carbon atoms, so that the compounds can exist in different stereoisomeric forms.
- asymmetric elements such as stereogenic centers, stereogenic axes and the like, e.g. asymmetric carbon atoms, so that the compounds can exist in different stereoisomeric forms.
- These compounds can be, for example, racemates or optically active forms.
- these compounds with two or more asymmetric elements these compounds can additionally be mixtures of diastereomers.
- optical isomers and mixtures thereof are encompassed.
- single enantiomers i.e., optically active forms, can be obtained by asymmetric synthesis, synthesis from optically pure precursors, or by resolution of the racemates.
- Racemates can also be accomplished, for example, by conventional methods such as crystallization in the presence of a resolving agent, or chromatography, using, for example using a chiral HPLC column.
- compounds with carbon-carbon double bonds may occur in Z- and E-forms, with all isomeric forms of the compounds being included in the present disclosure.
- the disclosure includes deuterated compounds of Formula A and Formula I in which any hydrogen is replaced by a deuterium.
- “Deuterated” mean that a hydrogen at the specified position is replaced by deuterium.
- some discrete molecules of the compound of Formula I will likely have hydrogen, rather than deuterium, at the specified position. However the percent of molecules of the compound of Formula I in the sample which have deuterium at the specified position will be much greater than would naturally occur.
- the deuterium at the deuterated position is enriched.
- the term “enriched” as used herein, refers to the percentage of deuterium versus other hydrogen species at that location.
- deuterated compounds of Formula I will have at least 10% deuterium enrichment at any deuterated position. In other embodiments, there will be at least 50%, at least 90%, or at least 95% deuterium enrichment at the specified deuterated position or positions.
- a “deuterated substituent” is a substituent in which at least one hydrogen is replaced by deuterium at the specified percent enrichment. “Optionally deuterated” means that the position may be at either hydrogen and the amount of deuterium at the position is only the naturally occurring level of deuterium or the position is enriched with deuterium above the naturally occurring deuterium level.
- the disclosure is not limited to any one of the specific tautomers, but rather includes all tautomeric forms.
- the compounds of the disclosure may exist in tautomeric forms, both mixtures and separate individual tautomers are included. For example
- variables e. g., R 1 , R 2 , R 3 , R 4 , R 5 , X 1 , X 2 , or Z in in Formula I or any of Formula I-A, I-B, I-C, or I-D may carry any of the definitions set forth in the SUMMARY section, or may carry any of the values set forth below.
- Formula I also includes subformulae (such as Formula I-A, I-B, I-C, and I-D) in which the variables carry any of the following definitions. Any of the variable definitions below can be combined so long as a stable compound results.
- Z can be absent and X 1 and X 2 can both be nitrogen.
- Z can be absent and one of X 1 and X 2 can be nitrogen and while the other is carbon.
- R 1 may carry the following definitions.
- R 1 is hydrogen or unsubstituted C 1 -C 6 alkyl.
- R 1 is hydrogen
- R 2 may carry the following definitions.
- R 2 is C 1 -C 12 alkyl, C 2 -C 8 alkenyl, or C 2 -C 8 alkynyl; in each C 0 -C 4 alkyl, C 1 -C 8 alkyl, C 2 -C 8 alkenyl, or C 2 -C 8 alkynyl one or more carbon atoms is optionally replaced by O, NR 10 , —C(O)—, —C(O)O—, —OC(O), —S(O)n-, —C(O)NR 10 —, or —NR 10 C(O)— where n is 0, 1, or 2, and in which the C 0 -C 4 alkyl, C 1 -C 8 alkyl, C 2 -C 8 alkenyl, or C 2 -C 8 alkynyl is optionally substituted with one or more substituents R 13 .
- R 2 is C 8 -C 12 alkyl, optionally substituted with one or more substituents independently chosen from halogen, hydroxyl, amino, nitro, cyano, and oxo.
- R 2 is —C 0 -C 4 alkyl(C 3 -C 7 cycloalkyl), —C 0 -C 4 alkyl(bridged C 7 -C 12 cycloalkyl), —C 0 -C 4 alkyl(aryl), —C 0 -C 4 alkyl(mono- or bi-cyclic heteroaryl), or —C 0 -C 4 alkyl(4- to 7-membered heterocycloalkyl), each of which is optionally substituted with one or more substituents independently chosen from R 11 and 0 or 1 substituents R 12 ; in each C 0 -C 4 alkyl or more carbon atoms is optionally replaced by O, NR 10 , —C(O)—, —C(O)O—, —OC(O), —S(O)n-, —C(O)NR 10 —, or —NR 10 C(O)— where n is 0, 1, or 2,
- R 2 is —C 0 -C 4 alkyl(bridged C 7 -C 12 cycloalkyl) or —C 0 -C 4 alkyl(aryl), each of which is optionally substituted with one or more substituents independently chosen from R 11 and 0 or 1 substituents R 12 ; in C 0 -C 4 alkyl one or more carbon atoms is optionally replaced by O, NR 10 , —C(O)—, —C(O)O—, —OC(O), —S(O)n-, —C(O)NR 10 —, or —NR 10 C(O)— where n is 0, 1, or 2, and in which the C 0 -C 4 alkyl is optionally substituted by R 13 .
- R 2 is C 0 -C 2 alkyl(bridged C 7 -C 12 cycloalkyl), which is optionally substituted with one or more substituents independently chosen from R 11 .
- R 2 is adamantan-1-yl or —CH 2 (adamantan-1-yl), each of which is unsubstituted or substituted with halogen, hydroxyl, amino, nitro, cyano, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, —C 0 -C 2 alkyl(mono- or di-C 1 -C 4 alkylamino), C 1 -C 2 haloalkyl, and C 1 -C 2 haloalkoxy.
- R 2 is —C 0 -C 4 alkyl(phenyl), naphthyl, benzo[d][1,3]dioxolyl, or fluorenyl, each of which is optionally substituted with one or more substituents independently chosen from R 11 and 0 or 1 substituents R 12 ; in C 0 -C 4 alkyl one or more carbon atoms is optionally replaced by O, NR 10 , —C(O)—, —C(O)O—, —OC(O), —S(O)n-, —C(O)NR 10 —, —S(O)nNR 10 , —NR 10 S(O)n-, —NR 10 C(O)NR 10 , or —NR 10 C(O)— where n is 0, 1, or 2, and in which the C 0 -C 4 alkyl is optionally substituted by R 13 .
- R 2 is phenyl, which is optionally substituted by one or more substituents independently chosen from R 11 .
- R 2 is phenyl, which is substituted with one or more substituents independently chosen from halogen, hydroxyl, C 1 -C 10 alkyl, C 1 -C 6 alkoxy, C 1 -C 2 haloalkyl, and C 1 -C 2 haloalkoxy.
- R 2 is phenyl, which is optionally substituted by one or more substituents independently chosen from halogen, hydroxyl, amino, nitro, cyano, oxo, halosulfanyl, and C 1 -C 8 alkyl, C 2 -C 8 alkenyl, and C 2 -C 8 alkynyl, wherein in each C 1 -C 8 alkyl, C 2 -C 8 alkenyl, and C 2 -C 8 alkynyl, in the definition of R 11 one or more carbon atoms is optionally replaced by O, NR 10 , —C(O)O—, —OC(O), or —S(O)n-, where n is 0, 1, or 2, and in which each C 1 -C 8 alkyl, C 2 -C 8 alkenyl, or C 2 -C 8 alkynyl is optionally substituted with one or more substituents R 13 .
- substituents independently chosen from halogen, hydroxyl, amino
- R 2 is —C 0 -C 4 alkyl(phenyl), which is optionally substituted with one or more substituents independently chosen from R 11 and 1 substituent R 12 ; in C 0 -C 4 alkyl one or more carbon atoms is optionally replaced by O, NR 10 , —C(O)—, —C(O)O—, —OC(O), —S(O)n-, —C(O)NR 10 —, or —NR 10 C(O)— where n is 0, 1, or 2, and in which the C 0 -C 4 alkyl is optionally substituted by R 13 , where R 12 is selected from —C 0 -C 4 alkyl(C 3 -C 7 cycloalkyl), —O—C 0 -C 4 alkyl(C 3 -C 7 cycloalkyl), —C 0 -C 4 alkyl(phenyl), —O—C 0 -C 4 alkyl(phen
- R 2 is phenyl, which is substituted with one substituent R 12 ; and R 12 is phenyl which is optionally substituted with one or more substituents independently chosen from halogen, hydroxyl, amino, nitro, cyano, —CHO, —COOH, oxo, C 1 -C 2 haloalkyl, C 1 -C 2 haloalkoxy, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylester, —C 0 -C 4 alkyl(mono- or di-C 1 -C 6 alkylamino), C 2 -C 6 alkanoyl, C 2 -C 6 alkenyl, and C 2 -C 6 alkynyl.
- substituents independently chosen from halogen, hydroxyl, amino, nitro, cyano, —CHO, —COOH, oxo, C 1 -C 2 haloalkyl, C 1
- R 3 may carry the following definitions.
- R 3 is hydrogen
- R 3 is C 1 -C 8 alkyl, C 2 -C 8 alkenyl, or C 2 -C 8 alkynyl,
- C 1 -C 8 alkyl In C 1 -C 8 alkyl, C 2 -C 8 alkenyl, or C 2 -C 8 alkynyl one or more carbon atoms is optionally replaced by O, NR 10 , C(O)O—, —OC(O), or —S(O)n-, where n is 0, 1, or 2, and in which the C 1 -C 8 alkyl, C 2 -C 8 alkenyl, or C 2 -C 8 alkynyl is optionally substituted with one or more substituents R 13 .
- R 3 is C 1 -C 6 alkyl.
- R 3 is C 1 -C 6 alkyl optionally substituted with hydroxyl.
- R 3 is —C 0 -C 4 alkyl(C 3 -C 7 cycloalkyl) or —C 0 -C 4 alkyl(aryl), which is optionally substituted with one or more independently chosen R 11 substituents.
- R 4 and R 5 can carry any of the following definitions
- R 4 and R 5 are both hydrogen.
- R 4 and R 5 is hydrogen, and the other is chosen from halogen, hydroxyl, CY C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 2 haloalkyl, and C 1 -C 2 haloalkoxy.
- the disclosure also includes compounds of Formula I (or Formula I-A, I-B, I-C, or I-D) and pharmaceutically acceptable salts thereof, in which the variables have the following definitions.
- R 1 is hydrogen or C 1 -C 4 alkyl.
- R 2 is C 8 -C 12 alkyl; or R 2 is phenyl, which is substituted with one or more substituents independently chosen from halogen, hydroxyl, C 1 -C 10 alkyl, C 1 -C 6 alkoxy, C 1 -C 2 haloalkyl, and CY C 2 haloalkoxy, or
- R 2 is phenyl, which is substituted with one substituent R 12 ; where R 12 is phenyl which is optionally substituted with one or more substituents independently chosen from halogen, hydroxyl, amino, nitro, cyano, —CHO, —COOH, oxo, C 1 -C 2 haloalkyl, C 1 -C 2 haloalkoxy, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, CY C 6 alkylester, —C 0 -C 4 alkyl(mono- or di-C 1 -C 6 alkylamino), C 2 -C 6 alkanoyl, C 2 -C 6 alkenyl, and C 2 -C 6 alkynyl.
- R 12 is phenyl which is optionally substituted with one or more substituents independently chosen from halogen, hydroxyl, amino, nitro, cyano, —CHO, —COOH, oxo, C
- R 3 is H or C 1 -C 6 alkyl.
- R 4 and R 5 are both hydrogen or one of R 4 and R 5 is hydrogen, and the other is chosen from halogen, hydroxyl, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 2 haloalkyl, and C 1 -C 2 haloalkoxy.
- X 1 and X 2 are both N and Z is absent.
- Processes for preparing compounds of a formula of the disclosure or for preparing intermediates useful for preparing compounds of Formula I or other formulas of the disclosure are provided as further embodiments.
- Intermediates useful for preparing compounds of Formula I or other formulas are also provided as further embodiments of the disclosure.
- the disclosure includes a pharmaceutical composition comprising a compound or salt thereof of the disclosure, together with a pharmaceutically acceptable excipient.
- compositions comprising compounds of the Formula I.
- the pharmaceutical composition may comprise one or more compounds of the disclosure and pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier.
- the compounds are administered as a pharmaceutical composition.
- the route of administration can vary depending on the type of compound being administered.
- the compounds are administered via routes such as oral, topical, rectal, intramuscular, intramucosal, intranasal, inhalation, ophthalmic, and intravenous.
- the present disclosure further provides for administration of a compound of Formula I as an immediate release or as a controlled-release formulation.
- the dosage of the active compound(s) being administered will depend on the condition being treated, the particular compound, and other clinical factors such as age, sex, weight, and health of the subject being treated, the route of administration of the compound(s), and the type of composition being administered (tablet, gel cap, capsule, solution, suspension, inhaler, aerosol, elixir, lozenge, injection, patch, ointment, cream, etc.). It is to be understood that the present disclosure has application for both human and veterinary use.
- Processes for preparing compounds of any of the formulas of the disclosure or for preparing intermediates useful for preparing compounds of any of the formulas of the disclosure are provided as further embodiments.
- Intermediates useful for preparing compounds of Formula I are also provided as further embodiments of the disclosure.
- compounds of the disclosure may be systemically administered, e.g., orally, in combination with a pharmaceutically acceptable carrier such as an inert diluent or an assimilable edible carrier. They may be enclosed in hard or soft shell gelatin capsules, may be compressed into tablets, or may be incorporated directly with the food of the patient's diet.
- a pharmaceutically acceptable carrier such as an inert diluent or an assimilable edible carrier.
- the active compound may be combined with one or more excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like.
- Such compositions and preparations should contain at least 0.1% of active compound.
- the percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 2 to about 60% of the weight of a given unit dosage form. The amount of active compound in such therapeutically useful compositions is such that an effective dosage level will be obtained.
- the tablets, troches, pills, capsules, and the like may also contain the following: binders such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, fructose, lactose or aspartame or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring may be added.
- a liquid carrier such as a vegetable oil or a polyethylene glycol.
- any material used in preparing any unit dosage form should be pharmaceutically acceptable and substantially non-toxic in the amounts employed.
- the active compound may be incorporated into sustained-release preparations and devices.
- the active compound may also be administered intravenously or intraperitoneally by infusion or injection.
- Solutions of the active compound or its salts can be prepared in water, optionally mixed with a nontoxic surfactant.
- Dispersions can also be prepared in glycerol, liquid polyethylene glycols, triacetin, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
- the pharmaceutical dosage forms suitable for injection or infusion can include sterile aqueous solutions or dispersions or sterile powders comprising the active ingredient which are adapted for the extemporaneous preparation of sterile injectable or infusible solutions or dispersions, optionally encapsulated in liposomes.
- the ultimate dosage form should be sterile, fluid and stable under the conditions of manufacture and storage.
- the liquid carrier or vehicle can be a solvent or liquid dispersion medium comprising, for example, water, ethanol, a polyol (for example, glycerol, propylene glycol, liquid polyethylene glycols, and the like), vegetable oils, nontoxic glyceryl esters, and suitable mixtures thereof.
- the proper fluidity can be maintained, for example, by the formation of liposomes, by the maintenance of the required particle size in the case of dispersions or by the use of surfactants.
- the prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, buffers or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate, and gelatin.
- Sterile injectable solutions are prepared by incorporating the active compound in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filter sterilization.
- the preferred methods of preparation are vacuum drying and the freeze-drying techniques, which yield a powder of the active ingredient plus any additional desired ingredient present in the previously sterile-filtered solutions.
- the present compounds may be applied in pure form, i.e., when they are liquids. However, it will generally be desirable to administer them to the skin as compositions or formulations, in combination with a dermatologically acceptable carrier, which may be a solid or a liquid.
- Useful solid carriers include finely divided solids such as talc, clay, microcrystalline cellulose, silica, alumina and the like.
- Useful liquid carriers include water, alcohols or glycols or water-alcohol/glycol blends, in which the present compounds can be dissolved or dispersed at effective levels, optionally with the aid of non-toxic surfactants.
- Adjuvants such as fragrances and additional antimicrobial agents can be added to optimize the properties for a given use.
- the resultant liquid compositions can be applied from absorbent pads, used to impregnate bandages and other dressings, or sprayed onto the affected area using pump-type or aerosol sprayers.
- Thickeners such as synthetic polymers, fatty acids, fatty acid salts and esters, fatty alcohols, modified celluloses or modified mineral materials can also be employed with liquid carriers to form spreadable pastes, gels, ointments, soaps, and the like, for application directly to the skin of the user.
- useful dermatological compositions which can be used to deliver the compounds of Formula I to the skin are known to the art; for example, see Jacquet et al. (U.S. Pat. No. 4,608,392), Geria (U.S. Pat. No. 4,992,478), Smith et al. (U.S. Pat. No. 4,559,157) and Wortzman (U.S. Pat. No. 4,820,508).
- Useful dosages of the compounds of the disclosure can be determined by comparing their in vitro activity, and in vivo activity in animal models. Methods for the extrapolation of effective dosages in mice, and other animals, to humans are known to the art; for example, see U.S. Pat. No. 4,938,949.
- the concentration of the compound(s) of the disclosure in a liquid composition will be from about 0.1-25 wt-%, preferably from about 0.5-10 wt-%.
- concentration in a semi-solid or solid composition such as a gel or a powder will be about 0.1-5 wt-%, preferably about 0.5-2.5 wt-%.
- the amount of the compound, or an active salt or derivative thereof, required for use in treatment will vary not only with the particular salt selected but also with the route of administration, the nature of the condition being treated and the age and condition of the patient and will be ultimately at the discretion of the attendant physician or clinician.
- a dosage of between approximately 0.1 and 300 mg/kg/day, or between approximately 0.5 and 50 mg/kg/day, or between approximately 1 and 10 mg/kg/day is generally sufficient, but will vary depending on such things as the disorder being treated, the length of treatment, the age, sex, weight, and/or health of the subject, etc.
- a unit dose is used.
- the unit dose is supplied in a syringe.
- the combinations of drugs can be administered in formulations that contain all drugs being used, or the drugs can be administered separately. In some cases, it is anticipated that multiple doses/times of administration will be required or useful.
- at least two compounds will be used. In one aspect, at least three compounds will be administered. The present disclosure further provides for varying the length of time of treatment.
- a suitable dose will be in the range of from about 0.5 to about 100 mg/kg, e.g., from about 10 to about 75 mg/kg of body weight per day, such as 3 to about 50 mg per kilogram body weight of the recipient per day, preferably in the range of 6 to 90 mg/kg/day, most preferably in the range of 15 to 60 mg/kg/day.
- the compound is conveniently administered in unit dosage form; for example, containing 5 to 1000 mg, conveniently 10 to 750 mg, most conveniently, 50 to 500 mg of active ingredient per unit dosage form.
- the active ingredient when the active ingredient needs to enter circulation and be delivered via blood, the active ingredient, in one embodiment, should be administered to achieve peak plasma concentrations of the active compound of from about 0.5 to about 75 ⁇ M, preferably, about 1 to 50 ⁇ M, most preferably, about 2 to about 30 ⁇ M. This may be achieved, for example, by the intravenous injection of a 0.05 to 5% solution of the active ingredient, optionally in saline, or orally administered as a bolus containing about 1-100 mg of the active ingredient. Desirable blood levels may be maintained by continuous infusion to provide about 0.01-5.0 mg/kg/hr or by intermittent infusions containing about 0.4-15 mg/kg of the active ingredient(s).
- the desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example, as two, three, four or more sub-doses per day.
- the sub-dose itself may be further divided, e.g., into a number of discrete loosely spaced administrations; such as multiple inhalations from an insufflator or by application of a plurality of drops into the eye.
- compositions of the disclosure can further comprise additional therapeutic additives, alone or in combination (e.g., 2, 3, or 4 additional additives).
- additional additives include but are not limited to: (a) antimicrobials, (b) steroids (e.g., hydrocortisone, triamcinolone); (c) pain medications (e.g., aspirin, an NSAID, and a local anesthetic); (d) anti-inflammatory agents; and (e) combinations thereof.
- additional additives include but are not limited to: (a) antimicrobials, (b) steroids (e.g., hydrocortisone, triamcinolone); (c) pain medications (e.g., aspirin, an NSAID, and a local anesthetic); (d) anti-inflammatory agents; and (e) combinations thereof.
- Non-synthetic matrix proteins like collagen, glycosaminoglycans, and hyaluronic acid, which are enzymatically digested in the body, are useful for delivery (
- implantable media and devices can be used for delivery of the compounds of the disclosure in vivo. These include, but are not limited to, sponges, such as those from Integra, fibrin gels, scaffolds formed from sintered microspheres of polylactic acid glycolic acid copolymers (PLAGA), and nanofibers formed from native collagen, as well as other proteins.
- the compounds of the present disclosure can be further combined with growth factors, nutrient factors, pharmaceuticals, calcium-containing compounds, anti-inflammatory agents, antimicrobial agents, or any other substance capable of expediting or facilitating bone or tissue growth, stability, and remodeling.
- compositions of this disclosure can also be combined with inorganic fillers or particles.
- inorganic fillers or particles can be selected from hydroxyapatite, tri-calcium phosphate, ceramic glass, amorphous calcium phosphate, porous ceramic particles or powders, mesh titanium or titanium alloy, or particulate titanium or titanium alloy.
- antimicrobial agents examples include, but are not limited to, isoniazid, ethambutol, pyrazinamide, streptomycin, clofazimine, rifabutin, fluoroquinolones, ofloxacin, sparfloxacin, rifampin, azithromycin, clarithromycin, dapsone, tetracycline, erythromycin, cikprofloxacin, doxycycline, ampicillin, amphotericine B, ketoconazole, fluconazole, pyrimethamine, sulfadiazine, clindamycin, lincomycin, pentamidine, atovaquone, paromomycin, diclarazaril, acyclovir, trifluorouridine, foscarnet, penicillin, gentamicin, ganciclovir, iatroconazole, miconazole, Zn-pyrithione, and silver salts, such
- the compounds of the disclosure can first be encapsulated into microcapsules, microspheres, microparticles, microfibers, reinforcing fibers and the like to facilitate mixing and achieving controlled, extended, delayed and/or sustained release and combined other agents or drugs. Encapsulating the biologically active agent can also protect the agent against degradation during formation of the composite of the disclosure.
- the compound is controllably released into a subject when the composition of the disclosure is implanted into a subject, due to bioresorption relying on the time scale resulting from cellular remodeling.
- the composition may be used to replace an area of discontinuity in the tissue.
- the area of discontinuity can be the result of trauma, a disease, disorder, or condition, surgery, injury, etc.
- an “instructional material” includes a publication, a recording, a diagram, or any other medium of expression which can be used to communicate the usefulness of the composition of the disclosure for its designated use.
- the instructional material of the kit of the disclosure may, for example, be affixed to a container which contains the composition or be shipped together with a container which contains the composition. Alternatively, the instructional material may be shipped separately from the container with the intention that the instructional material and the composition be used cooperatively by the recipient.
- the method of the disclosure includes a kit comprising a compound identified in the disclosure and an instructional material which describes administering the compound or a composition comprising the compound to a subject.
- a kit comprising a (preferably sterile) solvent suitable for dissolving or suspending the composition of the disclosure prior to administering the compound to a subject.
- the subject is a human.
- the compounds of the disclosure, including are useful for treating and preventing these diseases and disorders and others described herein, as well as others where a mitochondrial uncoupler is useful.
- DNP mitochondrial uncoupler 2,4-dinitrophenol
- anti-diabetes drugs including agonists of thyroid hormone and inhibitors of 11- ⁇ hydroxysteroid dehydrogenase type 1 have off-target effects of increased energy expenditure that may mediate some of the protective effects of these compounds. Nevertheless, there are no drugs have been specifically targeted for increased energy expenditure.
- a compound of the disclosure is useful for treating disease, disorders, and conditions which are associated with defects in mitochondrial function or which can be treated with drugs or agents that act as uncoupling agents.
- the methods can comprise administering to a subject in need thereof a pharmaceutical composition comprising an effective amount of compound of Formula I, or a salt thereof as a first therapeutic agent, together with a pharmaceutically acceptable carrier, and optionally with at least one additional therapeutic agent.
- the present disclosure provides compositions and methods for increasing oxygen consumption, decreasing cellular reactive oxygen species, depolarizing a mitochondrial inner membrane, and increasing oxygen consumption rate without donating electrons to the electron transport chain using a mitochondrial uncoupler, said method comprising contacting a cell or mitochondria with a composition comprising at least one compound of the disclosure and optionally an additional therapeutic agent.
- the mitochondrial uncoupling agents of this disclosure both prevent and reverse body fat mass increases in mice fed a high fat and high sugar Western diet. Apart from body fat, the mitochondrial uncoupling agents decrease insulin levels, which is important because it corrects hyperinsulinemia, improves glucose tolerance, and protect against diet-induced glucose tolerance. It is also disclosed herein that administration of the mitochondrial uncoupling agents reverses insulin resistance, including diet-induced insulin resistance, and restores insulin sensitivity index. Therefore, the compounds of the disclosure are useful for preventing and treating diabetes. It is also disclosed that compounds of the disclosure decrease liver fat, thus providing a treatment for fatty liver disease. It is disclosed herein that a compound of the disclosure can prevent weight gain without altering food intake and can prevent di-t-induced fat accumulation. Compounds of the disclosure are also useful for reversing diet-induced weight or fat gain and can reverse diet-induced fat gain and fatty liver.
- Mitochondrial uncoupling decreases the production of reactive oxygen species, potentially lowering the risk of cancer, decreasing the effects of aging, and increasing lifespan. Mitochondrial uncouplers reverse or interfere with many aspects of cancer metabolism and are therefore effective in a broad range of cancer types.
- mitochondrial uncouplers are effective in treatment of cancers with impaired p53 expression or activity (https://www.nature.com/articles/s41467-018-05805-11 such as certain breast and ovarian cancers, Ras mutant cancers (https://www.cell.com/molecular-cell/pdf/S1097-2765(15)00004-0.pdf), and/or beta-catenin mutant cancers (https://www.ncbi.nlm.nih.gov/pubmed/28107588′).
- Mitochondrial uncouplers are demonstrated to treat adrenocortical carcinoma (http://clincancerres.aacriournals.org/content/clincanres/early/2017/02/12/1078-0432.CCR-15-2256.full.pdf) melanoma (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833689/), primary colon cancer (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6056247/) and metastasis to distant organs including the liver (https://www.nature.com/articles/s41419-017-0092-6′).
- a compound of the disclosure may exhibit at least one of the following properties or activities: energy expenditure agonist, mitochondrial uncoupler, antioxidant, increases oxygen consumption, depolarizes the mitochondrial inner membrane, stimulates respiration in isolated mitochondria, increases or stimulates oxygen consumption without donating electrons to the electron transport chain, lacks protonophore activity at the plasma membrane, decreases reperfusion-induced mitochondrial oxidative stress, decreases cellular reactive oxygen species, improves glucose tolerance, provides protection from high fat induce glucose tolerance, activates AMPK without depletion of ATP, prevents, reverses or treats insulin resistance, prevents, reverses or treats hyperinsulinemia, prevents, reverses or treats hyperlipidemia, improves blood lipid profiles, improves leanness, improves insulin sensitivity, protects from ischemic-reperfusion injury, and is less toxic than other mitochondrial inhibitors.
- a compound of the disclosure has two or more of these properties. In one embodiment, a compound of the disclosure has three or more of these properties. In one embodiment, a compound of the disclosure has four, five, six, seven, eight, nine, ten, eleven, twelve, or more of these properties. In one embodiment, a compound of the disclosure has one, two, three, four, five, six, seven, eight, nine, or ten of these properties.
- Compounds of the disclosure can be administered to a subject at various times, dosages, and more than once, depending on, for example, the age, sex, health, and weight of the subject, as well as on the particular disease, disorder, or condition to be treated or prevented.
- a compound is administered at a dosage ranging from about 0.1 mg/kg to about 500 mg/kg body weight.
- the compound is administered at a dosage ranging from about 0.5 mg/kg to about 100 mg/kg body weight or about 0.5 mg/kg to about 25 mg/kg body weight.
- the compound is administered at a dosage ranging from about 1.0 mg/kg to about 50 mg/kg body weight. In one aspect, about 3.0 mg/kg is administered.
- the dose is selected from 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97
- a compound is administered to a subject more than once.
- the compound is a mitochondrial protonophore uncoupler lacking protonophore activity at the plasma membrane.
- the disclosure provides a method of treating or preventing a condition responsive to mitochondrial uncoupling, comprising administering a therapeutically effective amount of a compound Formula I or salt thereof to a patient in need of such treatment.
- the disease, disorder or condition associated with a defect in mitochondria function is selected from the group consisting of obesity, ischemia reperfusion injury, hyperinsulinemia, hyperlipidemia, glycemia, glucose tolerance, insulin sensitivity, adiposity, insulin resistance, obesity, diabetes, cancer, neurodegeneration, heart disease, renal disease, heart failure, Parkinson's disease, traumatic brain injury, stroke, aging, and disorders standing to benefit from increased energy expenditure.
- the compound is a mitochondrial uncoupler.
- the condition responsive to mitochondrial uncoupling is obesity, type II diabetes, fatty liver disease, insulin resistance, multiple sclerosis, cancer, Huntington's disease, Alzheimer's dementia, Parkinson's disease, ischemia reperfusion injury, heart failure, non-alcoholic fatty liver disease (NALFD), or non-alcoholic steatohepatitis (NASH).
- NALFD non-alcoholic fatty liver disease
- NASH non-alcoholic steatohepatitis
- the disclosure also includes a method of increasing lifespan comprising administering an effective amount of a compound of Formula I, or salt thereof, to a human or non-human animal.
- Increasing lifespan can be via delaying aging by delaying the onset of age-related disease, or age related changes, including neurodegenerative diseases, an age related cognitive decline, or an age-related decrease in motorneuron responses.
- the disclosure includes a method of increasing lifespan by delaying the onset of diseases associated with aging, comprising administering an effective amount of a compound of Formula I, or salt thereof, to a human or non-human animal.
- the disclosure includes a method of regulating glucose homeostasis or insulin action in a patient comprising administering a therapeutically effective amount of a compound or salt of any one of Formula I to the patient.
- the disclosure includes a method of treating hyperlipidemia, glycemia, glucose tolerance, insulin sensitivity, adiposity, insulin resistance, obesity, or diabetes in a patient comprising administering a therapeutically effective amount of a compound of Formula I to the patient.
- room temperature (rt) is about 21° C.
- Compound 3-15 was prepared according to a reported method (Bisballe N. et al., Eur. J. Org. Chem. 2018, 3904-3913) described as follows.
- a solution of LiTMP prepared by adding nBuLi (2.5M solution in hexanes, 70.48 mmol, 1.5 equiv., 28.0 mL) to a stirred, cooled (0° C.) solution of freshly distilled TMP (70.48 mmol, 1.5 equiv., 11.9 mL) in anhydrous THF (50 mL) and stirring for 5 min] cooled to approximately ⁇ 30° C.
- reaction was quenched with sat. aq. Na 2 S203 (10 mL) and extracted with EtOAc (3 ⁇ 20 mL). The combined organic layers were washed with brine (10 mL), and dried with Na 2 SO 4 . The solvent was removed under reduced pressure.
- a vial with a stir bar was charged with Pd(dba) 2 (5.2 ⁇ mol, 1 mol %, 2.99 mg), XPhos (5.2 ⁇ mol, 2 mol %, 4.95 mg), 3-17 (0.52 mmol, 1 equiv., 150.0 mg), aniline derivative (0.62 mmol, 1.2 equiv., 0.84 mL) and tBuONa (0.73 mmol, 1.4 equiv., 69.9 mg) and sealed with a septum containing cap.
- the vial was evacuated and flushed with N 2 three times and heated at 110° C. for 48 h.
- a sealed vial was charged with Pd 2 dba 3 (9.2 mg, 5 mol percent), Xantphos (14 mg, 12 mol percent), 1-iodo-4-(trifluoromethoxy)benzene (58 mg, 0.20 mmol), 3-24 (55 mg, 0.20 mmol) and Cs 2 CO 3 (82 mg 0.25 mmol).
- the flask was then evacuated and backfilled with argon 3 ⁇ .
- Degassed anhydrous toluene (2 mL) was added through the septum. The mixture was stirred at 110° C. for 16 h and then allowed to cool to room temperature. After cooling, the solid material was filtered off and washed with ethyl acetate.
- Biological activities of the compounds synthesized is determined by determining increase in oxygen consumption rate (OCR).
- Oxygen consumption rate (OCR) in whole cells is measured in general accordance with the method of Kenwood B M et al. (Mol. Met. (2014) 3: 114-123).
- OCR is measured using a Seahorse XF-24 Flux Analyzer (Seahorse Biosciences, North Billerica, Mass.).
- NMuLi, C2C12, and L6 cells are seeded in a Seahorse 24-well tissue culture plate at a density of 3.5 ⁇ 10 4 cells/well, isolated cardiomyocytes at a density of 4 ⁇ 10 4 cells/well, and human primary fibroblasts at a density of 1.1 ⁇ 10 4 cells/well. The cells are then allowed to adhere for 24 h.
- Fat and lean mass for mice given the high fat Western Diet or the Western Diet with the mitochondrial uncoupler compound 4c was determined by EchoMRI. Mice receiving WD+4c gain less fat mass than WD control without losing lean mass and without a significant change in food intake. Certain compounds of the disclosure have anti-inflammatory effects in the STAM mouse model of fatty liver disease.
- Certain compounds of the disclosure also decrease ROS production, which can be measured in this assay.
- L6 myoblasts are seeded into black-walled clear-bottom 96-well microplates in L6 growth media and grown to confluence. Cells are then washed twice with PBS and co-incubated with 7. ⁇ M CM-H 2 DCFDA and 0.5 ng/ ⁇ L of each hit compound or vehicle control (DMSO) in KRP buffer (136 mM NaCl, 4.7 mM KCl, 10 mM NaPO 4 , 0.9 mM MgSO 4 , 0.9 mM CaCl 2 , pH 7.4) supplemented with 25 mM D-glucose at 37° C.
- DMSO vehicle control
- ROS production is expressed in terms of percentage fluorescence of the vehicle control for each condition. Compounds which increase ROS levels by greater than 20% are eliminated.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Gastroenterology & Hepatology (AREA)
- Pyridine Compounds (AREA)
Abstract
The disclosure provides compounds of Formula I and the pharmaceutically acceptable salts thereof. The variables, R1, R2, R3, R4, R5, X1, X2, and Z are defined herein. Certain compounds of Formula I act as selective mitochondrial protonophore uncouplers that do not affect the plasma membrane potential. The disclosure includes pharmaceutical composition comprising a compound or salt Formula I, and a pharmaceutically acceptable carrier. Compounds and salts of Formula I are useful for treating or decreasing the risk of conditions responsive to mitochondrial uncoupling, such as obesity, cancer, type II diabetes, fatty liver disease, insulin resistance, Parkinson's disease, ischemia reperfusion injury, heart failure, non-alcoholic fatty liver disease (NALFD), and non-alcoholic steatohepatitis (NASH). Because mitochondrial uncouplers decrease the production of reactive oxygen species (ROS), which are known to contribute to age-related cell damage, compounds of Formula I are useful for increasing lifespan. Compounds and salts of Formula I are also useful for regulating glucose homeostasis or insulin action in a patient.
Description
- This application claims priority of U.S. Provisional Appl. No. 62/660,880, filed Apr. 20, 2018, which is hereby incorporated by reference in its entirety.
- Cellular respiration is a physiological process with a fundamental goal of producing energy in the form of ATP. During cellular respiration, chemical energy derived from nutrients is converted into ATP. Specifically, the oxidation of nutrients in the mitochondrial matrix generates high-energy electron carriers nicotinamide adenine dinucleotide (NADH) and flavin adenine dinucleotide (FADH2) that are oxidized by the mitochondrial electron transport chain (ETC) located in the mitochondrial inner-membrane (MIM). Electron flow through the ETC is an exergonic process that drives a series of proton pumps to efflux protons from the matrix into the inter-membrane space (IMS) against their concentration gradient. The resulting proton concentration (ΔpH) and electrical (ΔΨ) gradient is known as the proton-motive force (pmf). Protons that re-enter the mitochondrial matrix via ATP synthase drive endergonic production of ATP. Thus, mitochondrial ATP production involves the coupling of electron transport to phosphorylation reactions via a proton gradient across the MIM.
- Mitochondrial uncoupling describes processes that uncouple nutrient oxidation from ATP production. Mitochondrial uncoupling is a normal physiological process that occurs as either basal or inducible proton leak from the intermembrane space. Basal proton leak accounts for ˜20-25% of the basal metabolic rate of mammals. The reason for such metabolic inefficiency is not entirely understood; however, membrane lipid composition and abundance of the adenine nucleotide translocase (ANT) are factors that contribute to basal rates of proton leak. Induced proton leak is driven by reactive species and fatty acids that activate uncoupling proteins (UCPs). UCPs are located in the MIM and facilitate the transfer protons into the matrix independent of ATP synthase.
- There are five known UCPs in mammals, UCP1-5, that have distinct tissue localization. The best-characterized UCPs are UCP1 and UCP2. UCP1 is expressed in brown and beige adipose tissue and has a role in non-shivering thermogenesis. UCP1 is unlikely to operate as a simple proton channel, but instead transfers protons via a mechanism that requires long-chain fatty acids. In contrast, UCP2 has a broad tissue distribution and no role in thermogenesis. UCP2 uncouples mitochondria to prevent hyperpolarization and decrease mitochondrial superoxide production.
- Small molecule mitochondrial uncouplers either act directly as protonophores by transporting protons into the matrix independently of protein complexes or, alternatively, mediate uncoupling via proteins such as ANT. Protonophoric uncouplers are lipophilic enough to enable passage through the MIM and weakly acidic to enable partial and reversible pH-dependent ionization. Mitochondrial uncoupling has two major phenotypes of therapeutic relevance including increased nutrient oxidation to compensate for lack of efficiency in ATP production and decreasing superoxide production from the ETC. The ETC is a primary source of reactive oxygen species (ROS) in most tissues. ETC-derived superoxide formation occurs via a non-enzymatic process when single electrons on co-enzymes or prosthetic groups in redox centers interact with molecular oxygen. Single electrons in the ETC only transiently exist in redox centers and the dwell time for single electrons in an unstable state increases the likelihood of superoxide production. Mitochondrial uncouplers decrease mitochondrial superoxide production by stimulating faster electron transfer that decreases the dwell time for single electrons in the ETC.
- The therapeutic potential of mitochondrial uncouplers is related to their dual roles in increasing nutrient oxidation and decreasing ROS production from the ETC. On the one hand, increased nutrient oxidation promotes leanness and is a therapeutic strategy to treat obesity and related metabolic diseases. On the other hand, mitochondrial ROS are linked to numerous pathologies including ischemia-reperfusion injury, inflammation, insulin resistance, neurodegeneration, and many other pathologies. Importantly, mitochondrial uncouplers prevent ROS production, which is advantageous compared to antioxidants that scavenge ROS that has already been produced. As such, decreasing mitochondrial ROS production has significant therapeutic potential with advantages over antioxidant scavengers.
- Mitochondria regulate cellular metabolism and play an important role in the pathogenesis of some of the most prevalent human diseases including obesity, cancer, diabetes, neurodegeneration, and heart disease. Many of these diseases can be improved by the use of pharmacological agents like mitochondrial uncouplers that lessen mitochondrial oxidative damage and increase energy expenditure. Genetic and pharmacologic uncoupling have beneficial effects on disorders that are linked to mitochondrial oxidative stress, such as ischemic-reperfusion injury, Parkinson's disease, insulin resistance, aging, and heart failure, and disorders that stand to benefit from increased energy expenditure such as obesity.
- Mitochondrial uncouplers are known and have been shown to be effective for treating obesity. For example, 2,4-dinitrophenol (DNP) is a well-known small molecule mitochondrial protonophore that results in weight loss in humans. Patients consuming ˜300 mg/d steadily shed an average of 1.5 pounds per week over the course of several months without changes in food intake. Similarly, mice treated with DNP demonstrate improved serological glucose, triglyceride, and insulin levels, as well as decreased oxidative damage, reduced body weight, and increased longevity. However, DNP has off-target effects on other cellular membranes resulting in a narrow therapeutic index. DNP was subsequently withdrawn from the North American market by the US Food and Drug Administration in 1938. Currently, there are no uncoupler drugs that are safe enough for use in humans.
- The development of a selective mitochondrial protonophore uncoupler that does not affect the plasma membrane potential would broaden the safety margin of mitochondrial uncouplers and provide renewed hope that mitochondrial uncoupling can be targeted for the treatment of obesity, type II diabetes, and other diseases, disorders, and conditions related to mitochondrial function. There is a long felt need in the art for compositions and methods useful for preventing and treating obesity, diabetes, regulating glucose homeostasis, reducing adiposity, protecting from ischemic-reperfusion injury, and regulating insulin action using mitochondrial uncouplers as well as for compounds useful as mitochondrial uncouplers. The present disclosure satisfies these needs.
- This disclosure provides compounds of Formula I,
- and the pharmaceutically acceptable salt thereof. The variables in Formula I, e.g. X1, X2, Z, and R1-R5 carry the following values.
- X1 and X2 are chosen from N and CH, wherein at least one of X1 and X2 is N.
- Z is absent (R2 is bound to N) or Z is —C(═O)—.
- R1 is hydrogen or C1-C8alkyl, C2-C8alkenyl, or C2-C8alkynyl.
- R2 is C1-C12alkyl, C2-C8alkenyl, or C2-C8alkynyl; or
- R2 is —C0-C4alkyl(C3-C7cycloalkyl), —C0-C4alkyl(bridged C7-C12cycloalkyl), —C0-C4alkyl(aryl), —C0-C4alkyl(mono- or bi-cyclic heteroaryl), or —C0-C4alkyl(3- to 7-membered heterocycloalkyl), each of which is optionally substituted with one or more substituents independently chosen from R11 and 0 or 1 substituents R12.
- R3 is H or C1-C8alkyl, C2-C8alkenyl, or C2-C8alkynyl, or
- R3 is —C0-C4alkyl(C3-C7cycloalkyl) or —C0-C4alkyl(aryl), which is optionally substituted with one or more independently chosen R11 substituents.
- R4 and R5 are independently selected from halogen, hydroxyl, amino, nitro, cyano, —CHO, —COOH, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C6alkyl, C1-C6alkoxy, C1-C6alkylester, —C0-C4alkyl(mono- or di-C1-C6alkylamino), C2-C6alkanoyl, C2-C6alkenyl, C2-C6alkynyl, Wherein in each C0-C4alkyl, C1-C8alkyl, C1-C12alkyl, C2-C8alkenyl, or C2-C8alkynyl, aryl, optionally substituted with R13, and mono- or bicyclic heteroaryl, optionally substituted with R13.
- In the definitions of R1, R2, and R3 one or more carbon atoms is optionally replaced by O, NR10, —C(O)—, —C(O)O—, —OC(O), —S(O)n-, —C(O)NR10—, or —NR10C(O)— where n is 0, 1, or 2, and in which the C0-C4alkyl, C1-C8 alkyl, C2-C8alkenyl, or C2-C8alkynyl is optionally substituted with one or more substituents R13.
- R10 is independently chosen at each occurrence from hydrogen, C1-C6alkyl, and —C0-C2alkyl(C3-C7cycloalkyl).
- R11 is independently selected at each occurrence from halogen, hydroxyl, amino, nitro, cyano, —CHO, —COOH, oxo, halosulfanyl, and C1-C10alkyl, C2-C8alkenyl, and C2-C8alkynyl, wherein in each C1-C10alkyl, C2-C8alkenyl, and C2-C8alkynyl, in the definition of R11 one or more carbon atoms is optionally replaced by O, NR10, —C(O)—, —C(O)O—, —OC(O), —S(O)n-, —S(O)nNR10, —NR10S(O)n-, —NR10C(O)NR10, —C(O)NR10—, or —NR10C(O)— where n is 0, 1, or 2, and in which each C0-C4alkyl, C1-C8alkyl, C2-C8alkenyl, or C2-C8alkynyl is optionally substituted with one or more substituents R13.
- R12 is selected from —C0-C4alkyl(C3-C7cycloalkyl), —O—C0-C4alkyl(C3-C7cycloalkyl), —C0-C4alkyl(aryl), —O—C0-C4alkyl(aryl), —C0-C4alkyl(5- to 6-membered heteroaryl), —O—C0-C4alkyl(5- to 6-membered heteroaryl), —C0-C4alkyl(3- to 6-membered heterocycloalkyl), and —O—C0-C4alkyl(3- to 6-membered heterocycloalkyl), each of which is optionally substituted with one or more substituents independently chosen from halogen, hydroxyl, amino, nitro, cyano, —CHO, —COOH, oxo, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C6alkyl, C1-C6alkoxy, C1-C6alkylester, —C0-C4alkyl(mono- or di-C1-C6alkylamino), C2-C6alkanoyl, C2-C6alkenyl, and C2-C6alkynyl.
- R13 is independently chosen at each occurrence from halogen, hydroxyl, amino, nitro, cyano, —CHO, —COOH, oxo, C3-C7cycloalkyl, and phenyl.
- The disclosure includes a pharmaceutical composition, comprising a compound or salt of Formula I, together with a pharmaceutically acceptable excipient.
- The disclosure includes a method of treating or preventing a condition responsive to mitochondrial uncoupling, comprising administering a therapeutically effective amount of a compound or salt of Formula I to a patient in need of such treatment. Conditions responsive to mitochondrial uncoupling include obesity, type II diabetes, fatty liver disease, insulin resistance, Parkinson's disease, ischemia reperfusion injury, heart failure, non-alcoholic fatty liver disease (NALFD), and non-alcoholic steatohepatitis (NASH).
- The disclosure includes a method of regulating glucose homeostasis or insulin action in a patient comprising administering a therapeutically effective amount of a compound or salt of Formula I to a patient in need thereof.
- The disclosure also includes a method of treating hyperlipidemia, glycemia, glucose tolerance, insulin sensitivity, adiposity, insulin resistance, obesity, or diabetes in a patient comprising administering a therapeutically effective amount of a compound of Formula I to the patient.
- In the description and claims, terms will carry the definitions set forth in this section unless the stated otherwise or contrary to the context. Unless defined otherwise, all technical and scientific terms used herein have the commonly understood by one of ordinary skill in the art to which the disclosure pertains. Although any methods and materials similar or equivalent to those described herein may be useful in the practice or testing of the embodiments of this disclosure; preferred methods and materials are described below.
- The terms “a” and “an” do not denote a limitation of quantity, but rather denote the presence of at least one of the referenced item. The term “or” means “and/or”. The term “about,” as used herein, means approximately, in the region of, roughly, or around. When the term “about” is used in conjunction with a numerical range, it modifies that range by extending the boundaries above and below the numerical values set forth. In general, the term “about” is used herein to modify a numerical value above and below the stated value by a variance of 10%. Therefore, about 50% means in the range of 45%-55%.
- Numerical ranges recited herein by endpoints include all numbers and fractions subsumed within that range (e.g. 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.90, 4, and 5).
- The terms “additional therapeutically active compound” or “additional therapeutic agent,” refers to the use or administration of a compound for an additional therapeutic use for a particular injury, disease, or disorder being treated. Such a compound, for example, could include one being used to treat an unrelated disease or disorder, or a disease or disorder which may not be responsive to the primary treatment for the injury, disease or disorder being treated.
- As used herein, the terms “administration of” and or “administering” a compound should be understood to mean providing a compound of the disclosure to a subject in need of treatment.
- An “agonist” is a composition of matter which, when administered to a mammal such as a human, enhances or extends a biological activity attributable to the level or presence of a target compound or molecule of interest in the subject.
- “Alleviating a disease or disorder symptom,” means reducing the severity of the symptom or the frequency with which such a symptom is experienced by a subject, or both.
- An “antagonist” is a composition of matter which when administered to a mammal such as a human, inhibits a biological activity attributable to the level or presence of a compound or molecule of interest in the subject.
- A “Compound of Formula I” as used herein, refers to any compound within the scope of Formula I and, unless the context indicates otherwise, includes the pharmaceutically acceptable salts of Formula I.
- The terms “comprises,” “comprising,” and the alternate transitional phrases “includes,” “including,” “contain,” and “containing” are open ended transitional phrases having the meaning ascribed to them in U.S. Patent Law. “Comprises” and the other open-ended terms encompass the intermediate term “consisting essentially of” and the closed ended terms “consisting of” and “consists of.” Claims reciting one of the open-ended transitional phrases can be written with any other transitional phrase, which may be more limiting, unless clearly precluded by the context or art.
- The term “delivery vehicle” refers to any kind of device or material which can be used to deliver compounds in vivo or can be added to a composition comprising compounds administered to a plant or animal. This includes, but is not limited to, implantable devices, aggregates of cells, matrix materials, gels, etc.
- A “disease” is a state of health of an animal wherein the animal cannot maintain homeostasis, and wherein if the disease is not ameliorated then the animal's health continues to deteriorate. In contrast, a “disorder” in an animal is a state of health in which the animal is able to maintain homeostasis, but in which the animal's state of health is less favorable than it would be in the absence of the disorder. Left untreated, a disorder does not necessarily cause a further decrease in the animal's state of health.
- As used herein, an “effective amount” or “therapeutically effective amount” means an amount sufficient to produce a selected effect, such as alleviating symptoms of a disease or disorder. In the context of administering compounds in the form of a combination, such as multiple compounds, the amount of each compound, when administered in combination with another compound(s), may be different from when that compound is administered alone. Thus, an effective amount of a combination of compounds refers collectively to the combination as a whole, although the actual amounts of each compound may vary.
- As used in the specification and the appended claims, the terms “for example,” “for instance,” “such as,” “including” and the like are meant to introduce examples that further clarify more general subject matter. Unless otherwise specified, these examples are provided only as an aid for understanding the disclosure and are not meant to be limiting in any fashion.
- The terms “formula” and “structure” are used interchangeably herein.
- The term “inhibit,” as used herein, refers to the ability of a compound of the disclosure to reduce or impede a described function, such as having inhibitory sodium channel activity. Preferably, inhibition is by at least 10%, more preferably by at least 25%, even more preferably by at least 50%, and most preferably, the function is inhibited by at least 75%. The terms “inhibit”, “reduce”, and “block” are used interchangeably herein.
- As used herein “injecting or applying” includes administration of a compound of the disclosure by any number of routes and means including, but not limited to, topical, oral, buccal, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, vaginal, ophthalmic, pulmonary, or rectal means.
- As used herein, an “instructional material” includes a publication, a recording, a diagram, or any other medium of expression which can be used to communicate the usefulness of compound of the disclosure in the kit for effecting alleviation of the various diseases or disorders recited herein. Optionally, or alternately, the instructional material may describe one or more methods of alleviating the diseases or disorders in a cell or a tissue of a mammal. The instructional material of the kit of the disclosure may, for example, be affixed to a container which contains the identified disclosure compound or be shipped together with a container which contains the identified compound.
- Alternatively, the instructional material may be shipped separately from the container with the intention that the instructional material and the compound be used cooperatively by the recipient.
- The term, “mitochondrial uncoupling,” also referred to as “uncoupling,” refers to the process whereby protons enter the mitochondrial matrix via a pathway independent of ATP synthase and thereby uncouple nutrient oxidation from ATP production. This process can be pharmacologically induced by small molecule mitochondrial protonophores, which directly shuttle protons across the mitochondrial inner membrane into the matrix. The primary pathway for energy production in aerobic cells involves the oxidation of nutrients (including fats, carbohydrates, and amino acids) in mitochondria, which promotes the efflux of protons out of the mitochondrial matrix. This process creates a pH and electrochemical gradient across the mitochondrial inner membrane. Protons normally re-enter the mitochondrial matrix via ATP synthase, which results in ATP production. Protons can also re-enter the mitochondrial matrix via pathways independent of ATP synthase, which ‘uncouples’ nutrient oxidation and proton efflux from ATP production.
- The term “modulate,” means changing the level of an activity, function, or process. The term “modulate” encompasses both inhibiting and stimulating an activity, function, or process.
- As used herein, “parenteral administration” of a pharmaceutical composition includes any route of administration characterized by physical breaching of a tissue of a subject and administration of the pharmaceutical composition through the breach in the tissue. Parenteral administration thus includes, but is not limited to, administration of a pharmaceutical composition by injection of the composition, by application of the composition through a surgical incision, by application of the composition through a tissue-penetrating non-surgical wound, and the like. In particular, parenteral administration is contemplated to include, but is not limited to, subcutaneous, intraperitoneal, intramuscular, intrasternal injection, and kidney dialytic infusion techniques.
- The term “per application” as used herein refers to administration of a compositions, drug, or compound to a subject.
- The term “pharmaceutical composition” shall mean a composition comprising at least one active ingredient and a pharmaceutically acceptable carrier, such as a pharmaceutically acceptable excipient.
- A “pharmaceutically acceptable excipient” means an excipient that is useful in preparing a pharmaceutical composition/combination that is generally safe, non-toxic and neither biologically nor otherwise undesirable, and includes an excipient that is acceptable for veterinary use as well as human pharmaceutical use. The term also encompasses any of the inactive agents approved for use pharmaceutical compositions in by a regulatory agency of the US Federal government or listed in the US Pharmacopeia for use in animals, including humans.
- The term “pharmaceutically acceptable carrier” includes any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water, emulsions such as an oil/water or water/oil emulsion, and various types of wetting agents. The term also encompasses any of the agents approved by a regulatory agency of the US Federal government or listed in the US Pharmacopeia for use in animals, including humans.
- “Pharmaceutically acceptable” means physiologically tolerable, for either human or veterinary application. As used herein, “pharmaceutical compositions” include formulations for human and veterinary use.
- “Plurality” means at least two.
- The term “prevent,” as used herein, means to stop something from happening or to significantly reduce the likelihood of something happening, such as by taking advance measures against something possible or probable outcome. In the context of medicine, “prevention” includes an action taken to decrease the chance of getting a disease or condition.
- A “preventive” or “prophylactic” treatment is a treatment administered to a subject who does not exhibit signs, or exhibits only early signs, of a disease or disorder. A prophylactic or preventative treatment is administered for the purpose of decreasing the risk of developing pathology associated with developing the disease or disorder.
- A “prodrug” refers to an agent that is converted into the parent drug in vivo. Prodrugs are often useful because, in some situations, they may be easier to administer than the parent drug. They may, for instance, be bioavailable by oral administration whereas the parent is not. The prodrug may also have improved solubility in pharmaceutical compositions over the parent drug, or may demonstrate increased palatability or be easier to formulate.
- A “subject” of analysis, diagnosis, or treatment is an animal. Such animals include mammals, preferably a human. As used herein, a “subject in need thereof” is a patient, animal, mammal, or human, who will benefit from the method of this disclosure.
- The term “symptom,” as used herein, refers to any morbid phenomenon or departure from the normal in structure, function, or sensation, experienced by the patient and indicative of disease. In contrast, a “sign” is objective evidence of disease. For example, a bloody nose is a sign. It is evident to the patient, doctor, nurse and other observers.
- A “therapeutic” treatment is a treatment administered to a subject who exhibits signs of pathology for the purpose of diminishing or eliminating those signs.
- A “therapeutically effective amount” of a compound is that amount of compound which is sufficient to provide a beneficial effect to the subject to which the compound is administered.
- As used herein, “treat,” “treating”, or “treatment” includes treating, ameliorating, or inhibiting an injury or disease related condition or a symptom of an injury or disease related condition. In one embodiment the disease, injury or disease related condition or a symptom of an injury or disease related condition is prevented; while another embodiment provides prophylactic treatment of the injury or disease related condition or a symptom of an injury or disease related condition.
- “Alkyl” is a branched or straight chain saturated aliphatic hydrocarbon group, having the specified number of carbon atoms, generally from 1 to about 8 carbon atoms. The term C1-C6alkyl as used herein indicates an alkyl group having from 1, 2, 3, 4, 5, or 6 carbon atoms. Other embodiments include alkyl groups having from 1 to 6 carbon atoms, 1 to 4 carbon atoms or 1 or 2 carbon atoms, e.g. C1-C8alkyl, C1-C4-alkyl, and C1-C2-alkyl. Examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, 3-methylbutyl, t-butyl, n-pentyl, sec-pentyl, heptyl, and octyl. “C0-Cn alkyl” is used together with another group, e.g. C0-C4alkyl(C3-C7cycloalkyl), to indicate the other group, in this case C3-C7cycloalkyl, is bound to the group it substitutes either by a single covalent bond (C0) or attached through an alkylene linker having the indicated number of carbon atoms.
- “Alkenyl” is a branched or straight chain aliphatic hydrocarbon group having one or more double carbon-carbon bonds that may occur at any stable point along the chain, having the specified number of carbon atoms. Examples of alkenyl include, but are not limited to, ethenyl, propenyl, 1, 3-butadienyl, 1-butenyl, hexenyl, and pentenyl.
- “Alkynyl” is a branched or straight chain aliphatic hydrocarbon group having one or more triple carbon-carbon bonds that may occur at any stable point along the chain, having the specified number of carbon atoms. Examples of alkynyl include, but are not limited to, ethynyl, propynyl, 1-butynyl, 2-butynyl, and 1-pentynyl.
- “Alkanoyl” is an alkyl group as defined above covalently bound to the group it substitutes by an carbonyl bridge (—C(═O)—). The carbonyl oxygen is included in the count of carbons in the substituted group. A C2alkanoyl is —C(═O)CH3.
- “Alkoxy” is an alkyl group as defined above with the indicated number of carbon atoms covalently bound to the group it substitutes by an oxygen bridge (—O—). Examples of alkoxy include, but are not limited to, methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, 2-butoxy, t-butoxy, n-pentoxy, 2-pentoxy, 3-pentoxy, isopentoxy, neopentoxy, n-hexoxy, 2-hexoxy, 3-hexoxy, and 3-methylpentoxy.
- “Alkylamino” is an alkyl group as defined herein covalently bound to the group it substitutes by an amino linkage. An alkylamino group can be a mono-alkyl group in which the amino is a secondary amino (alkylNH—) or a di-alkyl group in which the amino is a tertiary amino (alkyll)(alkyl2)N—. The alkyl groups of a di-alkylamino are the same or different.
- “Alkylester” is an alkyl group as defined herein covalently bound to the group it substitutes by an ester linkage. The ester linkage may be in either orientation, e.g., a group of the formula —OC(O)-alkyl or a group of the formula —C(O)O-alkyl.
- “Aryl” indicates a mono-, bi- or tri-cyclic ring system having at least one aromatic ring. Aryl groups contain only carbon in the aromatic ring or rings. An aryl group may be fused to a non aromatic ring containing N, O, or S heteroatoms. Typical aryl groups contain 1 to 3 separate, fused, or pendant rings and from 6 to about 18 ring atoms, without heteroatoms as ring members. When indicated, such aryl groups may be further substituted with carbon or non-carbon atoms or groups. Example include phenyl, naphthyl, bi-phenyl, tetrahydronaphthyl, indanyl, and indenyl group.
- “Cycloalkyl” is a saturated hydrocarbon ring group, having the specified number of carbon atoms. Monocyclic cycloalkyl groups typically have from 3 to about 8 carbon ring atoms, from 3 to 7 ring atoms, or from 3 to 6 (3, 4, 5, or 6) carbon ring atoms. Cycloalkyl substituents may be pendant from a substituted nitrogen, oxygen, or carbon atom, or a substituted carbon atom that may have two substituents may have a cycloalkyl group, which is attached as a spiro group. Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
- A “bridged cycloalkyl” is a cycloalkyl group that has two or more rings containing only carbon ring atoms, and one of the carbon rings contains a “bridge” of 1 carbon atom or 2-3 unbranched carbon atoms connected to two “bridgehead” atoms in the carbon ring. The bridgehead atoms are usually non-adjacent carbon ring atoms. Examples of bridge cycloalkyl groups include, but are not limited to, bicyclo[2.2.2]octanyl, bicyclo[3.3.1]nonanyl, adamantanyl, and bicyclo[3.3.3]undecanyl groups.
- “Halogen” or “halo” includes bromo, chloro, fluoro, and iodo.
- “Haloalkyl” indicates both branched and straight-chain alkyl groups having the specified number of carbon atoms, substituted with 1 or more halogen atoms, up to the maximum allowable number of halogen atoms. Examples of haloalkyl include, but are not limited to, trifluoromethyl, difluoromethyl, 2-fluoroethyl, 2,2,2-trifluoroethyl, and penta-fluoroethyl.
- “Haloalkoxy” indicates a haloalkyl group as defined herein attached through an oxygen bridge (oxygen of an alcohol radical).
- “Halosulfanyl” is a sulfur substituted with one or more halogen atoms, up to the maximum allowable number of halogen atoms.
- “Heteroaryl” is a ring or ring system having at least one aromatic ring containing a heteroatom independently chosen from N, O, and S with remaining ring atoms being carbon. Fused rings may or may not contain heteroatoms and need not be aromatic. It is preferred that the total number of heteroatoms in a heteroaryl ring system is not more than 4 and that the total number of S and O atoms in a heteroaryl ring system is not more than 2. Monocyclic heteroaryl groups typically have from 5 to 7 ring atoms. In some embodiments bicyclic heteroaryl groups are 9- to 10-membered heteroaryl groups, that is, groups containing 9 or 10 ring atoms in which one 5- to 7-member aromatic ring is fused to a second aromatic or non-aromatic ring. When the total number of S and O atoms in an aromatic ring of the heteroaryl group exceeds 1, these heteroatoms are not adjacent to one another. Examples of heteroaryl groups include, but are not limited to, oxazolyl, pyranyl, pyrazinyl, pyrazolopyrimidinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, quinolinyl, tetrazolyl, thiazolyl, thienylpyrazolyl, thiophenyl, triazolyl, benzo[d]oxazolyl, benzofuranyl, benzothiazolyl, benzothiophenyl, benzoxadiazolyl, dihydrobenzodioxynyl, furanyl, imidazolyl, indolyl, and isoxazolyl.
- “Heterocycloalkyl” is a saturated cyclic group containing 1 or more ring atoms independently chosen from N, O, and S with remaining ring atoms being carbon. Examples of heterocycloalkyls include tetrahydropyranyl, tetrahydrofuranyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, oxazolidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, thiazolidinyl, and pyrrolidinyl.
- “Pharmaceutically acceptable salts” includes derivatives of the disclosed compounds in which the parent compound is modified by making inorganic and organic, non-toxic, acid or base addition salts thereof. The salts of the present compounds can be synthesized from a parent compound that contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting free acid forms of these compounds with a stoichiometric amount of the appropriate base (such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate, or the like), or by reacting free base forms of these compounds with a stoichiometric amount of the appropriate acid. Alkali metal (for example, sodium, potassium or lithium) or alkaline earth metal (for example calcium) salts of organic (e.g., carboxylic) acids can also be made.
- Such reactions are typically carried out in water or in an organic solvent, or in a mixture of the two.
- Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines or nitrogen-containing heteroaryl rings (e.g. pyridine, quinoline, isoquinoline); alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts include the conventional non-toxic salts and the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, conventional non-toxic acid salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, malonic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, mesylic, esylic, besylic, sulfanilic, 2-acetoxybenzoic, fumaric, succinic, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, α-ketoglutarate, α-glycerophosphate, isethionic, HO2C—(CH2)n—CO2H where n is 0-4, and the like.
- Salts derived from inorganic bases, include by way of example only, sodium, potassium, lithium, ammonium, calcium and magnesium salts. Salts derived from organic bases include, but are not limited to, salts of primary, secondary and tertiary amines, such as alkyl amines, dialkyl amines, trialkyl amines, substituted alkyl amines, di(substituted alkyl) amines, tri(substituted alkyl) amines, alkenyl amines, dialkenyl amines, trialkenyl amines, substituted alkenyl amines, di(substituted alkenyl) amines, tri(substituted alkenyl) amines, cycloalkyl amines, di(cycloalkyl) amines, tri(cycloalkyl) amines, substituted cycloalkyl amines, disubstituted cycloalkyl amine, trisubstituted cycloalkyl amines, cycloalkenyl amines, di(cycloalkenyl) amines, tri(cycloalkenyl) amines, substituted cycloalkenyl amines, disubstituted cycloalkenyl amine, trisubstituted cycloalkenyl amines, aryl amines, diaryl amines, triaryl amines, heteroaryl amines, diheteroaryl amines, triheteroaryl amines, heterocyclic amines, diheterocyclic amines, triheterocyclic amines, mixed di- and tri-amines where at least two of the substituents on the amine are different and are selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclic, and the like. Also included are amines where the two or three substituents, together with the amino nitrogen, form a heterocyclic or heteroaryl group. Examples of suitable amines include, by way of example only, isopropylamine, trimethyl amine, diethyl amine, tri(iso-propyl) amine, tri(n-propyl) amine, ethanolamine, 2-dimethylaminoethanol, tromethamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, Nalkylglucamines, theobromine, purines, piperazine, piperidine, morpholine, Nethylpiperidine, and the like. It should also be understood that other carboxylic acid derivatives would be useful in the practice of this disclosure, for example, carboxylic acid amides, including carboxamides, lower alkyl carboxamides, dialkyl carboxamides, and the like.
- Lists of additional suitable salts may be found, e.g., in G. Steffen Paulekuhn, et al, Journal of Medicinal Chemistry 2007, 50, 6665 and Handbook of Pharmaceutical Salts: Properties, Selection and Use, P. Heinrich Stahl and Camille G. Wermuth, Editors, Wiley-VCH, 2002.
- The term “substituted” means that any one or more hydrogens on the designated atom or group is replaced with a selection from the indicated group, provided that the designated atom's normal valence is not exceeded. Unless otherwise specified, each substituent is selected independently of other substituents. “Optionally substituted” means that 0 to the maximum allowable number of substituents are present. When the substituent is oxo (i.e., ═O) then 2 hydrogens on the atom are replaced. When an oxo group substitutes a heteroaromatic moiety, the resulting molecule can sometimes adopt tautomeric forms. For example a pyridyl group substituted by oxo at the 2- or 4-position can sometimes be written as a pyridine or hydroxypyridine. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds or useful synthetic intermediates. A stable compound or stable structure is meant to imply a compound that is sufficiently robust to survive isolation from a reaction mixture and subsequent formulation into an effective therapeutic agent. Unless otherwise specified, substituents are named into the core structure. For example, it is to be understood that aminoalkyl means the point of attachment of this substituent to the core structure is in the alkyl portion and alkylamino means the point of attachment is a bond to the nitrogen of the amino group. However, a dash indicates a point of attachment for a substituent. —C1-C4alkyl(cycloalkyl) is attached at the 1 to 4 carbon alkylene linker.
- Certain compounds of the disclosure may contain one or more asymmetric elements such as stereogenic centers, stereogenic axes and the like, e.g. asymmetric carbon atoms, so that the compounds can exist in different stereoisomeric forms. These compounds can be, for example, racemates or optically active forms. For compounds with two or more asymmetric elements, these compounds can additionally be mixtures of diastereomers. For compounds having asymmetric centers, it should be understood that all of the optical isomers and mixtures thereof are encompassed. In these situations, single enantiomers, i.e., optically active forms, can be obtained by asymmetric synthesis, synthesis from optically pure precursors, or by resolution of the racemates. Resolution of the racemates can also be accomplished, for example, by conventional methods such as crystallization in the presence of a resolving agent, or chromatography, using, for example using a chiral HPLC column. In addition, compounds with carbon-carbon double bonds may occur in Z- and E-forms, with all isomeric forms of the compounds being included in the present disclosure.
- The disclosure includes deuterated compounds of Formula A and Formula I in which any hydrogen is replaced by a deuterium. “Deuterated” mean that a hydrogen at the specified position is replaced by deuterium. In any sample of a compound of Formula I in which a position is deuterated some discrete molecules of the compound of Formula I will likely have hydrogen, rather than deuterium, at the specified position. However the percent of molecules of the compound of Formula I in the sample which have deuterium at the specified position will be much greater than would naturally occur. The deuterium at the deuterated position is enriched. The term “enriched” as used herein, refers to the percentage of deuterium versus other hydrogen species at that location. As an example, if it is said that a position in the compound of Formula I contains 50% deuterium enrichment, that means that rather than hydrogen at the specified position the deuterium content is 50%. For clarity, it is confirmed that the term “enriched” as used herein does not mean percentage enriched over natural abundance. In one embodiment, deuterated compounds of Formula I will have at least 10% deuterium enrichment at any deuterated position. In other embodiments, there will be at least 50%, at least 90%, or at least 95% deuterium enrichment at the specified deuterated position or positions. A “deuterated substituent” is a substituent in which at least one hydrogen is replaced by deuterium at the specified percent enrichment. “Optionally deuterated” means that the position may be at either hydrogen and the amount of deuterium at the position is only the naturally occurring level of deuterium or the position is enriched with deuterium above the naturally occurring deuterium level.
- Where a compound exists in various tautomeric forms, the disclosure is not limited to any one of the specific tautomers, but rather includes all tautomeric forms. The compounds of the disclosure may exist in tautomeric forms, both mixtures and separate individual tautomers are included. For example
- also includes
- Chemical Description
- The disclosure provides compounds of Formula I-A, I-B, I-C, and I-D and the pharmaceutically acceptable salts thereof:
- The variables, e. g., R1, R2, R3, R4, R5, X1, X2, or Z in in Formula I or any of Formula I-A, I-B, I-C, or I-D may carry any of the definitions set forth in the SUMMARY section, or may carry any of the values set forth below.
- Formula I also includes subformulae (such as Formula I-A, I-B, I-C, and I-D) in which the variables carry any of the following definitions. Any of the variable definitions below can be combined so long as a stable compound results.
- Z can be absent and X1 and X2 can both be nitrogen.
- Z can be absent and one of X1 and X2 can be nitrogen and while the other is carbon.
- The R1 Variable
- R1 may carry the following definitions.
- (i) R1 is hydrogen or unsubstituted C1-C6alkyl.
- (ii) R1 is hydrogen.
- The R2 Variable
- R2 may carry the following definitions.
- (i) R2 is C1-C12alkyl, C2-C8alkenyl, or C2-C8alkynyl; in each C0-C4alkyl, C1-C8alkyl, C2-C8alkenyl, or C2-C8alkynyl one or more carbon atoms is optionally replaced by O, NR10, —C(O)—, —C(O)O—, —OC(O), —S(O)n-, —C(O)NR10—, or —NR10C(O)— where n is 0, 1, or 2, and in which the C0-C4alkyl, C1-C8 alkyl, C2-C8alkenyl, or C2-C8alkynyl is optionally substituted with one or more substituents R13.
- (ii) R2 is C8-C12alkyl, optionally substituted with one or more substituents independently chosen from halogen, hydroxyl, amino, nitro, cyano, and oxo.
- (iii) R2 is —C0-C4alkyl(C3-C7cycloalkyl), —C0-C4alkyl(bridged C7-C12cycloalkyl), —C0-C4alkyl(aryl), —C0-C4alkyl(mono- or bi-cyclic heteroaryl), or —C0-C4alkyl(4- to 7-membered heterocycloalkyl), each of which is optionally substituted with one or more substituents independently chosen from R11 and 0 or 1 substituents R12; in each C0-C4alkyl or more carbon atoms is optionally replaced by O, NR10, —C(O)—, —C(O)O—, —OC(O), —S(O)n-, —C(O)NR10—, or —NR10C(O)— where n is 0, 1, or 2, and in which the C0-C4alkyl, C1-C8 alkyl, C2-C8alkenyl, or C2-C8alkynyl is optionally substituted with one or more substituents R13.
- (iv) R2 is —C0-C4alkyl(bridged C7-C12cycloalkyl) or —C0-C4alkyl(aryl), each of which is optionally substituted with one or more substituents independently chosen from R11 and 0 or 1 substituents R12; in C0-C4alkyl one or more carbon atoms is optionally replaced by O, NR10, —C(O)—, —C(O)O—, —OC(O), —S(O)n-, —C(O)NR10—, or —NR10C(O)— where n is 0, 1, or 2, and in which the C0-C4alkyl is optionally substituted by R13.
- (v) R2 is C0-C2alkyl(bridged C7-C12cycloalkyl), which is optionally substituted with one or more substituents independently chosen from R11.
- (vi) R2 is adamantan-1-yl or —CH2(adamantan-1-yl), each of which is unsubstituted or substituted with halogen, hydroxyl, amino, nitro, cyano, C1-C4alkyl, C1-C4alkoxy, —C0-C2alkyl(mono- or di-C1-C4alkylamino), C1-C2haloalkyl, and C1-C2haloalkoxy.
- (vii) R2 is —C0-C4alkyl(phenyl), naphthyl, benzo[d][1,3]dioxolyl, or fluorenyl, each of which is optionally substituted with one or more substituents independently chosen from R11 and 0 or 1 substituents R12; in C0-C4alkyl one or more carbon atoms is optionally replaced by O, NR10, —C(O)—, —C(O)O—, —OC(O), —S(O)n-, —C(O)NR10—, —S(O)nNR10, —NR10S(O)n-, —NR10C(O)NR10, or —NR10C(O)— where n is 0, 1, or 2, and in which the C0-C4alkyl is optionally substituted by R13.
- (viii) R2 is phenyl, which is optionally substituted by one or more substituents independently chosen from R11.
- (ix) R2 is phenyl, which is substituted with one or more substituents independently chosen from halogen, hydroxyl, C1-C10alkyl, C1-C6alkoxy, C1-C2haloalkyl, and C1-C2haloalkoxy.
- (x) R2 is phenyl, which is optionally substituted by one or more substituents independently chosen from halogen, hydroxyl, amino, nitro, cyano, oxo, halosulfanyl, and C1-C8alkyl, C2-C8alkenyl, and C2-C8alkynyl, wherein in each C1-C8alkyl, C2-C8alkenyl, and C2-C8alkynyl, in the definition of R11 one or more carbon atoms is optionally replaced by O, NR10, —C(O)O—, —OC(O), or —S(O)n-, where n is 0, 1, or 2, and in which each C1-C8alkyl, C2-C8alkenyl, or C2-C8alkynyl is optionally substituted with one or more substituents R13.
- (xi) R2 is —C0-C4alkyl(phenyl), which is optionally substituted with one or more substituents independently chosen from R11 and 1 substituent R12; in C0-C4alkyl one or more carbon atoms is optionally replaced by O, NR10, —C(O)—, —C(O)O—, —OC(O), —S(O)n-, —C(O)NR10—, or —NR10C(O)— where n is 0, 1, or 2, and in which the C0-C4alkyl is optionally substituted by R13, where R12 is selected from —C0-C4alkyl(C3-C7cycloalkyl), —O—C0-C4alkyl(C3-C7cycloalkyl), —C0-C4alkyl(phenyl), —O—C0-C4alkyl(phenyl), —C0-C4alkyl(5- to 6-membered heteroaryl), —O—C0-C4alkyl(5- to 6-membered heteroaryl), each of which is optionally substituted with one or more substituents independently chosen from halogen, hydroxyl, amino, nitro, cyano, —CHO, —COOH, oxo, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C6alkyl, C1-C6alkoxy, C1-C6alkylester, —C0-C4alkyl(mono- or di-C1-C6alkylamino), C2-C6alkanoyl, C2-C6alkenyl, and C2-C6alkynyl.
- (xii) R2 is phenyl, which is substituted with one substituent R12; and R12 is phenyl which is optionally substituted with one or more substituents independently chosen from halogen, hydroxyl, amino, nitro, cyano, —CHO, —COOH, oxo, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C6alkyl, C1-C6alkoxy, C1-C6alkylester, —C0-C4alkyl(mono- or di-C1-C6alkylamino), C2-C6alkanoyl, C2-C6alkenyl, and C2-C6alkynyl.
- The R3 Variable
- R3 may carry the following definitions.
- (i) R3 is hydrogen.
- (ii) R3 is C1-C8alkyl, C2-C8alkenyl, or C2-C8alkynyl,
- (iii) In C1-C8alkyl, C2-C8alkenyl, or C2-C8alkynyl one or more carbon atoms is optionally replaced by O, NR10, C(O)O—, —OC(O), or —S(O)n-, where n is 0, 1, or 2, and in which the C1-C8 alkyl, C2-C8alkenyl, or C2-C8alkynyl is optionally substituted with one or more substituents R13.
- (iv) R3 is C1-C6alkyl.
- (v) R3 is C1-C6alkyl optionally substituted with hydroxyl.
- (vi) R3 is —C0-C4alkyl(C3-C7cycloalkyl) or —C0-C4alkyl(aryl), which is optionally substituted with one or more independently chosen R11 substituents.
- The R4 and R5 Variables
- R4 and R5 can carry any of the following definitions
- (i) R4 and R5 are both hydrogen.
- (ii) One of R4 and R5 is hydrogen, and the other is chosen from halogen, hydroxyl, CY C4alkyl, C1-C4alkoxy, C1-C2haloalkyl, and C1-C2haloalkoxy.
- The disclosure also includes compounds of Formula I (or Formula I-A, I-B, I-C, or I-D) and pharmaceutically acceptable salts thereof, in which the variables have the following definitions.
- R1 is hydrogen or C1-C4alkyl.
- R2 is C8-C12 alkyl; or R2 is phenyl, which is substituted with one or more substituents independently chosen from halogen, hydroxyl, C1-C10alkyl, C1-C6alkoxy, C1-C2haloalkyl, and CY C2haloalkoxy, or
- R2 is phenyl, which is substituted with one substituent R12; where R12 is phenyl which is optionally substituted with one or more substituents independently chosen from halogen, hydroxyl, amino, nitro, cyano, —CHO, —COOH, oxo, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C6alkyl, C1-C6alkoxy, CY C6alkylester, —C0-C4alkyl(mono- or di-C1-C6alkylamino), C2-C6alkanoyl, C2-C6alkenyl, and C2-C6alkynyl.
- R3 is H or C1-C6alkyl.
- R4 and R5 are both hydrogen or one of R4 and R5 is hydrogen, and the other is chosen from halogen, hydroxyl, C1-C4alkyl, C1-C4alkoxy, C1-C2haloalkyl, and C1-C2haloalkoxy.
- In this embodiment it is preferred that X1 and X2 are both N and Z is absent.
- Processes for preparing compounds of a formula of the disclosure or for preparing intermediates useful for preparing compounds of Formula I or other formulas of the disclosure are provided as further embodiments. Intermediates useful for preparing compounds of Formula I or other formulas are also provided as further embodiments of the disclosure.
- Pharmaceutical Compositions
- The disclosure includes a pharmaceutical composition comprising a compound or salt thereof of the disclosure, together with a pharmaceutically acceptable excipient.
- This disclosure provides pharmaceutical compositions comprising compounds of the Formula I. The pharmaceutical composition may comprise one or more compounds of the disclosure and pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier. In one embodiment, the compounds are administered as a pharmaceutical composition.
- The route of administration can vary depending on the type of compound being administered. In one aspect, the compounds are administered via routes such as oral, topical, rectal, intramuscular, intramucosal, intranasal, inhalation, ophthalmic, and intravenous.
- The present disclosure further provides for administration of a compound of Formula I as an immediate release or as a controlled-release formulation.
- The dosage of the active compound(s) being administered will depend on the condition being treated, the particular compound, and other clinical factors such as age, sex, weight, and health of the subject being treated, the route of administration of the compound(s), and the type of composition being administered (tablet, gel cap, capsule, solution, suspension, inhaler, aerosol, elixir, lozenge, injection, patch, ointment, cream, etc.). It is to be understood that the present disclosure has application for both human and veterinary use.
- Processes for preparing compounds of any of the formulas of the disclosure or for preparing intermediates useful for preparing compounds of any of the formulas of the disclosure are provided as further embodiments. Intermediates useful for preparing compounds of Formula I are also provided as further embodiments of the disclosure.
- Processes for preparing compounds of any of the formulas of the disclosure are provided as further embodiments of the disclosure and are illustrated by the following procedures in which the meanings of the generic radicals are as given above unless otherwise qualified.
- In one embodiment, compounds of the disclosure may be systemically administered, e.g., orally, in combination with a pharmaceutically acceptable carrier such as an inert diluent or an assimilable edible carrier. They may be enclosed in hard or soft shell gelatin capsules, may be compressed into tablets, or may be incorporated directly with the food of the patient's diet. For oral therapeutic administration, the active compound may be combined with one or more excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations should contain at least 0.1% of active compound. The percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 2 to about 60% of the weight of a given unit dosage form. The amount of active compound in such therapeutically useful compositions is such that an effective dosage level will be obtained.
- The tablets, troches, pills, capsules, and the like may also contain the following: binders such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, fructose, lactose or aspartame or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring may be added. When the unit dosage form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier, such as a vegetable oil or a polyethylene glycol. Various other materials may be present as coatings or to otherwise modify the physical form of the solid unit dosage form. For instance, tablets, pills, or capsules may be coated with gelatin, wax, shellac or sugar and the like. A syrup or elixir may contain the active compound, sucrose or fructose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavoring such as cherry or orange flavor. Of course, any material used in preparing any unit dosage form should be pharmaceutically acceptable and substantially non-toxic in the amounts employed. In addition, the active compound may be incorporated into sustained-release preparations and devices.
- The active compound may also be administered intravenously or intraperitoneally by infusion or injection. Solutions of the active compound or its salts can be prepared in water, optionally mixed with a nontoxic surfactant. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, triacetin, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
- The pharmaceutical dosage forms suitable for injection or infusion can include sterile aqueous solutions or dispersions or sterile powders comprising the active ingredient which are adapted for the extemporaneous preparation of sterile injectable or infusible solutions or dispersions, optionally encapsulated in liposomes. In all cases, the ultimate dosage form should be sterile, fluid and stable under the conditions of manufacture and storage. The liquid carrier or vehicle can be a solvent or liquid dispersion medium comprising, for example, water, ethanol, a polyol (for example, glycerol, propylene glycol, liquid polyethylene glycols, and the like), vegetable oils, nontoxic glyceryl esters, and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the formation of liposomes, by the maintenance of the required particle size in the case of dispersions or by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, buffers or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate, and gelatin.
- Sterile injectable solutions are prepared by incorporating the active compound in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filter sterilization. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and the freeze-drying techniques, which yield a powder of the active ingredient plus any additional desired ingredient present in the previously sterile-filtered solutions.
- For topical administration, the present compounds may be applied in pure form, i.e., when they are liquids. However, it will generally be desirable to administer them to the skin as compositions or formulations, in combination with a dermatologically acceptable carrier, which may be a solid or a liquid.
- Useful solid carriers include finely divided solids such as talc, clay, microcrystalline cellulose, silica, alumina and the like. Useful liquid carriers include water, alcohols or glycols or water-alcohol/glycol blends, in which the present compounds can be dissolved or dispersed at effective levels, optionally with the aid of non-toxic surfactants. Adjuvants such as fragrances and additional antimicrobial agents can be added to optimize the properties for a given use. The resultant liquid compositions can be applied from absorbent pads, used to impregnate bandages and other dressings, or sprayed onto the affected area using pump-type or aerosol sprayers. Thickeners such as synthetic polymers, fatty acids, fatty acid salts and esters, fatty alcohols, modified celluloses or modified mineral materials can also be employed with liquid carriers to form spreadable pastes, gels, ointments, soaps, and the like, for application directly to the skin of the user.
- Examples of useful dermatological compositions which can be used to deliver the compounds of Formula I to the skin are known to the art; for example, see Jacquet et al. (U.S. Pat. No. 4,608,392), Geria (U.S. Pat. No. 4,992,478), Smith et al. (U.S. Pat. No. 4,559,157) and Wortzman (U.S. Pat. No. 4,820,508). Useful dosages of the compounds of the disclosure can be determined by comparing their in vitro activity, and in vivo activity in animal models. Methods for the extrapolation of effective dosages in mice, and other animals, to humans are known to the art; for example, see U.S. Pat. No. 4,938,949.
- Generally, the concentration of the compound(s) of the disclosure in a liquid composition, such as a lotion, will be from about 0.1-25 wt-%, preferably from about 0.5-10 wt-%. The concentration in a semi-solid or solid composition such as a gel or a powder will be about 0.1-5 wt-%, preferably about 0.5-2.5 wt-%. The amount of the compound, or an active salt or derivative thereof, required for use in treatment will vary not only with the particular salt selected but also with the route of administration, the nature of the condition being treated and the age and condition of the patient and will be ultimately at the discretion of the attendant physician or clinician.
- For example, in one embodiment relating to oral administration to humans, a dosage of between approximately 0.1 and 300 mg/kg/day, or between approximately 0.5 and 50 mg/kg/day, or between approximately 1 and 10 mg/kg/day, is generally sufficient, but will vary depending on such things as the disorder being treated, the length of treatment, the age, sex, weight, and/or health of the subject, etc. In one aspect, a unit dose is used. In one aspect, the unit dose is supplied in a syringe. The combinations of drugs can be administered in formulations that contain all drugs being used, or the drugs can be administered separately. In some cases, it is anticipated that multiple doses/times of administration will be required or useful. Additionally, for some treatment regimens, at least two compounds will be used. In one aspect, at least three compounds will be administered. The present disclosure further provides for varying the length of time of treatment.
- In general, however, a suitable dose will be in the range of from about 0.5 to about 100 mg/kg, e.g., from about 10 to about 75 mg/kg of body weight per day, such as 3 to about 50 mg per kilogram body weight of the recipient per day, preferably in the range of 6 to 90 mg/kg/day, most preferably in the range of 15 to 60 mg/kg/day.
- The compound is conveniently administered in unit dosage form; for example, containing 5 to 1000 mg, conveniently 10 to 750 mg, most conveniently, 50 to 500 mg of active ingredient per unit dosage form.
- Ideally, when the active ingredient needs to enter circulation and be delivered via blood, the active ingredient, in one embodiment, should be administered to achieve peak plasma concentrations of the active compound of from about 0.5 to about 75 μM, preferably, about 1 to 50 μM, most preferably, about 2 to about 30 μM. This may be achieved, for example, by the intravenous injection of a 0.05 to 5% solution of the active ingredient, optionally in saline, or orally administered as a bolus containing about 1-100 mg of the active ingredient. Desirable blood levels may be maintained by continuous infusion to provide about 0.01-5.0 mg/kg/hr or by intermittent infusions containing about 0.4-15 mg/kg of the active ingredient(s).
- The desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example, as two, three, four or more sub-doses per day. The sub-dose itself may be further divided, e.g., into a number of discrete loosely spaced administrations; such as multiple inhalations from an insufflator or by application of a plurality of drops into the eye.
- Pharmaceutical compositions of the disclosure can further comprise additional therapeutic additives, alone or in combination (e.g., 2, 3, or 4 additional additives). Examples of additional additives include but are not limited to: (a) antimicrobials, (b) steroids (e.g., hydrocortisone, triamcinolone); (c) pain medications (e.g., aspirin, an NSAID, and a local anesthetic); (d) anti-inflammatory agents; and (e) combinations thereof. Non-synthetic matrix proteins like collagen, glycosaminoglycans, and hyaluronic acid, which are enzymatically digested in the body, are useful for delivery (see U.S. Pat. Nos. 4,394,320; 4,472,840; 5,366,509; 5,606,019; 5,645,591; and 5,683,459) and are suitable for use with the present disclosure. Other implantable media and devices can be used for delivery of the compounds of the disclosure in vivo. These include, but are not limited to, sponges, such as those from Integra, fibrin gels, scaffolds formed from sintered microspheres of polylactic acid glycolic acid copolymers (PLAGA), and nanofibers formed from native collagen, as well as other proteins. The compounds of the present disclosure can be further combined with growth factors, nutrient factors, pharmaceuticals, calcium-containing compounds, anti-inflammatory agents, antimicrobial agents, or any other substance capable of expediting or facilitating bone or tissue growth, stability, and remodeling.
- The compositions of this disclosure can also be combined with inorganic fillers or particles. For example for use in implantable grafts the inorganic fillers or particles can be selected from hydroxyapatite, tri-calcium phosphate, ceramic glass, amorphous calcium phosphate, porous ceramic particles or powders, mesh titanium or titanium alloy, or particulate titanium or titanium alloy.
- Examples of other antimicrobial agents that can be used in the present disclosure include, but are not limited to, isoniazid, ethambutol, pyrazinamide, streptomycin, clofazimine, rifabutin, fluoroquinolones, ofloxacin, sparfloxacin, rifampin, azithromycin, clarithromycin, dapsone, tetracycline, erythromycin, cikprofloxacin, doxycycline, ampicillin, amphotericine B, ketoconazole, fluconazole, pyrimethamine, sulfadiazine, clindamycin, lincomycin, pentamidine, atovaquone, paromomycin, diclarazaril, acyclovir, trifluorouridine, foscarnet, penicillin, gentamicin, ganciclovir, iatroconazole, miconazole, Zn-pyrithione, and silver salts, such as chloride, bromide, iodide, and periodate.
- In one embodiment, the compounds of the disclosure can first be encapsulated into microcapsules, microspheres, microparticles, microfibers, reinforcing fibers and the like to facilitate mixing and achieving controlled, extended, delayed and/or sustained release and combined other agents or drugs. Encapsulating the biologically active agent can also protect the agent against degradation during formation of the composite of the disclosure.
- In another embodiment of the disclosure, the compound is controllably released into a subject when the composition of the disclosure is implanted into a subject, due to bioresorption relying on the time scale resulting from cellular remodeling. In one aspect, the composition may be used to replace an area of discontinuity in the tissue. The area of discontinuity can be the result of trauma, a disease, disorder, or condition, surgery, injury, etc.
- As used herein, an “instructional material” includes a publication, a recording, a diagram, or any other medium of expression which can be used to communicate the usefulness of the composition of the disclosure for its designated use. The instructional material of the kit of the disclosure may, for example, be affixed to a container which contains the composition or be shipped together with a container which contains the composition. Alternatively, the instructional material may be shipped separately from the container with the intention that the instructional material and the composition be used cooperatively by the recipient.
- The method of the disclosure includes a kit comprising a compound identified in the disclosure and an instructional material which describes administering the compound or a composition comprising the compound to a subject. This should be construed to include other embodiments of kits that are known to those skilled in the art, such as a kit comprising a (preferably sterile) solvent suitable for dissolving or suspending the composition of the disclosure prior to administering the compound to a subject. Preferably the subject is a human.
- In accordance with the present disclosure, as described above or as discussed in the Examples below, there can be employed conventional chemical, cellular, histochemical, biochemical, molecular biology, microbiology, and in vivo techniques which are known to those of skill in the art. Such techniques are explained fully in the literature.
- Without further description, it is believed that one of ordinary skill in the art can, using the preceding description and the following illustrative examples, make and utilize the compounds of the present disclosure.
- Methods of Treatment
- Mitochondria regulate cellular metabolism and play an important role in the pathogenesis of some of the most prevalent human diseases including obesity, cancer, diabetes, neurodegeneration, and heart disease. The compounds of the disclosure, including are useful for treating and preventing these diseases and disorders and others described herein, as well as others where a mitochondrial uncoupler is useful.
- Many anti-diabetes drugs such as insulin-sensitizers promote glucose clearance from the blood by effectively ‘pushing’ glucose into nutrient overloaded tissues; however, in contrast to this approach our strategy is aimed at reducing cellular nutrient stores so that tissues will ‘pull’ glucose from the circulation. The present method is modeled after exercise and calorie restriction interventions which also reduce cellular nutrient stores to improve glycemia and insulin sensitivity. The proof of principle is validated in humans treated with the mitochondrial uncoupler 2,4-dinitrophenol (DNP). DNP decreases adiposity and improves metabolism in humans; however, it also has a very narrow therapeutic window and was removed from FDA approval in 1938. Other anti-diabetes drugs including agonists of thyroid hormone and inhibitors of 11-β hydroxysteroid dehydrogenase type 1 have off-target effects of increased energy expenditure that may mediate some of the protective effects of these compounds. Nevertheless, there are no drugs have been specifically targeted for increased energy expenditure.
- In one embodiment, a compound of the disclosure is useful for treating disease, disorders, and conditions which are associated with defects in mitochondrial function or which can be treated with drugs or agents that act as uncoupling agents. The methods can comprise administering to a subject in need thereof a pharmaceutical composition comprising an effective amount of compound of Formula I, or a salt thereof as a first therapeutic agent, together with a pharmaceutically acceptable carrier, and optionally with at least one additional therapeutic agent.
- In one embodiment, the present disclosure provides compositions and methods for increasing oxygen consumption, decreasing cellular reactive oxygen species, depolarizing a mitochondrial inner membrane, and increasing oxygen consumption rate without donating electrons to the electron transport chain using a mitochondrial uncoupler, said method comprising contacting a cell or mitochondria with a composition comprising at least one compound of the disclosure and optionally an additional therapeutic agent.
- For example, it is disclosed herein that the mitochondrial uncoupling agents of this disclosure both prevent and reverse body fat mass increases in mice fed a high fat and high sugar Western diet. Apart from body fat, the mitochondrial uncoupling agents decrease insulin levels, which is important because it corrects hyperinsulinemia, improves glucose tolerance, and protect against diet-induced glucose tolerance. It is also disclosed herein that administration of the mitochondrial uncoupling agents reverses insulin resistance, including diet-induced insulin resistance, and restores insulin sensitivity index. Therefore, the compounds of the disclosure are useful for preventing and treating diabetes. It is also disclosed that compounds of the disclosure decrease liver fat, thus providing a treatment for fatty liver disease. It is disclosed herein that a compound of the disclosure can prevent weight gain without altering food intake and can prevent di-t-induced fat accumulation. Compounds of the disclosure are also useful for reversing diet-induced weight or fat gain and can reverse diet-induced fat gain and fatty liver.
- Reactive oxygen species generated during respiration contribute to biological damage over time, causing mutations and other biological changes that lead to cancer, aging, and decreased lifespan. Mitochondrial uncoupling decreases the production of reactive oxygen species, potentially lowering the risk of cancer, decreasing the effects of aging, and increasing lifespan. Mitochondrial uncouplers reverse or interfere with many aspects of cancer metabolism and are therefore effective in a broad range of cancer types. For example, mitochondrial uncouplers are effective in treatment of cancers with impaired p53 expression or activity (https://www.nature.com/articles/s41467-018-05805-11 such as certain breast and ovarian cancers, Ras mutant cancers (https://www.cell.com/molecular-cell/pdf/S1097-2765(15)00004-0.pdf), and/or beta-catenin mutant cancers (https://www.ncbi.nlm.nih.gov/pubmed/28107588′). Mitochondrial uncouplers are demonstrated to treat adrenocortical carcinoma (http://clincancerres.aacriournals.org/content/clincanres/early/2016/02/12/1078-0432.CCR-15-2256.full.pdf) melanoma (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833689/), primary colon cancer (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6056247/) and metastasis to distant organs including the liver (https://www.nature.com/articles/s41419-017-0092-6′).
- A compound of the disclosure may exhibit at least one of the following properties or activities: energy expenditure agonist, mitochondrial uncoupler, antioxidant, increases oxygen consumption, depolarizes the mitochondrial inner membrane, stimulates respiration in isolated mitochondria, increases or stimulates oxygen consumption without donating electrons to the electron transport chain, lacks protonophore activity at the plasma membrane, decreases reperfusion-induced mitochondrial oxidative stress, decreases cellular reactive oxygen species, improves glucose tolerance, provides protection from high fat induce glucose tolerance, activates AMPK without depletion of ATP, prevents, reverses or treats insulin resistance, prevents, reverses or treats hyperinsulinemia, prevents, reverses or treats hyperlipidemia, improves blood lipid profiles, improves leanness, improves insulin sensitivity, protects from ischemic-reperfusion injury, and is less toxic than other mitochondrial inhibitors. In one embodiment, a compound of the disclosure has two or more of these properties. In one embodiment, a compound of the disclosure has three or more of these properties. In one embodiment, a compound of the disclosure has four, five, six, seven, eight, nine, ten, eleven, twelve, or more of these properties. In one embodiment, a compound of the disclosure has one, two, three, four, five, six, seven, eight, nine, or ten of these properties.
- Compounds of the disclosure can be administered to a subject at various times, dosages, and more than once, depending on, for example, the age, sex, health, and weight of the subject, as well as on the particular disease, disorder, or condition to be treated or prevented. In one aspect, a compound is administered at a dosage ranging from about 0.1 mg/kg to about 500 mg/kg body weight. In another aspect, the compound is administered at a dosage ranging from about 0.5 mg/kg to about 100 mg/kg body weight or about 0.5 mg/kg to about 25 mg/kg body weight. In yet another aspect, the compound is administered at a dosage ranging from about 1.0 mg/kg to about 50 mg/kg body weight. In one aspect, about 3.0 mg/kg is administered. In another aspect, about 5.0 mg/kg is administered. In one aspect, the dose is selected from 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 300, 400, and 500 mg/kg body weight, as well as all fractions, decimals, and integers in the range of numbers listed. In another aspect, the compound is administered as a unit dose ranging from about 10 mg to about 500 mg/unit dose.
- In one aspect, a compound is administered to a subject more than once. In one aspect, the compound is a mitochondrial protonophore uncoupler lacking protonophore activity at the plasma membrane.
- In one aspect the disclosure provides a method of treating or preventing a condition responsive to mitochondrial uncoupling, comprising administering a therapeutically effective amount of a compound Formula I or salt thereof to a patient in need of such treatment.
- In one aspect, the disease, disorder or condition associated with a defect in mitochondria function is selected from the group consisting of obesity, ischemia reperfusion injury, hyperinsulinemia, hyperlipidemia, glycemia, glucose tolerance, insulin sensitivity, adiposity, insulin resistance, obesity, diabetes, cancer, neurodegeneration, heart disease, renal disease, heart failure, Parkinson's disease, traumatic brain injury, stroke, aging, and disorders standing to benefit from increased energy expenditure. In one aspect, the compound is a mitochondrial uncoupler.
- In one aspect the condition responsive to mitochondrial uncoupling is obesity, type II diabetes, fatty liver disease, insulin resistance, multiple sclerosis, cancer, Huntington's disease, Alzheimer's dementia, Parkinson's disease, ischemia reperfusion injury, heart failure, non-alcoholic fatty liver disease (NALFD), or non-alcoholic steatohepatitis (NASH).
- The disclosure also includes a method of increasing lifespan comprising administering an effective amount of a compound of Formula I, or salt thereof, to a human or non-human animal. Increasing lifespan can be via delaying aging by delaying the onset of age-related disease, or age related changes, including neurodegenerative diseases, an age related cognitive decline, or an age-related decrease in motorneuron responses. The disclosure includes a method of increasing lifespan by delaying the onset of diseases associated with aging, comprising administering an effective amount of a compound of Formula I, or salt thereof, to a human or non-human animal.
- The disclosure includes a method of regulating glucose homeostasis or insulin action in a patient comprising administering a therapeutically effective amount of a compound or salt of any one of Formula I to the patient.
- The disclosure includes a method of treating hyperlipidemia, glycemia, glucose tolerance, insulin sensitivity, adiposity, insulin resistance, obesity, or diabetes in a patient comprising administering a therapeutically effective amount of a compound of Formula I to the patient.
- One of ordinary skill in the art will appreciate that not all configurations need to be effective or as effective as other compounds of the genus based on the teachings disclosed herein.
- The disclosure is now described with reference to the following Examples and Embodiments. Without further description, it is believed that one of ordinary skill in the art can, using the preceding description and the following illustrative examples, make and utilize the present disclosure and practice the claimed methods. The following working examples therefore, are provided for the purpose of illustration only and specifically point out the preferred embodiments of the present disclosure, and are not to be construed as limiting in any way the remainder of the disclosure. Therefore, the examples should be construed to encompass any and all variations which become evident as a result of the teaching provided herein.
- The following starting materials and general procedures are used in synthetic examples that follow.
- In all synthetic examples room temperature (rt) is about 21° C.
- NMR Solvent Reference: (CD3)2CO (2.05/29.84 ppm); (CD3)2SO (2.50/39.52 ppm).
- NMR Abbreviations: aq.=aqueous, app=apparent, br=broad, s=singlet, d=doublet, t=triplet, q=quartet, p=pentet. * means rotamers.
- To anhydrous THF (25 mL) was added sodium hydride (1.5 equiv., 60 percent dispersion) and allowed to stir for 5 min. Benzyl alcohol (1.0 equiv.) in anhydrous THF (15 mL) was added dropwise over a minute and allowed to stir for 30 min. 2,3-Dichloropyrazine (1.0 equiv.) in THF (10 mL) was added and the reaction was allowed to stir at room temperature for 2 h (TLC monitoring) and the reaction was quenched slowly with isopropanol. The solvent was evaporated under reduced pressure and the product purified via silica chromatography (2.5% ethyl acetate:hexanes.)
- A sealed vial was charged with Pd2dba3 (45.8 mg, 10 mol percent), Xantphos (67.21 mg, 10 mol percent), 2-(benzyloxy)-3-chloropyrazine (1.162 mmol) and K2CO3 (2.323 mmol). The flask was then evacuated and backfilled with argon 3×. Deoxygenated anhydrous dioxane (4 mL) was added through the septum, with the requisite aniline (1.278 mmol). The mixture stirred at 110° C. for 16 h and then allowed to cool to room temperature. After cooling, the solid material was filtered off and washed with ethyl acetate. The solvent was evaporated, and methanol (4 mL) was added. The round bottom flask was flushed with nitrogen gas for 5 min. Pd/C 10% (62 mg) was added and the mixture was stirred under a hydrogen balloon for 1.5 h at room temperature. The reaction was then filtered through a Celite plug washing with ethyl acetate, concentrated under reduced pressure, and purified via silica gel chromatography (ethyl acetate:hexanes 40%-55%) to provide the desired product (109 mg 37%).
- To a mixture of 3-amino-6-bromopyrazin-2-ol (3-20) (100 mg, 0.31 mmol), 4-dimethylaminopyridine (4 mg, 0.03 mmol) and triethylamine (47 mg, 0.47 mmol) in dry dichloromethane (2 mL) was added o-fluorobenzoyl chloride (60 mg, 0.38 mmol) in dry DCM (1 mL) via syringe. The resulting mixture was stirred at room temperature for 16 h. The solvent was concentrated under reduced pressure. The residue was dissolved in methanol (5 mL) and potassium carbonate (1 equiv.) was added. The mixture was refluxed for 2 h, concentrated under reduced pressure, dissolved in THF, filtered, and concentrated under reduce pressure to afford the desired compound.
-
- Compound 3-1 was synthesized by general procedure 3-A to yield 3-1 clear oil that crystallizes into a white solid. (87% Yield). 1H NMR (400 MHz, Chloroform-d) δ 8.02 (d, J=2.7 Hz, 1H), 7.94 (d, J=2.7 Hz, 1H), 7.49 (m, 2H), 7.42-7.33 (m, 3H), 5.48 (s, 2H). 13C NMR (101 MHz, Chloroform-d) δ 139.14, 138.16, 135.95, 135.68, 135.18, 128.69, 128.35, 127.98, 69.00.
-
- Compound 3-2 was synthesized by general procedure 3-B to yield 3-2 as brown solid. (20% Yield). HRMS (ESI+): Calc'd for C16H30N3O+ [M+H]+: 280.2383 Found: 280.2385
-
- Compound 3-3 was synthesized by general procedure 3-B to yield 3-3 as an off white solid. (33% Yield). 1H NMR (400 MHz, Chloroform-d) δ 12.16 (s, 1H), 8.04 (s, 1H), 7.68 (d, J=8.1 Hz, 2H), 7.17 (d, J=8.1 Hz, 2H), 7.09 (d, J=4.4 Hz, 1H), 6.67 (d, J=4.4 Hz, 1H), 2.58 (t, J=7.7 Hz, 2H), 1.60 (p, J=7.2 Hz, 2H), 1.37-1.24 (m, 14H), 0.88 (t, J=6.6 Hz, 3H). 13C NMR (101 MHz, Chloroform-d) δ 153.11, 148.87, 138.02, 136.53, 129.03, 123.44, 119.37, 114.03, 35.53, 32.04, 31.73, 29.77, 29.76, 29.67, 29.48, 29.42, 22.83, 14.27. HRMS (ESI+): Calc'd. for C20H30N3O+ [M+H]+: 328.2383 Found: 328.2383.
-
- Compound 3-4 was synthesized by general procedure 3-B to yield 3-4 as a yellow solid. (29% Yield). 1H NMR (400 MHz, Acetone-d6) δ 11.13 (s, 1H), 8.42 (s, 1H), 6.91 (d, J=4.4 Hz, 1H), 6.81 (d, J=4.5 Hz, 1H). 19F NMR (376 MHz, Acetone-d6) δ −145.72-−146.43 (m), −161.22 (t, J=21.1 Hz), −166.08 (dd, J=21.1, 16.4 Hz). HRMS (ESI+): Calc'd. for C10H5F5N3O+ [M+H]+: 278.0347 Found: 278.0335.
-
- Compound 3-5 was synthesized by general procedure 3-B to yield 3-5 as an off white solid. (32% Yield). 1H NMR (400 MHz, Acetone-d6) δ 10.98 (s, 1H), 8.79-8.68 (m, 1H), 8.42 (s, 1H), 7.27-7.14 (m, 2H), 7.08-7.00 (m, 1H), 6.97 (d, J=4.5 Hz, 1H), 6.91 (d, J=4.5 Hz, 1H). 19F NMR (376 MHz, Acetone-d6) δ −134.06-−134.15 (m, 1F). 13C NMR (101 MHz, Acetone-d6) δ 153.35 (d, J=241.9 Hz), 149.73, 139.10, 136.51, 125.34 (d, J=3.9 Hz), 123.36 (d, J=7.7 Hz), 121.50, 120.70 (d, J=1.6 Hz), 116.91, 115.37 (d, J=19.1 Hz). HRMS (ESI+): Calc'd. for C10H9FN3O+ [M+H]+: 206.0724 Found: 206.0716
-
- Compound 3-6 was synthesized by general procedure 3-B to yield 3-6 as an off white solid. (12% Yield). 1H NMR (400 MHz, Acetone-d6) δ 10.90 (s, 1H), 8.77 (s, 1H), 8.21-8.13 (m, 2H), 7.33-7.26 (m, 2H), 6.94 (d, J=4.4 Hz, 1H), 6.87 (d, J=4.4 Hz, 1H). 19F NMR (376 MHz, Acetone-d6) δ −58.87 (s, 3F). 13C NMR (101 MHz, Acetone-d6) δ 152.40, 150.03, 144.26 (q, J=2.1 Hz), 121.55 (q, J=255 Hz), 121.50, 116.60. HRMS (ESI+): Calc'd. for C11H9F3N3O2+ [M+H]+: 272.0641 Found: 272.0627.
-
- Compound 3-7 was synthesized by general procedure 3-B to yield 3-7 as an off yellow solid. (36% Yield). 1H NMR (400 MHz, Acetone-d6) δ 11.02 (s, 1H), 9.18 (s, 1H), 8.86-8.79 (m, 2H), 7.68-7.56 (m, 1H), 7.02 (d, J=4.5 Hz, 1H), 6.97 (d, J=4.5 Hz, 1H). 19F NMR (376 MHz, Acetone-d6) δ −63.53. 13C NMR (101 MHz, Acetone-d6) δ 152.16, 150.03, 142.83, 132.33 (q, J=33.2 Hz), 125.94 (q, J=272.3 Hz), 121.06, 119.87-119.11 (m), 117.92, 115.54-115.05 (m). HRMS (ESI+): Calc'd. for C12H8F6N3O+ [M+H]+:324.0566 Found: 324.0556.
-
- Compound 3-8 was synthesized by general procedure 3-B to yield 3-8 as an off white solid. (37% Yield). 1H NMR (400 MHz, Acetone-d6) δ 10.98 (s, 1H), 8.87 (s, 1H), 8.30-8.21 (m, 2H), 7.73-7.62 (m, 2H), 6.98 (d, J=4.5 Hz, 1H), 6.92 (d, J=4.4 Hz, 1H). 19F NMR (376 MHz, Acetone-d6) δ −62.14 (s, 3F). HRMS (ESI+): Calc'd. for C11H9F3N3O+ [M+H]+: 256.0692 Found: 256.0698
-
- Compound 3-9 was synthesized by general procedure 3-B to yield 3-9 a brown solid. (35% Yield). 1H NMR (400 MHz, Acetone-d6) δ 10.86 (s, 1H), 8.87 (s, 1H), 8.70-8.39 (m, 1H), 8.31-8.15 (m, 1H), 7.54 (t, J=8.0 Hz, 1H), 7.42-7.23 (m, 1H), 6.98 (d, J=4.4 Hz, 1H), 6.91 (d, J=4.5 Hz, 1H). 19F NMR (376 MHz, Acetone-d6) δ −63.13 (s, 3F). 13C NMR (101 MHz, Acetone-d6) δ 152.36 (d, J=2.7 Hz), 150.10, 141.70, 131.24 (d, J=31.6 Hz), 130.33, 125.40 (d, J=271.3 Hz), 123.21 (d, J=1.5 Hz), 121.42, 119.14 (q, J=4.2 Hz), 116.98, 115.93 (q, J=3.9 Hz).; HRMS (ESI+): Calc'd. for C11H9F3N3O+ [M+H]+: 256.0692 Found: 256.0687.
-
- Compound 3-10 was synthesized by general procedure 3-B to yield 3-10 as an off brown solid. (30% Yield). 1H NMR (500 MHz, DMSO-d6) δ 11.97 (s, 1H), 9.20 (s, 1H), 8.17-8.02 (m, 2H), 7.69-7.53 (m, 2H), 7.35 (t, J=7.9 Hz, 1H), 7.26-7.20 (m, 1H), 7.18 (t, J=2.1 Hz, 1H), 6.92 (d, J=4.3 Hz, 1H), 6.89 (dd, J=8.2, 2.5 Hz, 1H), 6.82 (d, J=4.3 Hz, 1H), 3.82 (s, 3H). HRMS (ESI+): Calc'd for C17H16N3O2+ [M+H]+: 294.1237 Found: 294.1236
-
- Compound 3-11 was synthesized by general procedure 3-B to yield 3-11 as an off brown solid. (16% Yield). 1H NMR (400 MHz, DMSO-d6) δ 11.95 (s, 1H), 9.18 (s, 1H), 8.18-7.91 (m, 2H), 7.79-7.59 (m, 2H), 7.61-7.42 (m, 2H), 7.32-7.14 (m, 2H), 6.90-6.84 (m, 1H), 6.81-6.72 (m, 1H). 19F NMR (376 MHz, DMSO-d6) δ −116.47 (tt, J=8.9, 5.4 Hz, 1F). 13C NMR (101 MHz, DMSO-d6) δ 162.70, 160.28, 150.19 (d, J=252.5 Hz), 139.43, 136.44 (d, J=3.0 Hz), 132.52, 128.04 (d, J=8.0 Hz), 126.60, 120.51, 119.49, 115.63 (d, J=21.9 Hz). HRMS (ESI+): Calc'd. for C16H13FN3O+ [M+H]+: 282.1037 Found: 282.1037.
-
- NaH (0.37 g, 9.26 mmol 60% dispersion) was added to a solution of 2-chloropyridin-3-ol (1.00 g, 7.72 mmol) in dry DMF (20 ml) at 0° C. The mixture was stirred for 30 min and benzyl bromide (1.10 ml, 9.26 mmol) was added to the mixture. The mixture was then stirred at room temperature overnight. Upon completion, the mixture was poured into ice-water, and extracted with ethyl acetate 3×. The combined organic layers were washed with water, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to yield 3-(benzyloxy)-2-chloropyridine 3-12 as a grey solid. (83% Yield). 1H NMR (400 MHz, Chloroform-d) δ 8.02-7.90 (m, 1H), 7.45-7.28 (m, 6H), 7.16-7.09 (m, 1H), 5.15 (s, 2H).
-
- Compound 3-13 was synthesized by general procedure 3-B to yield 3-13 as a greyish solid. (62% Yield). 1H NMR (400 MHz, Acetone-d6) δ 9.21 (s, 1H), 8.26-8.08 (m, 2H), 7.96 (s, 1H), 7.88-7.68 (m, 1H), 7.66-7.48 (m, 2H), 7.20-7.09 (m, 1H), 6.84-6.64 (m, 1H). 19F NMR (376 MHz, Acetone-d6) δ −61.81 (s, 3F). 13C NMR (126 MHz, Acetone-d6) δ 146.45, 146.06, 141.11, 138.39, 126.54 (q, J=3.8 Hz), 125.94 (q, J=270.0 Hz), 121.98 (q, J=32.2 Hz), 120.36, 118.40, 116.50. HRMS (ESI+): Calc'd. for (C12H10F3N2O)+: 255.0740 Found: 255.0775.
-
- Compound 3-14 was synthesized by general procedure 3-B to yield 3-14 as a greyish solid. (59% Yield). 1H NMR (400 MHz, Acetone-d6) δ 8.42 (s, 1H), 8.10-7.98 (m, 1H), 7.94-7.80 (m, 1H), 7.80-7.50 (m, 3H), 7.35-7.28 (m, 1H), 7.26-7.16 (m, 1H), 6.96-6.78 (m, 1H). 19F NMR (376 MHz, Acetone-d6) δ −63.05 (s, 3F). HRMS (ESI−): Calc'd. for (C12H8F3N2O−) [M−H]−: 253.0594 Found: 253.0637
-
- Compound 3-15 was prepared according to a reported method (Bisballe N. et al., Eur. J. Org. Chem. 2018, 3904-3913) described as follows. A solution of LiTMP [prepared by adding nBuLi (2.5M solution in hexanes, 70.48 mmol, 1.5 equiv., 28.0 mL) to a stirred, cooled (0° C.) solution of freshly distilled TMP (70.48 mmol, 1.5 equiv., 11.9 mL) in anhydrous THF (50 mL) and stirring for 5 min] cooled to approximately −30° C. (ACN+CO2 (s) bath) was slowly transferred to a solution of the 2,3-dichloropyrazine (46.99 mmol, 1.0 equiv., 7.00 g) and ZnCl2.TMEDA (46.99 mmol, 1.0 equiv., 11.86 g) in anhydrous THF (50 mL) at the same temperature. The resulting mixture was stirred for 15 min at −30° C. and then cooled down to −78° C. (acetone+CO2 (s) bath). A solution of I2 (70.48 mmol, 1.5 equiv., 17.89 g) in THF (60 mL) was introduced to the reaction mixture and it was stirred for 1.5 h at room temperature. The reaction was quenched with sat. aq. Na2S203 (10 mL) and extracted with EtOAc (3×20 mL). The combined organic layers were washed with brine (10 mL), and dried with Na2SO4. The solvent was removed under reduced pressure. The crude product was purified by flash column chromatography on silica gel to yield 3-15 (9.25 g, 72%) as an, off-white solid: Rf=0.62 (hex:EtOAc 15:1); 1H NMR (CDCl3, 400 MHz) δ 8.53 (1H, s); 13C NMR (125 MHz, CDCl3) δ 149.86, 147.57, 147.42, 111.03; HRMS (ESI-TOF) m/z calc'd. for C4HCl2IN2 [M+] 273.8560; found 273.8275.
-
- A mixture of compounds 3-15 (9.97 mmol, 1 equiv., 2.74 g), KF (13.96 mmol, 1.4 equiv., 0.81 g) and CuI (15.95 mmol, 1.6 equiv., 3.04 g) were sealed in a high-pressure tube with a septum-containing cap, evacuated, and refilled with N2 three times. Then DMSO (6 mL) and TMSCF3 (19.94 mmol, 2 equiv., 2.94 mL) were added via syringe and the mixture was stirred at 70° C. for 4 hours. After cooling to rt, the solution was diluted with water and extracted with Et2O (5×20 mL). Combined organic layers were washed with water, dried with MgSO4, filtered and slowly evaporated without additional heating. Brown slurry product 3-16 (1.95 g, 91%) was used without further purification to yield: Rf=0.41 (hex:EtOAc 15:1); 1H NMR (CDCl3, 400 MHz) δ 9.21 (1H, s); 19F NMR (CDCl3, 376 MHz) δ −67.25; HRMS (ESI-TOF)=calc'd. for C5HCl2F3N2 [M+] 215.9; found 215.9.
-
- A round bottom flask was charged with anhydrous THF (5 mL) and NaH (90% in mineral oil, 2.05 mmol, 1.2 equiv., 55 mg). To this stirred mixture, a solution of BnOH (2.05 mmol, 1.2 equiv., 0.21 mL) in anhydrous THF (5 mL) was added. The mixture was stirred at rt for 30 minutes until the bubbling has stopped and then a solution of 3-16 (1.71 mmol, 1 equiv., 370 mg) in anhydrous THF (5 mL) was added. The reaction was then stirred overnight at rt. After quenching with iPrOH, the reaction mixture was extracted between Et2O and water. The combined organic layers were washed with brine and dried with MgSO4, filtered, evaporated under vacuum and purified by column chromatography to yield 3-17 (218 mg, 44%) as a white solid: Rf=0.60 (hex:EtOAc 15:1, blue spot); 1H NMR (CDCl3, 400 MHz) δ 8.96 (1H, s), 7.53-7.44 (2H, m), 7.43-7.30 (3H, m), 5.54 (2H, s); 19F NMR (CDCl3, 376 MHz) δ −66.70; HRMS (ESI-TOF)=calc'd. for C12H8ClOF3N2 [M+] 288.0277; found 288.8559.
-
- A vial with a stir bar was charged with Pd(dba)2 (5.2 μmol, 1 mol %, 2.99 mg), XPhos (5.2 μmol, 2 mol %, 4.95 mg), 3-17 (0.52 mmol, 1 equiv., 150.0 mg), aniline derivative (0.62 mmol, 1.2 equiv., 0.84 mL) and tBuONa (0.73 mmol, 1.4 equiv., 69.9 mg) and sealed with a septum containing cap. The vial was evacuated and flushed with N2 three times and heated at 110° C. for 48 h. After completion of reaction, the tube was allowed to cool to room temperature and the mixture was immediately purified by silica gel column chromatography to yield 3-18 (12.0 mg, 6%) as a yellow solid: Rf=0.15 (hex:EtOAc 15:1). 1H NMR (CDCl3, 400 MHz) δ 7.87 (1H, br s), 7.73 (2H, d, J=9.1 Hz), 7.44-7.37 (5H, m), 7.25 (1H, s), 7.17 (2H, d, J=8.3 Hz), 5.51 (2H, s); 19F NMR (CDCl3, 376 MHz) δ −58.19, −67.51; HRMS (ESI-TOF)=calc'd. for C19H13F6N3O2 [M+H+] 430.0912; found 430.0890.
-
- Pd(OH)2 (0.20 mmol, 20.0 mg) and 3-18 (10 μmol, 1 equiv., 5.0 mg) were dissolved in EtOAc (1 mL) in a round bottom flask with a stir bar. Flask was degassed 5 times and filled with H2 and the reaction mixture was stirred overnight. The reaction mixture was then filtered through a Celite pad, washed with MeOH and concentrated. The mixture was purified by silica gel column chromatography to yield 3-19 (3.1 mg, 90%) as a colorless solid: Rf=0.11 (hex:EtOAc 15:1). 1H NMR ((CD3)2CO, 400 MHz) δ 8.97 (1H, br s), 8.18 (2H, d, J=9.2 Hz), 7.45 (1H, s), 7.34 (2H, d, J=9.2 Hz); 19F NMR ((CD3)2CO, 376 MHz) δ=−58.89, −68.70; HRMS (ESI-TOF)=calc'd. for C12H7F6N3O2 [M+H+]340.0442; found 340.0535.
-
- In a round-bottom flask, to 5-bromo-3-chloropyrazin-2-amine (1.00 g) was added potassium hydroxide (1.346 g, 5 equiv) in water (15 mL) and the resulting mixture was stirred at 100° C. for 16 h. The solution was allowed to cool to room temperature and then acidified with HCl (1 M) to pH 1 where a white precipitate formed. The solid was filtered, washed with water, and collected to afford (3-20) as a white solid (720 mg, 79%). 1H NMR (400 MHz, DMSO-d6) δ 12.41 (s, 1H), 6.97 (s, 1H), 6.58 (s, 2H).
-
- Compound 3-21 was synthesized by general procedure 3-C as a tan solid (11% yield). 1H NMR (400 MHz, DMSO-d6) δ 10.53 (s, 1H), 7.99 (s, 1H), 7.79-7.72 (m, 1H), 7.69 (dt, J=9.9, 2.1 Hz, 1H), 7.53 (td, J=8.0, 5.8 Hz, 1H), 7.42 (td, J=8.4, 2.6 Hz, 1H) —OH not visible. 19F NMR (376 MHz, DMSO-d6) δ −112.49 (td, J=9.3, 6.1 Hz, 1F). Calc'd. for C11H7FN3O2 + [M+H]+: 311.9739, Observed: 311.9748.
-
- Compound 3-22 was synthesized by general procedure 3-C as a tan solid (40% yield). 1H NMR (400 MHz, DMSO d6) δ 13.13 (s, 1H), 10.34 (d, J=3.7 Hz, 1H), 7.91 (s, 1H), 7.73 (td, J=7.5, 1.7 Hz, 1H), 7.65-7.57 (m, 1H), 7.38-7.30 (m, 2H). 19F NMR (376 MHz, DMSO-d6) δ −113.49 (s, 1F). Calc'd. for C11H7FN3O2 + [M+H]+: 311.9739, Observed: 311.9748.
-
- A sealed vial was charged with Pd2dba3 (158 mg, 3 mol percent), triphenyl phosphine (181 mg, 12 mol percent), 5-bromopyrazin-2-amine (1.00 g, 5.75 mmol), (4-(trifluoromethyl)phenyl)boronic acid (1.20 g, 5.75 mmol) and Na2CO3 (1.83 g, 17.2 mmol). The flask was then evacuated and backfilled with argon 3×. Degassed dioxane:water (22 mL, 2:1) was added through the septum and the mixture was stirred at 110° C. for 16 h. The reaction was allowed to cool to room temperature, filtered, and concentrated under reduced pressure. The residue was then purified via silica gel chromatography (ethyl acetate:hexanes) to afford 3-23 as a yellow solid (818 mg, 60%). GCMS (EI): Calc'd for C1H8F3N3 [M]: 239.07 Found: 239.1.
-
- 5-(4-(trifluoromethyl)phenyl)pyrazin-2-amine 3-23 (1.637 g, 6.844 mmol) was stirred in dry DMF (15 mL) and N-chlorosuccinimide (1.005 g, 7.53 mmol) was added. The reaction mixture was stirred at rt for 16 h and then extracted with sat. sodium thiosulfate and ethyl acetate. The organic layer was washed with water 3×, and then brine. The organic layer was concentrated under reduced pressure and the residue was purified via silica gel chromatography (ethyl acetate:hexanes) to afford 3-24 as a yellow solid (1.10 g, 59%). GCMS (EI): Calc'd for C1H7CF3N3 [M]: 273.6 Found: 273.0.
-
- A sealed vial was charged with Pd2dba3 (9.2 mg, 5 mol percent), Xantphos (14 mg, 12 mol percent), 1-iodo-4-(trifluoromethoxy)benzene (58 mg, 0.20 mmol), 3-24 (55 mg, 0.20 mmol) and Cs2CO3 (82 mg 0.25 mmol). The flask was then evacuated and backfilled with argon 3×. Degassed anhydrous toluene (2 mL) was added through the septum. The mixture was stirred at 110° C. for 16 h and then allowed to cool to room temperature. After cooling, the solid material was filtered off and washed with ethyl acetate. The solvent was removed under reduced pressure and the residue was purified via silica gel chromatography (ethyl acetate:hexanes) to afford 3-25 as a clear yellow oil (82 mg, 92%). 1H NMR (400 MHz, Acetone-d6) δ 8.78 (d, J=0.3 Hz, 1H), 8.56 (s, 1H), 8.23-8.13 (m, 2H), 7.97-7.91 (m, 2H), 7.84-7.76 (m, 2H), 7.35-7.28 (m, 2H). 19F NMR (376 MHz, Acetone-d6) δ −58.81 (s, 3F), −63.07 (s, 3F).
-
- 3-25 (60 mg, 0.14 mmol), KOH (78 mg, 1.4 mmol) were loaded in a sealed tube and dissolved with dioxane:water (1:1, 2 mL). The tube was sealed and stirred for 16 h at 140° C. The reaction was allowed to cool to room temperature, acidified with HCl (1M), extracted with ethyl acetate and washed with water. The organic layer was then dried with sodium sulfate, and solvent was removed under reduced pressure. The solid was then dissolved in minimal amounts of acetone, precipitated with hexanes, filtered and collected to afford 3-26 as a beige solid (14 mg, 24%). 1H NMR (400 MHz, Acetone-d6) δ 11.17 (s, 1H), 8.86 (s, 1H), 8.26-8.18 (m, 2H), 8.05-7.89 (m, 2H), 7.88-7.77 (m, 2H), 7.43 (s, 1H), 7.38-7.26 (m, 2H). 19F NMR (376 MHz, Acetone-d6) δ −58.87 (s, 3F), −63.15 (s, 3F). HRMS (ESI−): Calcd. for (C18H10F6N3O2−) [M−H]−: 414.2880 Found: 414.0683
- Biological activities of the compounds synthesized is determined by determining increase in oxygen consumption rate (OCR).
- Oxygen consumption rate (OCR) in whole cells is measured in general accordance with the method of Kenwood B M et al. (Mol. Met. (2014) 3: 114-123).
- OCR is measured using a Seahorse XF-24 Flux Analyzer (Seahorse Biosciences, North Billerica, Mass.). NMuLi, C2C12, and L6 cells are seeded in a Seahorse 24-well tissue culture plate at a density of 3.5×104 cells/well, isolated cardiomyocytes at a density of 4×104 cells/well, and human primary fibroblasts at a density of 1.1×104 cells/well. The cells are then allowed to adhere for 24 h. Prior to the assay, the media is changed to unbuffered DMEM containing pyruvate and glutamine (Gibco #12800-017, pH=7.4 at 37° C.) and the cells are equilibrated for 30 mins at 37° C. Compounds are injected during the assay and OCR is measured using 2 min measurement periods.
- 2-3 wells are used per condition and averaged over three plates (n=6-9). Statistical significance is determined by two-way ANOVA with Bonferroni's posttest.
- Compounds 3-18, 3-19, and 3-26 have observable activity in this assay.
- Male C57BL/6J mice aged 3 months (n=6) are assigned to one of three treatment groups: normal chow diet (Chow), western diet (WD) or western diet containing compound 4c (WD+4c). Mice fed WD and WD+4c are individually housed and given 3 grams of fresh food daily. WD+4c contained a dose of 4c equivalent to 50 mg/kg/day. For all treatments pre-weighed food is placed in cages and food intake is calculated daily. Fat and lean mass are measured by EchoMRI.
- Fat and lean mass for mice given the high fat Western Diet or the Western Diet with the mitochondrial uncoupler compound 4c was determined by EchoMRI. Mice receiving WD+4c gain less fat mass than WD control without losing lean mass and without a significant change in food intake. Certain compounds of the disclosure have anti-inflammatory effects in the STAM mouse model of fatty liver disease.
- Certain compounds of the disclosure also decrease ROS production, which can be measured in this assay. L6 myoblasts are seeded into black-walled clear-bottom 96-well microplates in L6 growth media and grown to confluence. Cells are then washed twice with PBS and co-incubated with 7. μM CM-H2DCFDA and 0.5 ng/μL of each hit compound or vehicle control (DMSO) in KRP buffer (136 mM NaCl, 4.7 mM KCl, 10 mM NaPO4, 0.9 mM MgSO4, 0.9 mM CaCl2, pH 7.4) supplemented with 25 mM D-glucose at 37° C. in 5% CO2/95% air for 1 hr. 100 nM H2O2 is used as a positive control for ROS production. Following incubation, cells are washed three times with PBS to remove excess probe. Cells are then covered with 100 L/well PBS and fluorescence intensity is measured by a Tecan Infinite® M200 microplate reader (Tecan Group Ltd., Switzerland) using a top-read configuration and with the excitation and emission filters set at 495±9 nm and 530±20 nm, respectively. Fluorescence data are recorded on Magellan (version 6.4) software and exported to Microsoft Excel for subsequent analysis. After subtracting the background fluorescence (that emitted from a well which does not receive the CM-H2DCFDA probe) from each well, ROS production is expressed in terms of percentage fluorescence of the vehicle control for each condition. Compounds which increase ROS levels by greater than 20% are eliminated.
Claims (26)
1. A compound of Formula I,
or a pharmaceutically acceptable salt thereof, wherein:
X1 and X2 are both N;
Z is absent (R2 is bound to N) or Z is —C(═O)—;
R1 is hydrogen or C1-C8alkyl, C2-C8alkenyl, or C2-C8alkynyl;
R2 is C1-C12alkyl, C2-C8alkenyl, or C2-C8alkynyl; or
R2 is —C0-C4alkyl(C3-C7cycloalkyl), —C0-C4alkyl(bridged C7-C12cycloalkyl), —C0-C4alkyl(aryl), —C0-C4alkyl(mono- or bi-cyclic heteroaryl), or —C0-C4alkyl(3- to 7-membered heterocycloalkyl), each of which is optionally substituted with one or more substituents independently chosen from R11 and 0 or 1 substituents R12;
R3 is H or C1-C8alkyl, C2-C8alkenyl, or C2-C8alkynyl, or
R3 is —C0-C4alkyl(C3-C7cycloalkyl) or —C0-C4alkyl(aryl), which is optionally substituted with one or more independently chosen R11 substituents;
R4 and R5 are independently selected from halogen, hydroxyl, amino, nitro, cyano, —CHO, —COOH, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C6alkyl, C1-C6alkoxy, C1-C6alkylester, —C0-C4alkyl(mono- or di-C1-C6alkylamino), C2-C6alkanoyl, C2-C6alkenyl, C2-C6alkynyl, aryl, optionally substituted with R13, and mono- or bicyclic heteroaryl, optionally substituted with R13;
wherein in each C0-C4alkyl, C1-C8alkyl, C C1-C12alkyl, C2-C8alkenyl, or C2-C8alkynyl in the definitions of R1, R2, and R3 one or more carbon atoms is optionally replaced by O, NR10, —C(O)—, —C(O)O—, —OC(O), —S(O)n-, —S(O)NR10—, —C(O)NR10—, or —NR10C(O)— where n is 0, 1, or 2, and in which the C0-C4alkyl, C1-C8 alkyl, C2-C8alkenyl, or C2-C8alkynyl is optionally substituted with one or more substituents R13;
R10 is independently chosen at each occurrence from hydrogen, C1-C6alkyl, and —C0-C2alkyl(C3-C7cycloalkyl);
R11 is independently selected at each occurrence from halogen, hydroxyl, amino, nitro, cyano, —CHO, —COOH, oxo, halosulfanyl, and C1-C10alkyl, C2-C8alkenyl, and C2-C8alkynyl, wherein in each C1-C10alkyl, C2-C8alkenyl, and C2-C8alkynyl, in the definition of R11 one or more carbon atoms is optionally replaced by O, NR10, —C(O)—, —C(O)O—, —OC(O), —S(O)n-, —S(O)nNR10, —NR10S(O)n-, —NR10C(O)NR10, —C(O)NR10—, or —NR10C(O)— where n is 0, 1, or 2, and in which each C0-C4alkyl, C1-C8alkyl, C2-C8alkenyl, or C2-C8alkynyl is optionally substituted with one or more substituents R13;
R12 is selected from —C0-C4alkyl(C3-C7cycloalkyl), —O—C0-C4alkyl(C3-C7cycloalkyl), —C0-C4alkyl(aryl), —O—C0-C4alkyl(aryl), —C0-C4alkyl(5- to 6-membered heteroaryl), —O—C0-C4alkyl(5- to 6-membered heteroaryl), —C0-C4alkyl(3- to 6-membered heterocycloalkyl), and —O—C0-C4alkyl(3- to 6-membered heterocycloalkyl), each of which is optionally substituted with one or more substituents independently chosen from halogen, hydroxyl, amino, nitro, cyano, —CHO, —COOH, oxo, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C6alkyl, C1-C6alkoxy, C1-C6alkylester, mono- or di-(C1-C6alkyl)carboxamide, —C0-C4alkyl(mono- or di-C1-C6alkylamino), C2-C6alkanoyl, C2-C6alkenyl, and C2-C6alkynyl; and
R13 is independently chosen at each occurrence from halogen, hydroxyl, amino, nitro, cyano, —CHO, —COOH, oxo, C3-C7cycloalkyl, and phenyl.
2. A compound or salt thereof of claim 1 , wherein Z is absent.
3-4. (canceled)
5. A compound or salt thereof of claim 1 , wherein R1 is hydrogen.
6-7. (canceled)
8. A compound or salt thereof of claim 5 , wherein R2 is —C0-C4alkyl(C3-C7cycloalkyl), —C0-C4alkyl(bridged C7-C12cycloalkyl), —C0-C4alkyl(aryl), —C0-C4alkyl(mono- or bi-cyclic heteroaryl), or —C0-C4alkyl(4- to 7-membered heterocycloalkyl), each of which is optionally substituted with one or more substituents independently chosen from R11 and 0 or 1 substituents R12;
in each C0-C4alkyl one or more carbon atoms is optionally replaced by O, NR10, —C(O)—, —C(O)O—, —OC(O), —S(O)n-, —C(O)NR10—, or —NR10C(O)— where n is 0, 1, or 2, and in which the C0-C4alkyl, C1-C8 alkyl, C1-C8alkenyl, or C2-C8alkynyl is optionally substituted with one or more substituents R13.
9. A compound or salt thereof of claim 8 , wherein
R2 is —C0-C4alkyl(bridged C7-C12cycloalkyl) or —C0-C4alkyl(aryl), each of which is optionally substituted with one or more substituents independently chosen from R11 and 0 or 1 substituents R12;
in C0-C4alkyl one or more carbon atoms is optionally replaced by O, NR10, —C(O)—, —C(O)O—, —OC(O), —S(O)n-, —C(O)NR10—, or —NR10C(O)— where n is 0, 1, or 2, and in which the C0-C4alkyl is optionally substituted by R13.
10. A compound or salt thereof of claim 9 , wherein
R2 is phenyl, which is optionally substituted by one or more substituents independently chosen from R11.
11. A compound or salt thereof of claim 9 , wherein
R2 is phenyl, which is substituted with one or more substituents independently chosen from halogen, hydroxyl, C1-C10alkyl, C1-C6alkoxy, C1-C2haloalkyl, and C1-C2haloalkoxy.
12. A compound or salt thereof of claim 9 wherein:
R2 is —C0-C4alkyl(phenyl), which is optionally substituted with one or more substituents independently chosen from R11 and 1 substituent R12;
in C0-C4alkyl one or more carbon atoms is optionally replaced by O, NR10, —C(O)—, —C(O)O—, —OC(O), —S(O)n-, —C(O)NR10—, or —NR10C(O)— where n is 0, 1, or 2, and in which the C0-C4alkyl is optionally substituted by R13;
R12 is selected from —C0-C4alkyl(C3-C7cycloalkyl), —O—C0-C4alkyl(C3-C7cycloalkyl), —C0-C4alkyl(phenyl), —O—C0-C4alkyl(phenyl), —C0-C4alkyl(5- to 6-membered heteroaryl), —O—C0-C4alkyl(5- to 6-membered heteroaryl), each of which is optionally substituted with one or more substituents independently chosen from halogen, hydroxyl, amino, nitro, cyano, —CHO, —COOH, oxo, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C6alkyl, C1-C6alkoxy, C1-C6alkylester, —C0-C4alkyl(mono- or di-C1-C6alkylamino), C2-C6alkanoyl, C2-C6alkenyl, and C2-C6alkynyl.
13. A compound or salt of claim 12 , wherein
R2 is phenyl, which is substituted with one substituent R12; and
R12 is phenyl which is optionally substituted with one or more substituents independently chosen from halogen, hydroxyl, amino, nitro, cyano, —CHO, —COOH, oxo, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C6alkyl, C1-C6alkoxy, C1-C6alkylester, —C0-C4alkyl(mono- or di-C1-C6alkylamino), C2-C6alkanoyl, C2-C6alkenyl, and C2-C6alkynyl.
14. A compound or salt thereof of claim 9 , wherein
R3 is hydrogen.
15. A compound or salt thereof of claim 9 , wherein
R3 is C1-C8alkyl, C2-C8alkenyl, or C2-C8alkynyl,
in C1-C8alkyl, C2-C8alkenyl, or C2-C8alkynyl one or more carbon atoms is optionally replaced by O, NR10, C(O)O—, —OC(O), or —S(O)n-, where n is 0, 1, or 2, and in which the C1-C8 alkyl, C2-C8alkenyl, or C2-C8alkynyl is optionally substituted with one or more substituents R13.
16. A compound or salt thereof of claim 15 , wherein R3 is C1-C6alkyl.
17. A compound or salt thereof of claim 1 , wherein
R4 and R5 are both hydrogen.
18. A compound or salt thereof of claim 1 , wherein
one of R4 and R5 is hydrogen, and the other is chosen from halogen, hydroxyl, C1-C4alkyl, C1-C4alkoxy, C1-C2haloalkyl, and C1-C2haloalkoxy.
19. A compound or salt thereof of claim 1 , wherein
R1 is hydrogen or C1-C4alkyl;
R2 is C8-C12 alkyl; or
R2 is phenyl, which is substituted with one or more substituents independently chosen from halogen, hydroxyl, C1-C10alkyl, C1-C6alkoxy, C1-C2haloalkyl, and C1-C2haloalkoxy, or
R2 is phenyl, which is substituted with one substituent R12; where R12 is phenyl which is optionally substituted with one or more substituents independently chosen from halogen, hydroxyl, amino, nitro, cyano, —CHO, —COOH, oxo, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C6alkyl, C1-C6alkoxy, C1-C6alkylester, —C0-C4alkyl(mono- or di-C1-C6alkylamino), C2-C6alkanoyl, C2-C6alkenyl, and C2-C6alkynyl;
R3 is H or C1-C6alkyl; and
R4 and R5 are both hydrogen or one of R4 and R5 is hydrogen, and the other is chosen from halogen, hydroxyl, C1-C4alkyl, C1-C4alkoxy, C1-C2haloalkyl, and C1-C2haloalkoxy.
20. A compound or salt thereof of claim 19 in which Z is absent.
21. A compound or salt thereof of claim 1 , wherein the compound is:
3-(dodecylamino)pyrazin-2-ol;
3-((4-decylphenyl)amino)pyrazin-2-ol;
3-((perfluorophenyl)amino)pyrazin-2-ol;
3-((2-fluorophenyl)amino)pyrazin-2-ol;
3-((4-(trifluoromethoxy)phenyl)amino)pyrazin-2-ol;
3-((3,5-bis(trifluoromethyl)phenyl)amino)pyrazin-2-ol;
3-((4-(trifluoromethyl)phenyl)amino)pyrazin-2-ol;
3-((3-(trifluoromethyl)phenyl)amino)pyrazin-2-ol;
3-((3′-methoxy-[1,1′-biphenyl]-3-yl)amino)pyrazin-2-ol;
3-((4′-fluoro-[1,1′-biphenyl]-4-yl)amino)pyrazin-2-ol;
2-((4-(trifluoromethyl)phenyl)amino)pyridin-3-ol;
2-((3-(trifluoromethyl)phenyl)amino)pyridin-3-ol;
3-(benzyl oxy)-N-(4-(trifluoromethoxy)phenyl)-5-(trifluoromethyl)pyrazin-2-amine;
3-((4-(trifluoromethoxy)phenyl)amino)-6-(trifluoromethyl)pyrazin-2-ol;
N-(5-bromo-3-hydroxypyrazin-2-yl)-3-fluorobenzamide;
N-(5-bromo-3-hydroxypyrazin-2-yl)-2-fluorobenzamide;
3-(benzyl oxy)-N-(4-(trifluoromethoxy)phenyl)-5-(trifluoromethyl)pyrazin-2-amine;
3-((4-(trifluoromethoxy)phenyl)amino)-6-(trifluoromethyl)pyrazin-2-ol; or
3-((4-(trifluoromethoxy)phenyl)amino)-6-(4-(trifluoromethyl)phenyl) pyrazin-2-ol.
22. A pharmaceutical composition comprising a compound or salt thereof of claim 1 , together with a pharmaceutically acceptable carrier.
23. A method of treating or preventing a condition responsive to mitochondrial uncoupling, comprising administering a therapeutically effective amount of a compound or salt of claim 1 to a patient in need of such treatment;
wherein the condition responsive to mitochondrial uncoupling is obesity, type II diabetes, fatty liver disease, insulin resistance, multiple sclerosis, cancer, Huntington's disease, Alzheimer's dementia, Parkinson's disease, ischemia reperfusion injury, heart failure, non-alcoholic fatty liver disease (NALFD), or non-alcoholic steatohepatitis (NASH); or
wherein the condition responsive to mitochondrial uncoupling is cancer and the cancer is a cancer having cancerous cells with impaired p53 expression or activity, a cancer with cancerous cells having a Ras mutation, a cancer with cancerous cells having a beta-catenin mutation, an adrenocortical carcinoma, melanoma, primary colon cancer, or a cancer with metastasis to the liver
24. (canceled)
25. A method of regulating glucose homeostasis or insulin action or a method of treating hyperlipidemia, glycemia, glucose tolerance, insulin sensitivity, adiposity, insulin resistance, obesity, or diabetes in a patient comprising administering a therapeutically effective amount of a compound or salt of claim 1 to the patient.
26. (canceled)
27. A method for decreasing the risk of cancer in a patient at risk for cancer, comprising administering a therapeutically effective amount of a compound of claim 1 to the patient.
28. (canceled)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/049,145 US20210253538A1 (en) | 2018-04-20 | 2019-04-22 | Aminopyrazines and related compounds useful as mitochondrial uncouplers |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862660880P | 2018-04-20 | 2018-04-20 | |
PCT/US2019/028560 WO2019204819A1 (en) | 2018-04-20 | 2019-04-22 | Aminopyrazines and related compounds useful as mitochondrial uncouplers |
US17/049,145 US20210253538A1 (en) | 2018-04-20 | 2019-04-22 | Aminopyrazines and related compounds useful as mitochondrial uncouplers |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210253538A1 true US20210253538A1 (en) | 2021-08-19 |
Family
ID=67139787
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/049,145 Abandoned US20210253538A1 (en) | 2018-04-20 | 2019-04-22 | Aminopyrazines and related compounds useful as mitochondrial uncouplers |
US17/049,232 Active 2039-05-14 US11708376B2 (en) | 2018-04-20 | 2019-04-22 | Substituted imidazo[4,5-b]pyridines, imidazo[4,5-b]pyrazines, and oxazolo[4,5- b]pyrazines as mitochondrial uncouplers |
US17/048,897 Pending US20210253594A1 (en) | 2018-04-20 | 2019-04-22 | Oxadiazolopyrazines and oxadiazolopyridines useful as mitochondrial uncouplers |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/049,232 Active 2039-05-14 US11708376B2 (en) | 2018-04-20 | 2019-04-22 | Substituted imidazo[4,5-b]pyridines, imidazo[4,5-b]pyrazines, and oxazolo[4,5- b]pyrazines as mitochondrial uncouplers |
US17/048,897 Pending US20210253594A1 (en) | 2018-04-20 | 2019-04-22 | Oxadiazolopyrazines and oxadiazolopyridines useful as mitochondrial uncouplers |
Country Status (12)
Country | Link |
---|---|
US (3) | US20210253538A1 (en) |
EP (3) | EP3781165A4 (en) |
JP (3) | JP2021522327A (en) |
KR (3) | KR20210009321A (en) |
CN (3) | CN112262146A (en) |
AU (2) | AU2019256719A1 (en) |
BR (2) | BR112020021466A2 (en) |
CA (2) | CA3097752A1 (en) |
IL (2) | IL278069A (en) |
MX (2) | MX2020011050A (en) |
WO (3) | WO2019204819A1 (en) |
ZA (2) | ZA202006295B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112020021466A2 (en) * | 2018-04-20 | 2021-01-19 | Virginia Tech Intellectual Properties, Inc. | OXADIAZOLOPYRAZINS AND OXADIAZOLOPYRIDINES USEFUL AS MITOCHONDRIAL DETACHERS |
WO2020191503A1 (en) * | 2019-03-27 | 2020-10-01 | Algernon Pharmaceuticals Inc. | Methods and uses of bromantane and derivatives thereof for treating lung disease, fatty liver disease, and kidney disorders |
US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2501680A1 (en) | 1981-03-12 | 1982-09-17 | Elf Aquitaine | SYNTHESIS OF TETRA MERCAPTIDES STANNIQUES |
US4472840A (en) | 1981-09-21 | 1984-09-25 | Jefferies Steven R | Method of inducing osseous formation by implanting bone graft material |
US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
LU84979A1 (en) | 1983-08-30 | 1985-04-24 | Oreal | COSMETIC OR PHARMACEUTICAL COMPOSITION IN AQUEOUS OR ANHYDROUS FORM WHOSE FATTY PHASE CONTAINS OLIGOMER POLYETHER AND NEW OLIGOMER POLYETHERS |
US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
US5606019A (en) | 1987-10-29 | 1997-02-25 | Protien Polymer Technologies, Inc. | Synthetic protein as implantables |
JP2668259B2 (en) * | 1988-02-18 | 1997-10-27 | 塩野義製薬株式会社 | Heterocyclic compounds and anti-ulcer agents |
GB2215209B (en) | 1988-03-14 | 1992-08-26 | Osmed Inc | Method and apparatus for biodegradable, osteogenic, bone graft substitute device |
US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
JPH0327172A (en) | 1989-06-19 | 1991-02-05 | Nissan Chem Ind Ltd | Method for bleaching cloth |
US5645591A (en) | 1990-05-29 | 1997-07-08 | Stryker Corporation | Synthetic bone matrix |
JPH0741461A (en) * | 1993-05-27 | 1995-02-10 | Eisai Co Ltd | Sulfonic acid ester derivative |
KR100396738B1 (en) * | 1999-03-03 | 2003-09-03 | 삼진제약주식회사 | Piperazine derivatives and process for the preparation thereof |
MXPA02007868A (en) * | 2000-02-16 | 2003-02-10 | Neurogen Corp | Substituted arylpyrazines. |
WO2002020463A2 (en) | 2000-09-05 | 2002-03-14 | Tularik Inc. | Fxr modulators |
AU2003252478A1 (en) * | 2002-07-10 | 2004-02-02 | Ono Pharmaceutical Co., Ltd. | Ccr4 antagonist and medicinal use thereof |
WO2005044270A1 (en) | 2003-11-04 | 2005-05-19 | 4Sc Ag | Oxadiazolopyrazine derivatives as pharmaceutically active compounds |
EP1529531A1 (en) | 2003-11-04 | 2005-05-11 | 4Sc Ag | Oxadiazolopyrazine derivatives as pharmaceutically active compounds |
US20090131445A1 (en) | 2004-10-14 | 2009-05-21 | Compass Pharmaceuticals Llc | Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents |
WO2006124874A2 (en) | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibitors of b-raf kinase |
ES2270715B1 (en) * | 2005-07-29 | 2008-04-01 | Laboratorios Almirall S.A. | NEW DERIVATIVES OF PIRAZINA. |
RU2008129679A (en) * | 2005-12-21 | 2010-01-27 | Янссен Фармацевтика Н.В. (Be) | NEW SUBSTITUTED PYRAZINONIC DERIVATIVES FOR USE IN SIT-1-MEDIATED DISEASES |
EP2017277A1 (en) | 2007-06-29 | 2009-01-21 | 4Sc Ag | Thiophene-imidazopyridines |
JP2011507910A (en) | 2007-12-21 | 2011-03-10 | ユニバーシティー オブ ロチェスター | Methods for changing the lifetime of eukaryotes |
ES2562957T3 (en) * | 2009-04-30 | 2016-03-09 | Midwestern University | Method and composition for the treatment of diabetic ketoacidosis |
JP6075621B2 (en) * | 2010-08-10 | 2017-02-08 | 塩野義製薬株式会社 | Novel heterocyclic derivatives and pharmaceutical compositions containing them |
US9957271B2 (en) * | 2011-10-20 | 2018-05-01 | Glaxosmithkline Llc | Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators |
KR101481952B1 (en) * | 2012-04-13 | 2015-01-22 | 한국과학기술연구원 | Urea analogs as neuroprotective agents |
WO2013192388A1 (en) * | 2012-06-20 | 2013-12-27 | University Of Virginia Patent Foundation | Compositions and methods for regulating glucose homeostasis and insulin action |
TW201441203A (en) | 2012-11-05 | 2014-11-01 | Medeia Therapeutics Ltd | N-substituted 4-aminophenols and corresponding quinone imines |
EP3778598A3 (en) * | 2013-07-02 | 2021-08-04 | Syngenta Participations Ag | Pesticidally active bi- or tricyclic heterocycles with sulfur containing substituents |
KR101428622B1 (en) | 2014-01-07 | 2014-08-13 | 국방과학연구소 | Electrode containing oxadiazole pyrazine compounds or salt for lithium secondary batteries, and lithium secondary batteries containing the same |
JPWO2016068099A1 (en) * | 2014-10-28 | 2017-08-10 | 塩野義製薬株式会社 | Heterocyclic derivatives having AMPK activating action |
WO2016081599A1 (en) | 2014-11-18 | 2016-05-26 | Rutgers, The State University Of New Jersey | Novel mitochondrial uncouplers for treatment of metabolic diseases and cancer |
WO2017151063A1 (en) | 2016-03-03 | 2017-09-08 | Agency For Science, Technology And Research | Use of furazano[3,4-b]pyrazine derivatives for chemotherapy |
TWI754702B (en) * | 2016-12-28 | 2022-02-11 | 德商Ucb製藥有限公司 | (aza)indole- and benzofuran-3-sulfonamides |
WO2018217757A1 (en) | 2017-05-22 | 2018-11-29 | University Of Virginia Patent Foundation | Compositions and methods for preparing and using mitochondrial uncouplers |
BR112020021466A2 (en) * | 2018-04-20 | 2021-01-19 | Virginia Tech Intellectual Properties, Inc. | OXADIAZOLOPYRAZINS AND OXADIAZOLOPYRIDINES USEFUL AS MITOCHONDRIAL DETACHERS |
-
2019
- 2019-04-22 BR BR112020021466-3A patent/BR112020021466A2/en unknown
- 2019-04-22 MX MX2020011050A patent/MX2020011050A/en unknown
- 2019-04-22 KR KR1020207033356A patent/KR20210009321A/en unknown
- 2019-04-22 MX MX2020011049A patent/MX2020011049A/en unknown
- 2019-04-22 US US17/049,145 patent/US20210253538A1/en not_active Abandoned
- 2019-04-22 JP JP2021506388A patent/JP2021522327A/en active Pending
- 2019-04-22 CN CN201980038732.0A patent/CN112262146A/en active Pending
- 2019-04-22 EP EP19789309.2A patent/EP3781165A4/en not_active Withdrawn
- 2019-04-22 US US17/049,232 patent/US11708376B2/en active Active
- 2019-04-22 CA CA3097752A patent/CA3097752A1/en active Pending
- 2019-04-22 CN CN201980038852.0A patent/CN112261941A/en active Pending
- 2019-04-22 KR KR1020207033297A patent/KR20210003831A/en not_active Application Discontinuation
- 2019-04-22 BR BR112020021469-8A patent/BR112020021469A2/en not_active Application Discontinuation
- 2019-04-22 WO PCT/US2019/028560 patent/WO2019204819A1/en unknown
- 2019-04-22 EP EP19735420.2A patent/EP3781572A1/en active Pending
- 2019-04-22 US US17/048,897 patent/US20210253594A1/en active Pending
- 2019-04-22 JP JP2021506391A patent/JP2021523934A/en active Pending
- 2019-04-22 WO PCT/US2019/028544 patent/WO2019204813A1/en unknown
- 2019-04-22 CN CN201980038722.7A patent/CN112262141A/en active Pending
- 2019-04-22 AU AU2019256719A patent/AU2019256719A1/en active Pending
- 2019-04-22 WO PCT/US2019/028555 patent/WO2019204816A1/en unknown
- 2019-04-22 JP JP2021506390A patent/JP2021523933A/en active Pending
- 2019-04-22 AU AU2019256722A patent/AU2019256722A1/en active Pending
- 2019-04-22 KR KR1020207033337A patent/KR20210011928A/en not_active Application Discontinuation
- 2019-04-22 CA CA3097751A patent/CA3097751A1/en active Pending
- 2019-04-22 EP EP19735421.0A patent/EP3781567B1/en active Active
-
2020
- 2020-10-09 ZA ZA2020/06295A patent/ZA202006295B/en unknown
- 2020-10-09 ZA ZA2020/06296A patent/ZA202006296B/en unknown
- 2020-10-15 IL IL278069A patent/IL278069A/en unknown
- 2020-10-15 IL IL278070A patent/IL278070A/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3781567A1 (en) | 2021-02-24 |
BR112020021466A2 (en) | 2021-01-19 |
MX2020011049A (en) | 2021-01-08 |
KR20210003831A (en) | 2021-01-12 |
EP3781165A4 (en) | 2022-02-23 |
EP3781567B1 (en) | 2022-08-24 |
IL278070A (en) | 2020-11-30 |
US20210238181A1 (en) | 2021-08-05 |
WO2019204819A1 (en) | 2019-10-24 |
WO2019204813A1 (en) | 2019-10-24 |
MX2020011050A (en) | 2021-03-09 |
BR112020021469A2 (en) | 2021-01-19 |
JP2021523934A (en) | 2021-09-09 |
CN112262146A (en) | 2021-01-22 |
ZA202006295B (en) | 2023-03-29 |
US20210253594A1 (en) | 2021-08-19 |
KR20210009321A (en) | 2021-01-26 |
AU2019256722A1 (en) | 2020-11-05 |
CN112261941A (en) | 2021-01-22 |
EP3781165A1 (en) | 2021-02-24 |
CA3097752A1 (en) | 2019-10-24 |
EP3781572A1 (en) | 2021-02-24 |
JP2021522327A (en) | 2021-08-30 |
ZA202006296B (en) | 2023-03-29 |
WO2019204816A1 (en) | 2019-10-24 |
CA3097751A1 (en) | 2019-10-24 |
IL278069A (en) | 2020-11-30 |
JP2021523933A (en) | 2021-09-09 |
AU2019256719A1 (en) | 2020-11-05 |
KR20210011928A (en) | 2021-02-02 |
US11708376B2 (en) | 2023-07-25 |
CN112262141A (en) | 2021-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2428504B1 (en) | Small molecule inhibitors of the pleckstrin homology domain and method for using same | |
CN109415363B (en) | Novel mitochondrial uncoupling agents for the treatment of metabolic diseases and cancer | |
US20210253538A1 (en) | Aminopyrazines and related compounds useful as mitochondrial uncouplers | |
US11896591B2 (en) | Compositions and methods for preparing and using mitochondrial uncouplers | |
US10717727B2 (en) | Pyridinium compounds | |
KR100293867B1 (en) | Aminosteelbazole Derivatives and Medicines | |
EP4233871A2 (en) | Inhibiting the transient receptor potential a1 ion channel | |
AU2021105895A4 (en) | Lycoline B-aryl acrylate derivatives, preparation method and application thereof | |
CN101974016A (en) | Amide compound and preparation method and applications thereof | |
CN107556316B (en) | Bridged ring-containing imidazole derivatives | |
US20230219894A1 (en) | Disubstituted adamantyl derivative or pharmaceutically acceptable salt thereof, and pharmaceutical composition for suppressing cancer growth comprising same as active ingredient | |
AU2015201306B2 (en) | Small molecule inhibitors of the pleckstrin homology domain and methods for using same | |
US20230416191A1 (en) | Compounds, Compositions and Methods for the Treatment of CREB-dependent Diseases | |
JP2016534049A (en) | Functionalized furan-2-sulfonamide showing endothelial lipase inhibition | |
WO2023060173A1 (en) | Compounds, compositions and methods of use | |
KR101048748B1 (en) | Novel galvanic acid derivative or pharmaceutically acceptable salt thereof, preparation method thereof and pharmaceutical composition for inhibiting multi-drug resistance containing the same as an active ingredient | |
CN115109040A (en) | Antifungal compounds, pharmaceutical compositions and formulations comprising the same, and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: VIRGINIA TECH INTELLECTUAL PROPERTIES, INC., VIRGINIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SANTOS, WEBSTER L.;MURRAY, JACOB H.;NEKVINDA, JAN;AND OTHERS;SIGNING DATES FROM 20210217 TO 20210322;REEL/FRAME:056228/0514 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |